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Introduction générale 
 
 
 
La méthode Monte Carlo est un algorithme de calcul permettant de modéliser au plus près la 
physique liée aux processus de dépôts d’énergie, les algorithmes Monte Carlo sont donc prévus 
pour être plus précis que d’autres types d’algorithmes de calcul. 
Cependant, des calculs précis utilisant Monte Carlo conduisent à des temps de calcul très importants 
en comparaison avec les logiciels analytiques utilisés en routine clinique pour la planification des 
traitements du cancer. Pour résoudre ce problème, différents codes Monte Carlo ont déjà été 
développés pour un usage dédié à la radiothérapie. Les approximations ou les compromis mis en jeu 
dans ces codes, comme une modification du transport des électrons, une limitation du suivi des 
événements les moins probables, une méthode de transport des particules basée sur le passage de 
voxels, etc, permettent effectivement une réduction des temps de calcul. 
Dans l’équipe PCSV (Plate-forme de Calcul pour les Sciences du Vivant), membre du Laboratoire 
de Physique Corpusculaire de Clermont-Ferrand, la plate-forme de simulation Monte Carlo GATE 
(GEANT4 Application for Tomographic Emission) est utilisée dans les domaines d’applications liés 
à l’imagerie SPECT, TEP, à la radiothérapie et à la curiethérapie. 
De manière à étendre les qualités intrinsèques de GATE aux applications en dosimétrie, et après la 
release publique de GATE en mai 2004, la collaboration OpenGATE a mis en place deux groupes 
de travail pour étudier plus spécifiquement les aptitudes de la plate-forme de simulation pour la 
dosimétrie, un deuxième groupe est consacré à la réduction des temps de calcul des simulations en 
les divisant entre autre sur de multiples processeurs. 
Ces nouveaux champs de travail permettront à la plate-forme de rivaliser avec les codes de calcul 
Monte Carlo existant pour une utilisation en dosimétrie personnalisée exploitant des images 
voxélisées pour modéliser l’anatomie du patient. 
L’objectif de cette thèse était de valider la plate-forme GATE pour des calculs en dosimétrie 
utilisant des électrons  et de déployer cette plate-forme sur un environnement de grille de calcul afin 
de réduire son temps d’exécution. Un prototype permettant la division, la répartition et le lancement 
des simulations GATE sur une architecture de grille est proposé pour permettre aux praticiens et 
physiciens médicaux de délivrer des distributions de dose de manière rapide et précise en utilisant 
un algorithme Monte Carlo. La curiethérapie oculaire utilisant des applicateurs ophtalmiques 
émetteurs bétas est l’application qui a bénéficié de nos recherches concernant les électrons et les 
calculs sur grille. 
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Les traitements utilisant des faisceaux d’électrons ainsi que la curiethérapie utilisant ces mêmes 
rayonnements représentent 10 à 15 % des traitements quotidiens en routine clinique. Au Centre Jean 
Perrin de Clermont-Ferrand, les traitements de curiethérapie oculaire utilisant des applicateurs 
ophtalmiques de 106Ru/106Rh émetteurs béta sont préconisés dans le traitement des mélanomes de 
l’uvée ainsi que des kystes oculaires bénins. Environ deux patients bénéficient de ce traitement tous 
les mois. Les logiciels de planification de traitement (TPS) utilisés dans les départements 
d’oncologie des centres hospitaliers fournissent le moyen d’élaborer des planifications de traitement 
permettant une prescription de la dose au volume cible tout en préservant autant que possible les 
tissus sains alentours. Pour cela, le TPS doit être capable de calculer des distributions de dose avec 
une précision suffisante. A titre indicatif, il est recommandé de délivrer une dose avec une précision 
ne dépassant pas 2 à 3% ; pour des traitements plus spécifiques près de régions hétérogènes (cavités 
air/os), des différences significatives ont été démontrées entre les calculs Monte Carlo et les TPS. 
Même si, depuis quelques années, un intérêt grandissant est né pour les algorithmes de calcul de 
dose par Monte Carlo, ces codes doivent être néanmoins évalués de manière à devenir la meilleure 
alternative aux calculs analytiques pour des applications spécifiques en routine clinique, notamment 
avec l’utilisation d’images scanner pour modéliser le corps du patient.   
Le fait est que la simulation du transport des électrons et des positrons est bien plus difficile que 
celle des photons, c’est pourquoi, les traitements utilisant des électrons devraient bénéficier d’une 
amélioration de la précision du calcul de dose. La principale raison étant que la perte d’énergie 
moyenne d’un électron par interaction est très faible (quelques dizaines d’électron volts). Ceci a 
pour conséquence que des électrons d’énergie relativement élevée (quelques MeV) vont subir un 
très grand nombre d’interactions avant d’être effectivement absorbés dans le milieu. 
Un des objectifs de cette thèse était de valider l’utilisation de la plate-forme GATE pour une 
dosimétrie impliquant des électrons. Pour cela, les différentes librairies de GEANT4 avaient besoin 
d’être testées et comparées avec d’autres codes Monte Carlo ainsi que des mesures expérimentales. 
Pour la simulation du transport des électrons et des positrons, GEANT4 et la plupart des codes 
Monte Carlo actuellement disponibles ont recours aux théories de diffusion multiple qui permettent 
de simuler l’effet global d’un grand nombre d’événements sur un segment de trace pour une 
distance donnée (step). Du fait que les théories de diffusion multiple implémentées dans les codes 
Monte Carlo dits condensés, comme GEANT4, sont uniquement approximées et peuvent aboutir à 
des erreurs systématiques rendues évidentes par une dépendance des résultats de simulation envers 
la longueur de step adoptée dans le suivi des particules, nous avons étudié l’impact de 
l’implémentation de la diffusion multiple dans GEANT4 sur les simulations de points kernels pour 
des électrons mono-énergétiques et poly-énergétiques (distribution spatiale de l’énergie déposée 
dans des volumes cibles centrés sur une source radioactive ponctuelle par unité de masse du volume 
cible et par décroissance du point source). Les points kernels représentent la base du calcul de dose 
pour des distributions de source étendue en milieu homogène ou pour des doses moyennées dans 
des volumes finis. 
Les algorithmes de passage de frontière jouent également un rôle important dans la dose déposée 
par les électrons, en particulier lorsque les électrons déposent leur énergie dans des voxels de taille 
inférieure à 1 mm de côté lors d’une utilisation d’images scanner décrivant l’anatomie du patient 
dans les simulations. 
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Nous utilisons ensuite la plate-forme GATE pour simuler les traitements de curiethérapie oculaire 
utilisant des applicateurs de 106Ru/106Rh qui demandent une connaissance précise de la dose 
déposée par les électrons sur de faibles distances. Ceci rend ces simulations d’autant plus 
intéressantes à comparer avec d’autres codes Monte Carlo, des calculs théoriques, des logiciels de 
planification de traitement et des mesures expérimentales. 
De manière à appliquer notre étude dosimétrique en milieu hétérogène, nous avons étudié l’impact 
des inhomogénéités des tissus sur la distribution de dose calculée avec GATE. Ce travail a été fondé 
sur la conversion des nombres Hounsfield en densité et poids élémentaires des tissus humains, 
données qui sont ensuite nécessaires aux calculs Monte Carlo. Pour valider notre transcription, nous 
avons développé un outil permettant la visualisation, la rotation et la coloration des images scanner 
obtenues en échelle de gris en fonction des paramètres tissulaires. Nous avons ensuite testé 
l’influence de la composition des tissus sur la dose déposée par des faisceaux de photons et 
d’électrons en utilisant GATE. 
 
Même si le coût des ressources de calcul est en constante baisse, facilitant ainsi le calcul intensif, 
les simulations GATE ne peuvent être envisagées dans une utilisation en routine clinique comme 
logiciel de planification de traitement du fait de leur temps de calcul prohibitifs sur simple 
processeur. Ajouté au fait que les chercheurs de la collaboration GATE ont exprimé un besoin 
d’accéder à de grandes ressources de calculs pour leurs simulations, une solution a été trouvée. 
Depuis 2000, les technologies de grille sont financées par l’union européenne pour faire face aux 
besoins de la communauté scientifique en terme de calcul, partage de données et stockage massif. 
Le projet européen IST DataGrid (2001-2004) puis le projet EGEE (Enabling Grids for E-SciencE) 
(2004-2006), identifient les simulations Monte Carlo utilisant GATE comme un domaine 
d’application pouvant bénéficier des technologies de grille pour un usage de celles-ci en routine 
clinique. 
Depuis le début du projet DataGrid, l’équipe PCSV et le Laboratoire de Physique Corpusculaire de 
Clermont-Ferrand ont été impliqués dans le calcul « gridifié » en déployant au sein des applications 
biomédicales, les simulations GATE pour des traitements utilisant des rayonnements. Durant le 
projet DataGrid, la priorité du travail s’est focalisée sur la méthode de parallélisation à adopter pour 
diviser les simulations GATE sur des processeurs distribués. Cette méthode est basée sur une 
méthode de division de séquences de nombres pseudo-aléatoires permettant à l’utilisateur d’allouer 
une séquence de nombres pseudo-aléatoires indépendante à chaque simulation Monte Carlo divisée 
et soumise sur grille. 
Le déploiement de GATE durant le projet DataGrid ayant été prometteur dans la réduction des 
temps de simulation, GATE est devenu une des applications pilotes au sein du projet EGEE, 
bénéficiant ainsi de ressources de calcul encore plus importantes ainsi que d’un environnement de 
production. De manière à permettre une utilisation transparente et interactive de GATE sur grille en 
routine clinique, une autre étude a été conduite au cours de cette thèse visant à développer toutes les 
fonctionnalités pour utiliser GATE sur un environnement de grille à partir d’un portail web 
sécurisé. 
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Le Chapitre I est dédié à une description complète des traitements de curiethérapie oculaire, 
notamment ceux utilisant les applicateurs ophtalmiques de 106Ru/106Rh. Après une description des 
diagnostics de tumeurs oculaires et des caractéristiques des applicateurs ophtalmiques (géométrie, 
radio-émetteur), nous détaillons la prescription de la dose et l’efficacité des traitements en 
comparant les traitements de curiethérapie avec d’autres modalités de traitements utilisant d’autres 
radioéléments ou bien encore la protonthérapie. Les difficultés et les spécificités rencontrées dans le 
contrôle qualité et la mesure de la dose des plaques ophtalmiques sont développées ; une description 
complète du système de planification de traitement utilisé actuellement en routine clinique pour le 
calcul de dose en curiethérapie oculaire est ensuite effectuée. 
Les technologies de grille sont détaillées dans le Chapitre II, les deux projets de grille pour lesquels 
GATE a été déployé sont particulièrement décrits : les projets DataGrid et EGEE. L’intergiciel de 
grille ainsi que l’infrastructure de grille du projet EGEE sont discutés précisément en détaillant la 
fonction de chaque machine de grille, le suivi d’un job sur la grille ainsi que l’allocation des 
ressources pour les applications biomédicales. Les solutions pour une meilleure efficacité du calcul 
sur grille sont discutées en s’intéressant en particulier au système de gestion des jobs sur les noeuds 
de grille et la politique de soumission des jobs qui pourrait être améliorée. Finalement, nous 
insistons sur les besoins spécifiques rencontrés par les applications liées à la santé dans un 
environnement de grille. Nous mettons en évidence les services existant fournis par la grille dans un 
but d’utilisation de celle-ci à des fins médicales ainsi que les problématiques restant à résoudre en 
ce qui concerne le stockage et l’accès sécurisé aux données médicales.  
Après une analyse des caractéristiques clés de GATE lui permettant de devenir une plate-forme 
dédiée aux applications en dosimétrie, la validation des processus physiques de GEANT4 pour une 
étude de point kernel utilisant les électrons est détaillée dans le Chapitre III. Après une description 
des processus physiques mis en jeu dans les interactions électroniques, nous expliquons les 
implémentations successives de la diffusion multiple dans GEANT4 pour les versions 5.2.p02, 
6.2.p02 et 7.0.p01. Les résultats obtenus avec les versions de GEANT4 (effet des implémentations 
différentes de la diffusion multiple) pour la modélisation des points kernels d’électrons mono-
énérgétiques ainsi que du 106Rh sont comparés avec d’autres codes Monte Carlo. Une étude 
spécifique concernant la distribution angulaire des électrons après le passage d’une fine couche 
d’eau est ensuite conduite. 
Le Chapitre IV se destine à la validation des simulations GATE pour les traitements de 
curiethérapie oculaire utilisant le 106Ru/106Rh. Des comparaisons de GATE avec d’autres codes 
Monte Carlo, des calculs théoriques et des mesures sont présentées pour le calcul de la dose 
déposée sur l’axe central d’un œil d’eau virtuel ainsi que pour le calcul des isodoses dans le plan 
médian de l’œil. Est également présentée une étude concernant la transcription des nombres 
Hounsfield d’une image scanner en paramètres tissulaires nécessaires à l’exécution des simulations 
GATE en milieu hétérogène. Cette étude est préliminaire à l’utilisation des informations fournies 
par les images scanner pour des calculs dosimétriques avec GATE. 
 
Dans le Chapitre V, nous expliquons le travail effectué dans les projets de grille pour le 
déploiement des simulations Monte Carlo GATE. La modalité de parallélisation des simulations en 
divisant le générateur de nombres aléatoires est détaillé. Des tests de consistance du générateur 
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aléatoire ont été conduits pour produire mille fichiers décrivant des séquences indépendantes de 
nombres aléatoires. Ensuite, des tests de temps de calcul obtenus dans un premier temps sur 
l’infrastructure DataGrid puis sur celle d’EGEE illustrent le gain en temps obtenu pour nos 
simulations. Une description des fonctionnalités développées pour une soumission parallèle, 
transparente et sécurisée des simulations GATE à partir d’un portail web est enfin présentée. 
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General Introduction 
 
 
 
Monte Carlo method  is the calculation algorithm that most closely models the actual physics of the 
energy deposition process, so Monte Carlo algorithms are expected to be capable of more accuracy 
than other kind of calculation algorithms. However, accurate calculations using Monte Carlo 
involve a very high computing time compared to analytic calculations used in routine cancer 
treatment planning. To address this problem, several codes have been already developed more 
specifically for use in radiotherapy. Approximations or compromises including modified electron 
transport, limited tracking for low probability events, voxel based transport method, etc, allow the 
reduction of calculation times. 
In the PCSV team (Plate-forme de Calcul pour les Sciences du Vivant) part of the Laboratoire de 
Physique Corpusculaire of Clermont-Ferrand, the GATE (GEANT4 Application for Tomographic 
Emission) Monte Carlo simulation platform is widely used in the fields of SPECT, PET, 
radiotherapy and brachytherapy. As a consequence of the attractive features of GATE for dosimetry 
applications, the OpenGATE collaboration, after the release of the open source package GATE in 
May 2004, set up two working groups to study specifically the features of the platform in dosimetry 
and in the reduction of the computation time by among other things split simulations on multiple 
processors. These new features will enable the GATE platform to compete with existing Monte 
Carlo codes for a usage in personnalized dosimetry treatments using voxelized images to model the 
patient’s anatomy. 
Our objective in this thesis was to validate the GATE platform for dosimetry calculations using 
electrons and deploy it on a grid environment to reduce the computation time. A prototype enabling 
the division, splitting and launching of GATE simulations on a grid architecture is proposed to face 
the needs of praticians and medical physicists into delivering accurate and fast dose distributions. 
Ocular brachytherapy using beta emitter ophthalmic applicators is the treatment that benefits of our 
work concerning electron transport and grid calculations. 
 
Electron beam treatments and brachytherapy using electrons represent about 10%-15% of the daily 
workload in clinical practice. In Centre Jean Perrin of Clermont-Ferrand, ocular brachytherapy 
treatments using 106Ru/106Rh beta emitter ophthalmic applicators are practised for eradication of 
uveal melanoma and benign ocular kystes. About two patients are treated per month with such 
technique. The treatment planning system (TPS) used in radiation oncology departments at hospital 
provides the means to design treatment plans for delivery of the prescribed dose to the target 
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volume while sparing the surrounding normal tissue as much as possible. This implies that the TPS 
must be able to calculate dose distributions with sufficient accuracy. As an indication, an accuracy 
in the dose distribution of 2-3% is considered as presently acceptable; for some specific treatments 
particularly in regions near air cavities and/or bones, significant differences have been demonstrated 
between pencil beam dose distributions and Monte Carlo calculations.  
Even if, since recent years, there has been widespread interest in the implementation of Monte 
Carlo dose calculation algorithms, those codes must be evaluated in order to become the best 
alternative to analytic calculations in clinical routine for some specific applications in particularly 
when using CT images to model the patient’s body.  
The fact is that the simulation of electron and positron transport is much more difficult than that of 
photons and therefore, treatments using electron radiations might benefit from improved dose 
calculation accuracy. The main reason is that the average energy loss of an electron in a single 
interaction is very small (few tens of eV). As a consequence, high-energy electrons suffer a large 
number of interactions before being effectively absorbed in the medium.  
One of the goal of this PhD thesis was to validate the usage of the GATE platform for dosimetry 
implying electrons. For that, the different GEANT4 physics packages needed to be tested and 
compared to other Monte Carlo codes and measurements. For high energy electrons and positrons, 
GEANT4 and most of the Monte Carlo codes currently available have recourse to multiple 
scattering theories which allow the simulation of the global effect of a large number of events in a 
track segment of a given length (step). Because multiple scattering theories implemented in 
condensed Monte Carlo, such like GEANT4, are only approximate and may lead to systematic 
errors, which can be made evident by the dependence of the simulation results on the adopted step 
length, we studied the impact of the GEANT4 multiple scattering implementation on monoenergetic 
and polyenergetic electron dose point kernels (spatial distribution of the energy deposited in target 
volumes centered about a point radionuclide source per mass of the target volume per decay of the 
point source) simulations. Point kernels are the basis for calculating doses from extended source 
distributions in homogeneous media or for averaging doses over finite volumes.  
Boundary crossing algorithms play also an important role in dose deposited by electrons, 
particularly when using CT images to describe patient’s body in the simulations where electrons 
deposit their energy in voxels less than 1 mm in size. 
We use then the GATE platform to simulate 106Ru/106Rh ocular brachytherapy treatments that 
require an accurate knowledge of the dose deposited by electrons over very short distances, which 
made those simulations particularly interesting to compare with other Monte Carlo codes, 
theoretical calculations, treatment planning and measurements.  
In order to apply our dosimetry study in heterogeneous media, we studied the impact of tissue 
inhomogeneities on clinical dose distributions calculated with GATE. This work was first based on 
the conversion of CT numbers into mass density and elemental weights of tissues that are required 
as input in our Monte Carlo calculations. To validate our transcription, we developed a tool to 
enable the visualization, rotation and colouring of gray scaled CT images in function of the tissue 
parameters and tested the influence of tissue compound on dose deposited by photon and electron 
beams using GATE. 
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Even though the cost of computing resources is continually decreasing thereby facilitating 
consequent calculations, GATE simulations couldn’t currently be used for clinical treatments 
planning for which the computing time remains too high on a single machine. In addition, a need 
from researchers part of the GATE collaboration willing to have access to large computing 
resources to run long simulations emerged. 
Since 2000, grid technologies are financed by the European Union to face the scientific community 
needs in terms of computing, data sharing and large storage. The European IST DataGrid (2001-
2004) project and next the EGEE (Enabling Grids for E-sciencE) project (2004-2006), identify 
Monte Carlo simulations using GATE as an application domain that can benefit from grid 
technologies for the usage of the code in clinical practice. 
Since the beginning of the DataGrid project, the PCSV team and the Laboratoire de Physique 
Corpusculaire of Clermont-Ferrand got involved by deploying all along the work done during this 
thesis, among other biomedical applications, GATE simulations for radiation therapy. During the 
DataGrid project, the priority of this work was focused on the parallelization method necessary to 
split GATE simulations on distributed processors. This method is based on a pseudorandom 
sequence splitting method that allow the user to allocate independent random numbers sequence in 
each of the Monte Carlo sub-simulations divided and launched on the grid. 
As the deployment of GATE during the DataGrid project was promising in the reduction of the 
computation time, GATE became then a pilot application in the EGEE project by benefiting of 
larger computing resources and a production testbed. In order to enable a transparent and interactive 
use of GATE applications on the grid for an envisaged usage in clinical routine, an other work 
driven in this thesis was to develop all the functionalities to run GATE simulations from a secure 
web portal.  
 
The Chapter I is dedicated to a complete description of ocular brachytherapy clinical treatments 
using 106Ru/106Rh ophthalmic applicators. After a description of ocular tumour diagnosis and of the 
characteristics of the ophthalmic applicators (geometry, radionuclide), we detail the dose 
prescription and the treatment efficacy by comparing this brachytherapy treatments with other 
treatment modalities using other radionuclides or protontherapy. The difficulties and specificities 
encountered in the quality control and dose measurements of ocular plaques are developed to finish 
with a complete description of the treatment planning system dose calculation that is currently 
performed in clinical routine to deliver dose to tumours.   
 
Grid technologies are detailed in Chapter II, with a special focus on the two grid projects for which 
the deployment of GATE simulations was involved in: the DataGrid and the EGEE projects. The 
grid middleware and infrastructure concerning the last project is particularly discussed by detailing 
each grid machine functionnality, a typical job flow and resources allocated to biomedical 
applications. Solutions concerning a better grid computing efficacy is argued by interesting to the 
cluster batch queuing management and to the jobs submission policy that could improve gain in 
computing time. Finally we focus on the specific needs encounter by health related applications in a 
grid environment. We highlight the existing services of the grid for medical issues and the 
problematics that remain to be solved concerning the storage and secure access to medical data.  
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After an analysis of the key features for GATE to become a platform intended to dosimetry 
applications, GEANT4 physics validation for electron dose point kernels is detailed in Chapter III. 
After a description of the physic processes involved in electron interactions, we focus particularly 
our explanations on multiple scattering implementation in GEANT4 following the last versions 
5.2.p02, 6.2.p02 and 7.0.p01. Comparisons of monoenergetic and 106Rh dose point kernels 
calculated using different GEANT versions (e.g different implementations of the Multiple scattering 
theory) are done with other Monte Carlo codes. A specific study of the angular distribution of 
electrons after the crossing of a thin water foil is presented. 
 
The Chapter IV is intended to the validation of GATE simulations for 106Ru/106Rh ocular 
brachytherapy treatments. Comparisons of GATE with other Monte Carlo codes, theoretical 
calculations and measurements are shown for the dose deposited along the central axis of a virtual 
water eye and on the median plan by calculating isodose contours. A study concerning the 
translation of CT numbers in tissue parameters for GATE calculations in heterogeneous media is 
presented. This study is a preliminary work to enable the use of CT image information in GATE 
calculations for dosimetry applications. 
 
In Chapter V, we explain the work done in Grid projects to deploy GATE Monte Carlo simulations. 
The modality of parallelization of simulations by splitting the random number generator is detailed. 
Consistency tests have been performed to produce the thousand files describing independent 
sequences of random numbers. Then,  tests of computation time obtained first on the DataGrid and 
on the EGEE infrastructures, illustrate the gain in time obtained. A description of the functionalities 
developed for the transparent and secure submission of parallel GATE simulations from a web 
portal is presented. 
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Chapter I.  
 
 
Ocular brachytherapy using 106Ru/106Rh 
ophthalmic applicators 
 
 
 
INTRODUCTION 
Beta-ray emitting 106Ru/106Rh ophthalmic applicators have been used for close to 4 decades in the 
treatment of uveal melanoma, and also for benign tumours, it is now a well-practiced treatment in 
Centre Jean Perrin of Clermont-Ferrand. The specific shape of the applicators, the size of the tissue 
to irradiate and the use of beta particles make the calculation of dose distribution complicated. The 
very high dose gradient produced by such treatments on the distances relative to the size of an eye 
require accurate and fast tools for the dose calculations. Monte Carlo simulations are the best 
alternative to answer the specific needs for an accurate determination of the dose distributions. In 
the case of an utilization of such calculations in clinical routine, the reduction of the computation 
time is therefore the other priority to  treat. This chapter is intended to understand better the 
incidence of uveal tumours and their treatment using brachytherapy technique with electrons. An 
accurate description of the features of the current analytic treatment planning system used for the 
dosimetry is discussed.  
The first part of this chapter describes the occurrence of ocular tumours and their treatments. After a 
description of eye tissues, an accurate description of the 106Ru/106Rh ocular brachytherapy is 
explained; first by describing the radioactive source and then the ophthalmic applicator designs. The 
dose prescription and comparison of treatments such like other brachytherapy treatments using 
photons or protontherapy are discussed next. A second part describes the measurements and quality 
control usually performed on 106Ru/106Rh plaques to calibrate the source, to determine the relative 
dose distribution along the central axis of the source and to determine the relative dose distribution 
as a function of position off of the central axis. Thanks to those measurements the dose is specified 
at any point. A final part is dedicated to the Plaque Simulator treatment planning system used in 
clinical routine in Centre Jean Perrin to calculate the dose distribution of clinical brachytherapy 
treatments, the duration of the treatment and the incidence of radiation field on soft tissues. A 
detailed description of the dose kernels calculations is done. 
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I.1. OCULAR BRACHYTHERAPY: A CLINICAL APPROACH  
I.1.1. Ocular melanoma and benign tumour 
I.1.1.A. Eye anatomy and tumour incidence 
I.1.1.A.1. Eye tissues 
In the following, we make a brief description of the principle tissues which compose eye. This 
description isn’t exhaustive and is there to enable the reader to understand better ophthalmologic 
terms employed in the occurrence of eye tumours.  
 
Figure I- 1: Simplified schema of the eye anatomy 
The sclera 
The sclera is commonly known as "the white of the eye."  It is the tough, opaque tissue that serves 
as the eye's protective outer coat.  Six tiny muscles connect to it around the eye and control the eye's 
movements.  The optic nerve is attached to the sclera at the very back of the eye. 
The choroid 
The choroid lies between the retina and sclera. It is composed of layers of blood vessels that nourish 
the back of the eye.  The choroid connects with the ciliary body toward the front of the eye and is 
attached to edges of the optic nerve at the back of the eye.  
The ciliary body 
The ciliary body lies just behind the iris. Attached to the ciliary body are tiny fiber "guy wires" 
called zonules.  The crystalline lens is suspended inside the eye by the zonular fibers.  Nourishment 
for the ciliary body comes from blood vessels which also supply the iris. One function of the ciliary 
body is the production of aqueous humor, the clear fluid that fills the front of the eye.  It also 
controls accommodation by changing the shape of the crystalline lens.   
The retina 
The retina is a multi-layered sensory tissue that lines the back of the eye.  It contains millions of 
photoreceptors that capture light rays and convert them into electrical impulses. These impulses 
travel along the optic nerve to the brain where they are turned into images.   
There are two types of photoreceptors in the retina:  rods and cones.  The retina contains 
approximately 6 million cones.  The cones are contained in the macula, the portion of the retina 
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responsible for central vision.  They are most densely packed within the fovea, the very center 
portion of the macula. Cones function best in bright light and allow us to appreciate color.  
There are approximately 125 million rods. They are spread throughout the peripheral retina and 
function best in dim lighting.  The rods are responsible for peripheral and night vision. 
The lens 
The crystalline lens is located just behind the iris.  Its purpose is to focus light onto the retina.  The 
nucleus, the innermost part of the lens, is surrounded by softer material called the cortex.  The lens 
is encased in a capsular-like bag and suspended within the eye by tiny "guy wires" called zonules.   
The cornea 
The cornea is the transparent, dome-shaped window covering the front of the eye.  It is a powerful 
refracting surface, providing 2/3 of the eye's focusing power.  Like the crystal on a watch, it gives 
us a clear window to look through. Because there are no blood vessels in the cornea, it is normally 
clear and has a shiny surface.  The cornea is extremely sensitive - there are more nerve endings in 
the cornea than anywhere else in the body.  The adult cornea is only about 1/2 millimeter thick and 
is comprised of 5 layers:  epithelium, Bowman's membrane, stroma, Descemet's membrane and the 
endothelium. 
The iris 
The colored part of the eye is called the iris.  It controls light levels inside the eye similar to the 
aperture on a camera.  The round opening in the center of the iris is called the pupil. The iris is 
embedded with tiny muscles that dilate (widen) and constrict (narrow) the pupil size.   
The iris is flat and divides the front of the eye (anterior chamber) from the back of the eye (posterior 
chamber).  Its color comes from microscopic pigment cells called melanin.  The color, texture, and 
patterns of each person's iris are as unique as a fingerprint. 
I.1.1.A.2. Different type of tumours treated with 106Ru plaques 
Uveal melanoma are the most frequent and dangerous among ocular tumours. 
The gravity of this type of cancer can lead to the loss of visual acuity until the total loss of eyesight 
and in a final step to the apparition of metastases. This type of malignant melanoma can be 
observed in specific eye tissues: the iris, the ciliary body and the choroid with respectively the 
corresponding frequency 1%, 18% and 81%. 
Benign tumours can also be treated using ocular brachytherapy, particularly the choroidal angiom 
and the anterior chamber kyste. 
In 1999, a study shown that the incidence of uveal melanomas in Western Europe was 0.7 per year 
per 100 000 persons [1 ]. Approximatively one patient per month is treated using 106Ru/106Rh ocular 
brachytherapy in Centre Jean Perrin of Clermont-Ferrand. 
I.1.1.B. Tumour diagnosis 
Three medical imaging modalities are used for the diagnosis, the location of the tumour in the eye 
and the determination of its size by the ophthalmologist. 
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I.1.1.B.1. Photography 
There are two types of special photographs ophthalmologists use to assist in diagnosis: fluorescein 
angiography and fundus photographs. 
§ In fluorescein angiography, a special dye is injected into a vein in the arm. As the dye passes 
through the blood vessels in the back of the eye, this allows for a view of the circulation of 
the retina and the layers beneath the retina, highlighting any abnormalities.  
§ The fundus of the eye includes the retina, macula, fovea, optic disc and retinal vessels. In 
fundus photography, the inner lining of the eye is photographed with specially designed 
cameras through the dilated pupil. This is a non-invasive and painless procedure that 
produces a sharp view of the retina, the optic nerve and the retinal vessels. 
 
Figure I- 2: Fundus of patient’s eye 
 
 
Figure I- 3: Fundus image of a choroidal melanoma 
I.1.1.B.2. Ultrasound (echography) 
Ultrasound is one the most useful technique to determine the size of the tumour. Both A-scan and 
B-scan ultrasound show choroidal melanomas to have low to moderate internal reflectivity, 
sometimes called acoustic hollowing because part of the tumor typically appears dark on B scan. 
The A scan is accurate in helping to estimate the height of the tumor, which aides in distinguishing 
thin melanomas from nevi and in assessing growth over time.  
Ultrasound is particularly useful in the diagnosis of melanoma in eyes in which the posterior pole 
cannot be visualized directly. Melanomas in such eyes are often unsuspected.  
 
Figure I- 4: Ocular echography of a patient 
 
Figure I- 5: Echography image of an ocular melanoma 
I.1.1.B.3. Magnetic Resonnance Imaging (MRI) 
MRI has been proposed as a helpful diagnostic technique because melanin is paramagnetic and has 
specific characteristics (enhanced proton relaxation with shortened T1 and T2 relaxation times) on 
imaging. However, melanomas vary in degree of pigmentation as well as other intrinsic features so 
that the so-called "characteristic" pattern is seen in only approximately 20% of cases. 
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Figure I- 6: Frontal view of a patient eye obtain with 
MRI (choroidal melanoma) 
 
Figure I- 7: Sagittal view of a patient eye obtained with 
MRI (choroidal melanoma)  
CT scans can also be performed to image the tumour in the eye. 
I.1.1.B.4. Other diagnosis modalities: Biopsy and metastases detection 
Biopsy is a technique that may be useful in the differential diagnosis in selected cases. A needle is 
inserted directly into the tumor from the vitreous side, and the tumour is sampled for cytologic 
analysis. In this way, benign simulating lesions can be diagnosed, thus avoiding a mistaken 
enucleation or radiation treatment. 
A general physical examination and additional tests are done to diagnose metastatic disease. The 
most frequent site of metastasis is the liver, so the workup should include liver enzyme levels, and, 
if indicated, liver ultrasound or scan. Early liver metastases can be difficult to diagnose, which is 
unfortunate since prompt palliative treatment may enhance survival somewhat. 
During the operation, transilluminating the globe helps to show tumour size. This technique can be 
useful for delineating anteriorly located melanomas and is an excellent method to assess the basal 
size of the tumor. 
I.1.2. 106Ru/106Rh definition 
Ruthenium (Z=44) is a member of the platinium group. This hard, white, noble metal has a mass 
density of 12.41 g.cm-3, a melting point of 2334 °C and a boiling point of 4150 °C. Whereas the 
metal is very inert, the tetroxide is highly toxic. Carrier-free 106Ru/106Rh can be obtained 
commercially, usually as a dry or dissolved salt (e.g chloride or nitrate). Freshly prepared 
106Ru/106Rh may contain a significant amount of 103Ru, which may be eliminated by decay as its 
half-life (39.35 d) is about ten times less than that of 106Ru. 
The radioactive nucleus 106Ru disintegrates to the stable nuclide 106Pd via 106Rh. The half life of 
106Ru is 373.59 days and for the state of 106Rh, which mainly contributes to the b- particle emission, 
the half-life is 29.80 seconds. The electron spectrum of the 106Ru has a maximum energy of 39.4 
keV, whereas in the later disintegration of 106Rh the mean energies of the continuous b- particle 
spectra for the three transitions with the highest yield are 1.508 MeV (78.6%), 0.976 MeV (10.0%) 
and 1.267 MeV (8.1%), with a maximum energy of 3.541 MeV. 
Figure I- 8 represents the decay scheme of the 106Ru/106Rh nuclide.  
Table I- 1 and Table I- 2 describe the energy and the probability of the beta and photon emissions 
respectively. 
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Figure I- 8: Decay scheme of 106Ru/106Rh nuclide
 
 
Table I- 1: Beta emisions of 106Ru/106Rh nuclide 
 
Table I- 2: Photon emissions of 106Rh nuclide 
 
Table I- 3: Beta energy spectrum 
of 106Rh 
 
In our simulations, we have considered the b  transitions of the 
106Rh nuclear decay, therefore the simulated electrons are randomly 
selected from the 106Rh b-spectrum. For that, the ICRU values [2 ] 
of the 106Rh nucleus have been taken as reference. The spectrum 
was fitted with a fifth order polynomial serie expansion 
5 4 3 2( )P E a E b E c E d E e E f= ´ + ´ + ´ + ´ + ´ +  
where the coefficients of the fit were: 
0.026776, 0.290614, 0.930780, 0.38568, 1.49044, 0.427923a b c d e f= - = = - = = =
 
Figure I- 9: Beta spectrum of 106Rh 
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I.1.3. The ophthalmic applicators 
The details of the ophthalmic applicators are given in Figure I- 10, and they are shown shematically 
in Figure I- 12. 
The ophthalmic applicators are manufactured by BEBIG GmbH. The activity of the plaques is 
electrodeposited on a 0.2 mm thick Ag substrate mounted on to a 0.7 mm Ag backing and covered 
with a 0.1 mm thick Ag window. The active diameter and the radius of curvature for all the 16 
plaque models are mentioned in Table I- 4. 
Treatments performed at Centre Jean Perrin of Clermont-Ferrand use in priority CCA and CCB 
applicators. 
 
Table I- 4: Description of the BEBIG ophthalmic applicators 
 
Figure I- 10: Scheme of an ophthalmic applicator 
 
 
Figure I- 11: Photos of some 106Ru/106Rh ophthalmic applicators
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Figure I- 12: 16 types of Ru-106 ophthalmic plaques. The radioactive area is marked hatched.
I.1.4. Dose prescription and treatment efficacy 
I.1.4.A. The Collaborative Ocular Melanoma Study (COMS) 
In 1986, a COMS [3 ] sponsored by the National Eye Institute of the National Institute for Health 
among which 40 clinical centres of the United States and Canada participate, elaborate a 
prospective study in United states. The goal was to study the efficacy of the ocular brachytherapy 
treatments versus enucleation for the patient survival and the apparition of cancer metastasis. 
Enrollment of patients with ciliary body or choroidal melanoma began in 1987. Patients have been 
sorted into three groups: those with small, medium, and large tumors. Those with small tumors (up 
to 3 mm in elevation) are observed for tumor growth; if growth is sufficient to place the tumor in 
the medium group and if the patient remains eligible and willing, the eye is randomized for 
treatment. Patients with medium tumors (those between 3 mm and 8 mm in thickness and up to 16 
mm in largest basal diameter) are randomized to either enucleation or plaque irradiation with iodine 
125. Nearly 1200 patients have been enrolled in this arm of the study. Large tumors (greater than 8 
mm in elevation and 16 mm in basal diameter) are randomized to receive external irradiation or no 
irradiation before standard enucleation. The cutoff between medium and large tumors was changed 
from 8-mm elevation to 10-mm elevation partway through the recruitment period. Before 
enrollment closed in 1994, 1003 patients were enrolled in this arm of the study.  
Part of the purpose of the COMS is to assess the natural history of the tumor in order to design 
effective management and also to evaluate therapy in a nonbiased fashion. Also, the study includes 
assessment of quality of life as well as vision retention in patients whose tumors are irradiated. As 
with other multicenter trials, one objective is to standardize observation and treatment criteria so 
that patients from different institutions can be compared. Developing standardized criteria is the 
only way we will be able to obtain sufficient data on a large enough group of patients to draw valid 
conclusions about natural history and treatment. A weakness of the study is that external charged 
particle treatment was not included. Also, there is no plan to compare efficacy of different plaque 
isotopes.  
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More than a decade has passed since recruitment for the COMS began. Some preliminary results 
have been published recently, and one report confirms the very high accuracy rate of clinical 
diagnosis. Report No. 18 refers to I-125 Brachytherapy for Medium Choroidal Melanoma. No 
report has been written yet concerning 106Ru/106Rh brachytherapy. 
I.1.4.B. Treatments using 106Ru/106Rh ophthalmic applicators 
In Europe, Lommatzcsh pionneered the treatment of uveal melanomas in 1964 using ruthenium 
applicators, introducing these beta-emitting nuclides with directives for treatment [4 ][5 ][6 ][7 ].  As 
his results were good, many centres in Europe strated to use these applicators in the late 1970s and 
early 1980s [8 ][9 ][10 ][11 ][12 ][13 ][14 ]. 
A study performed in the Netherlands between 1984 and 1995 [1 ] explains the results of the 
treatment of 101 patients with 106Ru/106Rh ophthalmic applicators. It was demonstered that the 
tumour prominence and the given top dose were correlated strongly with the treatment outcome. 
93.9 % of the patients were treated successfully resulting in a clinically complete remission in 
62.6% whereas 31.3% kept a stable disease. It was shown that at a tumour top dose < 120 Gy five 
out of 22 tumours (23%) failed to respond, whereas at ³ 120 Gy treatment only one out of 77 
tumours did not respond, indicating that the top dose has to be at least 120 Gy. Müller et al. [15 
]and Pötter et al. [16 ] used a top dose of 150 Gy to obtain comparable results. 
A high success rate is also of vital importance as treatment failures are associated with a 2- to 3-fold 
increase in the rate of occurences of metastases [4 ]. 
The visual acuity is also of great importance for the patient’s quality of life. The Netheralnds study 
shown that a useful visual acuity of ³ 0.3 was preserved in 51.5% of the 99 patients and visual 
acuity > 0.5 in 42.4% of the patients. Furthermore, a final visual acuity > 0.5 was found in 22.7% of 
the patients by Lommatzsch et al. [5 ] and in 27% by Pötter at al.[16 ]. It has been demonstered that 
the visual outcome after irradiation was better for peripherally than for centrally located tumours. 
The main reason for loss of central vision is radiation retinopathy in the macular area. The macular 
capillaries are highly sensitive to radiation and may be damaged by a low dose of 11-17 Gy [17 ][18 
]. 
An application of beta sources is the treatment of choroidal melanoma and retinoblastoma. These 
malignant diseases are treated with concave ruthenium plaques that can be stitched to the eye. At 
low dose rate the tumor is irradiated during a period varying from two up to fourteen days, 
depending on the activity of the source. The highenergy beta emitter ruthenium is used because 
tumor thickness can be up to 10 mm. Because the largest part of the absorbed dose is deposited in 
the first 10 mm from the source surface, and most tumors are situated at the posterior side of the 
eyeball, the absorbed dose to the lens usually is limited. The prescribed dose for treating choroidal 
melanoma is typically 80-120 Gy at the apex of the tumor. This is, however, limited by the surface 
dose that should not exceed 1000 Gy. In the literature the use of strontium sources for treatment of 
eye melanoma has also been reported [19 ]. Of all eye melanoma, uveal melanoma has the highest 
(yearly) incidence with six out of one million people. Over a period of 15 years the overall survival 
rate is estimated to be about 48% and the cumulative local treatment failure is 37%. Ciliar body 
melanoma (near the iris) and melanoma close to the optical nerve require use of applicators with a 
special shape. 
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I.1.4.C. Other radiotherapy and brachytherapy treatments 
I.1.4.C.1. Ocular brachytherapy using 125I ophthalmic plaques 
COMS-type gold seeds carriers typically can be ordered in 5 sizes in 12-20 mm diameters. 125I 
rice-sized radioactive seeds are purchased and glued into the eye-plaque or seed carrier. The gold of 
the eye-plaque will block more than 99% of the radiation to the back and sides, creating a 
directional source. The active surface (facing us) is sewn onto the eye beneath the base of the 
intraocular tumor (just like it is done for 106Ru plaques). 
125I is a low energy gammas emitter, the energies of the gamma rays generated are 27.202 keV 
(40.6 %), 27.472 keV (75.7 %), 30.98 keV (20.2 %), 31.71 keV (4.39 %) and 35.492 keV (6.68 %). 
Comparative study have been performed between the both brachytherapy using 125I seeds and 
106Ru. 
 
Figure I- 13: COMS iodine-125 ophthalmic applicators 
 
Figure I- 14: Iodine-125 seeds in a COMS ophthalmic 
applicator.  
      
Figure I- 15: Encapsulation of the iodine-125 seeds in a 
COMS applicator
 
With the 106Ru, Lommatzsch recomands 80-100 Gy at the top of the tumour with a dose rate of 5-10 
Gy/h. With the iodine 125, by following the COMS protocol, for tumours of 3 to 5 mm in thickness, 
it is suitable to deliver 100 Gy at 5 mm in depth with a dose rate between 0.5 and 1.25 Gy/h to this 
point. Biological effects of such treatments have been compared in a lot of publications. We will 
refer here to the work performed at Centre Jean Perrin in collaboration with the ophthalmological 
clinic of the CHU G. Montpied of Clermont-Ferrand [20 ]. In that study, rabbit eyes have been 
irradiated with a CCZ ophthalmic plaques and with COMS iodine applicators of 12 mm in diameter. 
At 1 mm in depth the total dose deposited are comparable (317,1 Gy for 106Ru ophthalmic plaques 
and 326,9 Gy for iodine plaques), it is also the case for dose rate (3.07 Gy/h and 2.34 Gy/h 
respectively). The dose deposited is different for the both irradiation. High dose gradient from 106Ru 
plaques implies that the decreasing of the dose is very blunt, whereas for the iodine irradiation the 
decreasing of the dose is progressive (at 9mm far from the plaque, 6,6 Gy are delivered with the 
ruthenium-106 and 40,7 Gy with the iodine-125). The more important lesions have been observed 
using ruthenium-106 plaques whereas the dose delivered are lower for iodine-125. One year after 
the irradiation, irreversible lesions of the retina and optic nerve have been observed with the 
ruthenium-106 plaques whereas only few lesions of the external retina layer were observed. 
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In clinical routine, iodine-125 plaques are used for larger tumors (thicknesses ranging from 6.5 mm 
to 11 mm). Those plaques show a dose fall-off factor of 2 per 4-5 mm water. For 100 Gy at the apex 
of an 8 mm tumor, the average sclera dose is 400 Gy, a value which is well tolerated. It has been 
reported that severe complications at neighboring structures overcame with iodine-125 plaque 
therapy [21 ][22 ]. For the tumour located in the posterior part of the eye, this treatment implicates a 
significant risk of retinopathy or opticus radiopathy. For large tumors, the necessity of applying a 
sufficient apex dose increases the risk to irradiate soft tissues at higher dose in the eye. 
Improvements on the plaque were done to limit the side effects during the irradiation. X-ray 
fluorescent foils were introduced into the applicator design (above or below the seeds depending on 
the backscatter or transmitted radiation want to be modified). The foils absorbed the photons of 
iodine-125 and emitted characteristic energy x-rays (15.8 keV for zirconium foil). The increasing 
cross-section of the photoelectric effect for these lower energies reduced the absorption lengths, 
causing a steeper dose fall-off. The dose distributions were then similar to those obtained with 
103Pd radionuclide. 
Despite those modifications, it has been noticed that the iodine-125 plaques were not optimal for the 
treatments of the tumour in the range from 6.5 mm to 9 mm. It appeared also that dose to 
radiosensitive tissue in the eye remained high to preserve healthy tissues. 
Initial mortality findings published in 2001 (COMS Report No. 18) showed that survival rates for 
radiation therapy (I-125 brachytherapy) and enucleation (removal of the eye) are about the same. 
The five-year survival rate of patients who were treated with either radiation therapy or eye removal 
was 82 percent, considerably better than the 70 percent five-year survival rate that had been 
projected when the study was designed in 1985. Compared to immediate loss of vision when the 
eye is removed, eyes treated with radiation steadily lost vision gradually, with 63 percent having 
visual acuity of 20/200 or worse by three years after treatment (COMS Report No. 16). 
I.1.4.C.2. Ocular brachytherapy using bi-nuclide radioactive ophthalmic applicators 
Eye plaque brachytherapy with the radioactive nuclides 106Ru/106Rh and 125I has been established as 
an other standard treatment modality for years. In order to optimize the spatial dose distribution, the 
characteristics of both nuclides are exploited. The goal is to obtain a dose sparing effect at large 
distances contrary to iodine-125 plaques and give tolerable doses within the target volume and to 
the sclera for which the dose shouldn’t overlapp 1200 Gy during all the treatment. 
The bi-nuclide applicator consists of three elements. The design is based on a carrier calotte made 
of a gold alloy with lateral shielding rings and two fixation eyes for suturing the plaque onto the 
bulbus. In this calotte a 106Ru/106Rh plaque BEBIG type without fixation eyes is inserted and fixed 
with some silicone. The third part is a silicone inset with 8-12 symmetrically arranged iodine seeds, 
Amersham type 6711. 
However the dosimetry of a bi-nuclide applicator is difficult because the beta radiation of 106Ru has 
to pass through the silicone layer and the iodine seeds and because the iodine radiation is influenced 
by the silver 106Ru plaque (x-ray fluorescence effect), it has been shown that this type of applicators 
offers a considerable dose reduction at radiosensitive structures within the eye. 
For tumour thicknesses comprise between 6.5 and 9 mm, a bi-nuclide plaque reaches 40-80% of the 
dose deposition of an iodine-125 plaque at the opposite point. For tumours of 6.5 mm a sclera dose 
reduction of 20-30% can be observed compared to 106Ru/106Rh plaques. The gain of such plaque 
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comparing to iodine plaque is that the dose at the lens decreases much faster for the bi-nuclide than 
for iodine-125 due to the steep dose fall-off of 106Ru/106Rh. For tumours of thicknesses of 10 mm 
and more, the application of bi-nuclide plaques is not advantageous. 
I.1.4.C.3. The protontherapy 
For specific location of choroidal melanoma and for high tumour thicknesses, the protontherapy is 
prefered to the brachytherapy.  
 
Figure I- 16: Ocular nozzle and proton beam line schema of 
the Nice hadrontherapy platform. 
 
 
Figure I- 17: The ocular nozzle
 
The cyclotron provides 65 MeV protons. The accelerator is a fixed frequency 25 MHz isochronous 
cyclotron with a peak voltage of 50 kV. Negative hydrogen ions are produced by an external source, 
axially injected and accelerated to 65 MeV. They are then extracted by a 60´10- 6 g cm- 2 carbon 
stripping foil and exiting protons are transported down the beam line to the treatment room. The 
main components of the ocular beam line are presented in Figure I- 16 and Figure I- 17. The 
incoming proton beam is completely defocused after the achromatic focal point of the last 90° 
bending magnet (M4), regarded as the source point for calculations, before reaching a 5´ 10- 3 -cm-
thick tantalum foil. These elements act together as a single scatterer providing 12 m behind away, a 
flat beam at the irradiation point. In the vacuum part, upstream from the ocular nozzle, the beam 
aperture is limited to 5 cm diameter by two graphite collimators. Afterwards, decreasing the 
collimator size from 5 to 4.5 and finally 3.4 cm, only the central part of the beam is selected. The 
ocular nozzle part of the beam line is composed two brass collimators opened to a 5 cm diameter; a 
kapton foil 1.3´10-2 cm thick, sparing vacuum to air, also closes its upstream extremity. This 
empty box holds the range shifter and the Lucite propeller, which are used to adapt the incoming 
proton beam in range and modulation. The following part contains two monitor chambers made of 
aluminized mylar, two 4.5 cm brass collimators, and an exiting copper nozzle of 3.4 cm internal 
diameter, which supports the final individual brass patient collimator.  
In the clinical situation spread out Bragg peaks (SOBP) are required to provide homogeneous 
irradiation in depth, z. The corresponding depthdose curve D(z) is obtained by adding the weighted 
contribution of individual (i) reduced Bragg peak curves Di(z) achieved by the introduction of a 
thickness of Lucite t, 
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where pi represents the weighting factor of the reduced peak i, n is the total number of peaks needed 
to achieve a defined length of SOBP t, z is the depth of irradiation, and s is the thickness step of 
reducing material equal to 8´10-2 cm. 
The irradiation is preceded by the location of the tumour and the positionning of tantale clips 
sutured to the sclera. 
60 Gy are delivered to the tumour in four fractions and four days. A security margin of 2.5 mm 
around the tumour is fixed. The enucleation rate is about 10 % after a protontherapy treatment. 
I.2. QUALITY CONTROL AND DOSE MEASUREMENTS 
I.2.1. Measurements 
Physical measurements of dose distribution on ophthalmic applicators are difficult because the dose 
gradient of 106Ru/106Rh plaques is very high on a region of therapeutic interest which is less than 25 
mm. This requires very small detectors that have to be positionned very precisely whith a good 
determination of the effective point of measurement. 
In the following sections, detectors for absorbed dose measurements on beta sources are described 
with a special emphasis on radiochromic films used particularly in the quality control of the source 
and the plastic scintillators use for the dose distribution measurement and calibration thanks to their 
small design. 
I.2.1.A. Absolute calibration of beta sources: the extrapolation chamber 
Extrapolation chambers are considered as the standard device for the dosimetry of beta particle 
sources. The extrapolation chamber allows the ionization volume to be varied to a vanishingly small 
amount. The US standards laboratory NIST uses such a chamber as a primary standard for the 
calibration of sealed beta sources [23 ]. Recently, at the NMi a primary standard was built for the 
dosimetry of clinical sealed beta sources, based on the principle of the extrapolation chamber.  
The extrapolation chamber is a parallel plate ionization chamber with variable air volume. The 
ionization volume is determined by the distance between the parallel plates and by the effective area 
of the central electrode. The central electrode, surrounded by a guard electrode, is situated at the 
center of one of the parallel plates. The other parallel plate is the entrance window of the ionization 
chamber. The central and guard electrodes are constructed from an electrically conductive and 
water equivalent plastic resembling polystyrene, called D400 (Standard Imaging, Middleton, WI, 
USA). The ionization current collected by the central electrode is measured at different plate 
distances and extrapolated to zero air volume, in order to approximate the ideal Bragg-Gray 
conditions. The extrapolated ionization current is a measure for the absorbed dose to air, taking into 
account the geometrical conditions and the materials used to construct the extrapolation chamber. 
The absorbed dose rate to water ( WD
·
) can be determined from the ionization current measurements 
using Bragg-Gray theory. 
The extrapolation chamber requires no radiation calibration but the area of the collecting electrode 
is a major limitation in the absolute accuracy of the measurements.  
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I.2.1.B. Radiochromic film (RCF) 
Radiochromic film has turned into the most widely used method for verification of the uniformity 
of beta sources, it can also be used to measure dose deposited by sources in solid phantoms. 
GafChromicTM (ISP Technologies Inc., Wayne, NJ, USA) is available in single and double layer 
versions. A thin layer of almost colorless emulsion is coated on a Polyethylene TerePhthalate (PTP) 
backing, forming a single or double sandwich of layers. The sensitive emulsion layer is between 7 
and 40 µm thick, depending on the type of film. The total thickness can be between 0.1-0.3 mm. 
The sensitive layer turns blue upon irradiation and does not require post-irradiation processing. The 
sensitivity of most films is low, so that an absorbed dose of at least tens of Grays is needed. Films 
can be calibrated for absolute measurements [24 ]. The energy dependence is low in the energy 
range relevant for clinical beta sources (100 keV - 2 MeV, [42]). A major limitation of the 
radiochromic film is the variation in thickness of the sensitive layer resulting in a non-uniform 
response (up to 15% for MD55-2 [43]). Because of these variations, the measurement uncertainty is 
estimated to be about 7.5% for the absorbed dose. For absolute measurements a delay of at least 24 
hours needs to be taken into account to minimize effects of incomplete film development. 
Uniformity information can be quantified by film densitometry [25 ].  
Uniformity variations of more than ~ 10% can be detected (qualitatively) by the eye. In the 
literature radiochromic film measurements are described for both ophthalmic [26 ][27 ] and 
intravascular [24 ][28 ] sources.  
RCF will be used to measure dose deposited in a solid water phantom for some ophthalmic 
applicators. 
MD55-2 radiochromic films are used for the dosimetry of 106Ru/106Rh plaques. They support a dose 
range from 3 to 100 Gy, of 278 µm in thickness with two sensitive layers. 
I.2.1.B.1. Radiochromic film calibrations 
Because radiochromic film is tissue equivalent over a broad energy range, it was calibrated with a 
regular 6 MV photon beam of a linear accelerator. All measurements were performed at the dose 
maximum of the PDD. A fit was performed according to Equation I- 2, in which Dw is the absorbed 
dose to water and OD is the optical density according to the red channel of the RGB (Red-Green-
Blue) based TIF file. This channel has the strongest correlation with darkening of the film. The OD 
was calculated using Equation I- 1. T in this equation is transmittance, expressing the ratio of the 
pixel value at a given absorbed dose and the pixel value of film that was not irradiated. 
 10 log( )OD T= -  Equation I- 1 
 2 3
1 2 3wD a bOD b O D b OD= + + +  Equation I- 2 
The calibration curve is unique for each densitometer-film combination. Based on the specific shape 
of the curve a choice can be made for a 2nd or 3rd order polynomial. The uncertainty shown by the 
error bars is a combination of film non-uniformity and scanner noise. 
A flatbed transmission scanner is currently used for film densitometry (EPSON Expression 1680). 
This scanner is used in 3´16 bit mode with 12 bit colour depth. The films are scanned at 300 dpi 
(pixel size 0.08´0.08 mm2). 
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I.2.1.C. Thermoluminescence dosimeters (TLD) 
Although most hospitals make use of TLDs for dosimetry, dedicated TLDs are required for 
measurements on beta sources [28 ][29 ][30 ][31 ]. The most important property of these TLDs is 
their small size (as small as 0.1 mm thickness and 1 mm diameter for the active volume), which 
makes them suitable for determining the spatial distribution of the dose around a source. Due to 
their small size and water-equivalence these TLDs give only very small distortions of the radiation 
field. The TLDs are usually embedded in a solid phantom. Readout is performed afterwards by 
heating the TLDs and measuring the amount of light with a photomultiplier. Calibration is carried 
out in a clinical MeV electron beam or with a calibrated beta source. TLDs can also be used for 
measurements on concave ophthalmic applicators [32 ][33 ][34 ]. The estimated standard 
uncertainty (1s) is between 8-10% depending on knowledge of precise phantom dimensions and 
TLD characteristics [29 ]. 
I.2.1.D. Alanine pellets 
Dosimetry with alanine is based on the relative and non-destructive measurement of stable free 
radicals produced by radiation [29 ][35 ]. These dosemeters are read out with an X-band Electron 
Paramagnetic Resonance (EPR) spectrometer with a scan range of 0-2 mT. Advantages of the 
detector are the linear response and absence of energy dependence. The detector has a diameter of 
about 5 mm and a thickness of about 1 mm. These dimensions also determine the sensitive volume 
and therefore are a disadvantage of the method. Another disadvantage is the low sensitivity, because 
the EPR signal is very weak. An estimated standard uncertainty of 5-7% (1s) can be expected in the 
region between 10-20 Gy [29 ]. 
I.2.1.E. Scintillator 
Plastic scintillators were first introduced for dosimetry of brachytherapy sources at the University of 
Essen [36 ]. Plastic scintillator probes have a homogeneous sensitive volume with approximate 
water equivalence in density and atomic composition. Due to their high sensitivity, scintillation 
detectors can be designed with probe volumes as small as 1 mm3 or even less. Scintillation detectors 
offer the great advantage that they can be read out directly. The detector is based on light being 
generated in the plastic scintillator volume. The scintillation light is detected with a photomultiplier 
through an optical fiber that have to give sufficient transmission of scintillation light and the 
simultaneous Cerenkov compensation. The Essen plastic scintillator has a thickness of 0.4 mm and 
a diameter of 1 mm. Measurements on ophthalmic applicators (125I and 106Ru/106Rh) showed a 
contribution of Cherenkov light of no more than 2%.  
The OptidosTM is a commercial version of this system developed by PTW (PTW Freiburg GmbH, 
Freiburg, Germany). The plastic scintillator has a detection volume of 0.8 mm3 (1 mm thickness and 
1 mm diameter) and an outer diameter of 5.2 mm, in the last years plastic scintillator size was 
reduced to 1 mm in diameter and 0.5 mm in height (BEBIG calibration). The system has no blind 
fiber for Cherenkov compensation. Measurements need to be accompanied by check source 
measurements to correct for changes in the detector sensitivity. The estimated standard uncertainty 
(1s) is 3% for relative dosimetry with the larger plastic scintillator without Cherenkov 
compensation and 7% for the smaller scintillator with Cherenkov compensation [29 ]. 
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I.2.1.F. Diamond 
The diamond detector is based on radiosensitive resistance of the detection material. One of the 
characteristics of the detector is its high sensitivity. The variation of the stopping power ratio to 
water in the range 0.02-5 MeV is less than 2%. Diamond detectors are produced individually and 
their exact dimensions may vary. The detection volume is several mm3, but the exact position of the 
detection volume is one of the larger contributors to the overall estimated standard uncertainty of 
10% (1s) [29 ]. Dose rates higher than 25 mGy s-1 are underestimated, because of electron-hole 
recombination [29 ]. Pre-irradiation with 5-10 Gy is required to obtain a reliable signal. The 
detector can be used for measurements on concave ophthalmic applicators [37 ], despite the large 
outer diameter (~ 7 mm according to PTW specifications) [38 ]. 
I.2.1.G. Diode 
Most semiconductor detectors are based on p-type silicon, on one side doped with n-type material in 
order to create a p-n junction or a diode. During irradiation a current is present in the depletion layer 
(effective thickness of about 60 µm). There is significant variation in stopping power ratio between 
silicon and water (up to 8% between 0.5 and 3.5 MeV) [2 ]. Pre-irradiation with about 5 kGy by the 
manufacturer is needed for reliable response [66]. The standard uncertainty is estimated to be 5% 
(1s or 2 s, ?k is not quoted) [29]. With an outer diameter of 4-7 mm and a sensitive area of 1-2 mm 
(specifications Scanditronix Medical AB, Uppsala, Sweden) [39 ], the detector can be used for 
measurements on concave sources [8 ]. The sensitivity of the detector decreases with time, requiring 
regular recalibrations. Sensitivity decrease can be ~5% in a period of 5 years [40 ], but depends on 
the intensity of use. The detector is only used for relative measurements within the daily practice of 
radiotherapy. 
I.2.1.H. Polymer gel 
In a few cases BANG® polymer gels (MGS Research, Guilford, CT, USA) have been used for 3D-
dosimetry of line sources or ophthalmic plaques [41 ]. The technique is based on the radiation 
induced free-radical chain polymerization of acrylic monomers. The NMR relaxation of water 
protons in the gel is strongly affected by this polymerization. The proton relaxation rate (R2) of 
water protons in the polymerized gel increases linearly with absorbed dose, independent of dose 
rate or radiation quality. After irradiation, 3D dose maps can be created based on R2 maps 
calculated from MRI spin-echo images [42 ][43 ]. In a single measurement the full dose map of a 
source can be registered. For a ruthenium plaque an irradiation time of ~1h is needed [41 ]. The 
technique is highly sensitive to environmental conditions such as temperature, light and oxygen 
concentration. The resolution of the MRI scanner is one of the bottlenecks of the measurement. The 
introduction of a dedicated microscopic 3D optical density scanner for this application would 
significantly improve resolution and reduce environmental dependence [43 ]. 
I.2.1.I. Well type ionization chamber 
The well-type or re-entrant ionization chamber is an ionization chamber with a well-shape. In 
radiotherapy it is the most frequently used method for calibrating line sources or seeds. The 
detection volume surrounds the source, resulting in a high detection efficiency compared with other 
ionization chambers. Well-type ionization chambers can be either open (vented) or pressurized. 
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Pressurized chambers are filled with for example argon to increase the chamber sensitivity to 
photons. In contrast to pressurized chambers a temperature and pressure correction needs to be 
applied to open chambers. Well-type ionization chamber measurements do not provide spatial 
information. Usually, measurements are performed at the sweet spot of the chamber, where the 
response is at a maximum. The length of the “sweet spot” is one of the important characteristics of a 
well-type ionization chamber. The measurements are relatively simple and reliable (expanded 
standard uncertainty in the activity of 5% (2s)). The well-type ionization chamber was originally 
designed for measuring source activity. A conversion factor can be used to translate the activity to 
an absorbed dose rate in water. The dose rate at the reference point is calculated from the 
ionizations collected in the detection volume around the entire line source, under the assumption of 
a perfectly uniform activity distribution throughout the source. The insert that is used to fix the 
source at the measurement position is part of the calibration and– for beta sources – determines to a 
large extent the signal strength and whether mainly beta radiation or bremsstrahlung is detected 
within the ionization volume. Different detector inserts have been compared by Standard Imaging 
(Middleton, WI, USA) and the University of Wisconsin. It was concluded that the use of a 2 mm 
acrylic insert was the optimum between signal strength and reproducibility. This insert blocks 
clinically irrelevant low-energy betas and shows high reproducibility during the measurements. 
I.2.2. Utilization of detectors in clinical routine 
I.2.2.A. Detectors not well adapted 
I.2.2.A.1. Extrapolation chamber 
The extrapolation chamber is the primary standard for beta dosimetry. It is not commercially 
available with electrodes smaller than 1 cm. 
I.2.2.A.2. Polymer gel 
The use of polymer gel is still very uncommon within the daily practice of radiotherapy. 
Disadvantages are the strong environmental dependence and the offline measurements. The 
availability of read-out devices may be a bottleneck for application of polymer gels, although 
desktop optical readout devices are under development. 
I.2.2.A.3. TLD 
Although sensitive and reliable measurements can be made with TLDs, the processing time is an 
important disadvantage of this method. Furthermore, TLDs that have been used for dosimetry of 
beta sources are different in size from the regular TLDs in radiotherapy and are not readily 
available. The TLDs only give information for one point; for measuring the spatial distribution 
around the source more TLDs are required. 
I.2.2.A.4. Diamond detector 
The required pre-irradiation and possible underestimation of the dose rate are disadvantages of this 
detector. The detector is not part of the standard equipment, although it is (limited) commercially 
available. The diameter of the active volume of 2-4 mm is another limitation for these 
measurements. 
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I.2.2.A.5. Alanine 
Few institutes have experience with this detector. The low sensitivity, offline measurements and 
limited availability are disadvantages. 
I.2.2.B. Well adapted detectors 
I.2.2.B.1. Well-type ionization chamber 
The well-type ionization chamber is widely used for the calibration of line sources and is known for 
its high reproducibility. All Guidant users are equipped with a well-type ionization chamber. A 
disadvantage of the detector is that an additional measurement is required for determination of the 
source non-uniformity. 
I.2.2.B.2. Plastic scintillator 
This versatile detector is suitable for measurements on high and low dose rate sources and for 
strength, depth dose and uniformity measurements. It also has a high degree of water equivalence 
and a relatively small detector volume. It is generally available and routinely used by Novoste for 
source strength and uniformity verifications on their line sources. 
I.2.2.B.3. Plane-parallel ionization chamber 
The use of this detector for strength and depth dose measurements has been described as mentioned 
above. This detector is available in most radiotherapy departments. Size and sensitivity of the 
detector are factors that limit its use to high dose rates and relatively large sources such as the 
planar strontium applicators. 
I.2.2.B.4. Diode 
This detector is used in many institutes for relative measurements of the dose distribution of 
accelerator beams. Its use is also mentioned in the literature and the detector has a relatively high 
spatial resolution. In practice, the detector is rarely used for absolute measurements. 
I.2.2.B.5. Radiochromic film 
Radiochromic film is widely used for uniformity measurements on beta sources. Guidant users are 
provided with film by the manufacturer. The film is easy to use, but quantitative evaluation is more 
elaborate, as densitometry has to be applied. 
I.2.3. Phantom characterizations 
Following the recommendations described in the AAPM Report no.511 and in IAEA Technical 
Reports no.398 (TRS-398), water is defined as the reference medium, however, the water substitute 
solid phantoms (solid phantoms) are discouraged because they have the largest discrepancies in the 
determinations of absorbed dose. 
Anyway the use of solid water phantoms is necessary for measurements with radiochromic films. 
Measurements in water are done with the plastic scintillators (BEBIG calibration) and diodes. 
Table I- 5 represents different water equivalent plastics used for dosimetric applications. The WT1 
(GAMMEX RMI, Wisconsin, USA), RMI-457 (GAMMEX RMI, Wisconsin, USA), Plastic Water 
(Nuclear Associate, New York, USA), Virtual Water (Med-Tech, Iowa, USA), WE211 (Kyoto 
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Kagaku, Kyoto, Japan), Polystyrene, Polymethyl Methacrylate (PMMA) and MixDP are 
commercially available materials. 
 
Table I- 5: Water-equivalent plastics used for dosimetric measurements. 
 
Figure I- 18, Figure I- 19 represent the NIST phantoms in WT1 plastic water used for the dosimetry 
of 106Ru/106Rh ophthalmic applicators using radiochromic films. Figure I- 20 shows an other 
phantom configuration used at the NYU Cornell Medical Center, RMI457 plastic was used. MD55-
2 Gafchromic films of 278 µm in thickness are inserted between phantom slices to test the non-
uniformity (see section I.3.1.c) of the source and make some dosimetric studies. An elaboration of a 
phantom in virtual water is under development at Laboratoire de Physique Corpusculaire in order to 
perform quality control on ophthalmic beta sources at Centre Jean Perrin. 
 
Figure I- 18: NIST WT1 solid phantoms used for 
depth dose measurements. 
Image courtesy of C. Soares, NIST, Washington DC 
 
 
Figure I- 19: NIST WT1 solid phantom with 
different cap heights used for the concave 
ophthalmic applicators. 
Image courtesy of C. Soares, NIST, Washington DC
 
Figure I- 20: RMI457 solid water phantom and GAFCHROMIC MD-55 film, 
Image courtesy of Samuel Trichter, NYU Cornell Medical Center, New York 
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I.3. Quality control of ophthalmic applicators 
After the reception of ophthalmic sources, quality control on sources are highly recommended in 
order to check their uniformity and the dose distribution provided. Even if the sources are delivered 
with a calibration sheet provided by the manufacturer, it has been shown in the Report 14 of the 
Netherlands Commission on Radiation Dosimetry [44 ] that differences are observed by double 
checking the source strength and the non-uniformity of the sources. 
I.3.1. Parameters to study 
I.3.1.A. Average radius (R50) 
The average radius (R50) is defined as the mean radius of the 50% isodose contour of a dose 
distribution in which 100% is given by the maximum absorbed dose. A precise description of how 
this radius can be calculated is given in the section on source non-uniformity (see below). 
I.3.1.B. Source strength 
The source strength of all planar and concave sources is defined as the dose rate at (r, z) = (0,1) mm 
following the recommendations of the ICRU report [45 ]. The IAEA [46 ] recommends using the 
same point but recognizes that performing measurements at these short distances is a difficult task. 
Effectively, the curvature of concave sources and minimum thickness of spacers limit the 
possibilities of performing measurements at 1 mm, even if detector dimensions are sufficiently 
small. The recommendation that is to determine the source strength at (r0, z0) = (0,2) mm has been 
followed by the BEBIG company in their measurements protocols, the reference dose rate is 
measured at r=0 and z=2 mm.  
I.3.1.B.1. Source strength specification by manufacturer 
BEBIG introduced a new standard in 2002 based on the NIST measurement protocol. Uncertainties 
of both old and new standards are specified. BEBIG is the only manufacturer that actually specifies 
activity and provides a conversion factor for the absorbed dose to water. Other manufacturers 
specify in a reference point in water. 
I.3.1.C. Source non-uniformity 
The source non-uniformity for eye applicators, as introduced in the ICRU report, is given by 
Equation I- 4: 
 
max min( ) / 100%avgICRUU D D D
· · ·
= - ´  Equation I- 3 
in which:  
UICRU = source non-uniformity (%), maxD
·
= maximum absorbed dose rate, minD
·
= minimum 
absorbed dose rate, avgD
·
= average absorbed dose rate. 
The report recommends that the non-uniformity should be determined at a specified depth over a 
specified area of the source. Although the principle can also be used for measurements with a larger 
detector such as a diode, this concept is especially suitable for scanned radiochromic films. The 
ICRU proposes to determine the non-uniformity at z = 1 mm depth, using 80% of R50. The 
calculation of the source non-uniformity is performed as follows: 
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The maximum absorbed dose rate max maxD
·
 is determined. 
The pixels with 50% of max maxD
·
 are determined (for films, absorbed dose values are used, instead 
of dose rate values). 
The coordinate of the field center (xc,yc) is determined through: 
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In which n is the number of rows and m is the number of columns with a dose rate larger than or 
equal to 50% of max maxD
·
. The sign indicates the position with respect to the source center. 
The average radius R50 can be calculated through: 
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in which q is the total number of 50% pixels. 
Finally, analogous to the concept for line sources, Equation I- 3 is applied, in which minD
·
, maxD
·
, 
avgD
·
are taken from the pixels with a distance smaller than 0.8R50 to (xc,yc). The ICRU recommends 
a maximum source non-uniformity UICRU of 20%. 
For concave sources the concept of non-uniformity can be applied in different ways: 
§ in a concave surface parallel to the source surface, 
§ in a plane perpendicular to the source axis. 
Although uniformity measurements should preferably be performed parallel to the source surface, 
film measurements are only possible in a plane. In the literature, film measurements on concave 
ophthalmic sources are described in [29 ].  
The concept of non-uniformity proposed by the ICRU has some disadvantages: 
§ The non-uniformity does not give the maximum possible deviation from the source strength, 
but only the difference between minimum and maximum. 
§ The normalization is performed based on an average of the absorbed dose within the area of 
interest and can therefore not be related directly to the source strength that is defined in a 
point on the axis. 
I.3.1.D. Source asymmetry 
It was decided by the NCS (Netherlands Commission on Radiation Dosimetry) in their report 14 to 
use a wider margin for the non-uniformity and to introduce an additional parameter for evaluating 
sources with respect to the asymmetry of the dose distribution. 
To quantify the asymmetry of the dose distribution of ophthalmic sources, the parameter for source 
asymmetry UAS is introduced: 
 { }max minmax ( ) ( ) / ( ) 100%avgASU D r D r D r· · ·æ ö= - ´ç ÷è ø  Equation I- 6 
In this expression the variation of the dose rate is calculated over a circle with a radius r. The 
maximum of this variation, with r ranging from zero to 0.8R50, determines the value of the 
asymmetry UAS. The asymmetry is defined parallel to the source surface. For concave sources, a 
film measurement in a plane may be used as an approximation of UAS. 
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I.3.2. Ophthalmic applicators calibration performed by BEBIG 
All the plaque manufactured by the BEBIG company are supplied with a calibration sheet. 
Until January 2002, BEBIG measured the energy dose rate with a plastic scintillation detector with 
a height and a diameter of 2 mm each using the calibration of the standardization office of the 
former GDR (ASMW). This calibrabion uses special calibration factors for each type of plaque to 
compensate for the different geometry and the effects caused by the strong gradient. 
Since the beginning of 2002, the NIST became able to perform measurements using plastic 
scintillator. All the ophthalmic plaques have been measured with the 2 mm detector and ASMW 
calibration as well as with a new high resolution 0.5 mm detector (height h= 0.5mm; diameter d= 
1mm) and NIST calibration. This comparison involved changes for the dose prescription. 
Since May 2002, BEBIG delivers the new protocols of measurements generated with the NIST 
calibrated 0.5 mm detector. 
Eleven points of measurements are performed on the central axis of each applicator at 0.6; 1.0; 2.0; 
3.0; 4.0; 5.0; 6.0; 7.0; 8.0; 9.0; 10.0 mm (instead of four points of measurement with the ASMW 
protocol); interpolated data are obtained at 0.0 and 3.5 mm by fitting the measurement points with a 
third order polynome 
 2
1 2 3exp( )y P P x P x= + +  Equation I- 7 
The energy dose rate distribution over the surface of the plaque is measured and displayed at more 
points. 
With introduction to the new NIST calibration, the measurements uncertainty provided by BEBIG 
has improved and is now only ± 20%. NIST itself issues an uncertainty of ± 15% to their calibration 
measurements. 
I.3.2.A. Dose prescription modifications with NIST and ASMW calibrations 
The two calibrations give different energy dose rates for a large number of plaque types, some of 
the differences are with the ASMW measurement uncertainty (± 30%). 
Concersion factors F(type,z) from the ASMW calibrated measurement to the NIST calibrated 
measurement have been calculated depending on the plaque type and the distance z from the inner 
concave plaque surface along the central axis. The conversion factors were calculated by dividing 
the measurement results for the energy dose rate DR(type,z) with 0.5 mm detector and NIST 
calibration with the measurement results for the energy dose rate DR(type,z) with 2 mm detector 
and ASMW calibration: 
 ( , ) ( , ) / ( , )i i NIST i i ASMW i iF type z DR type z DR type z=  Equation I- 8 
where typei is the plaque type and zi the distance from the inner concave plaque surface along the 
central axis. 
As a consequence, the typical doses prescribed according to the ASMW calibrated measurements 
may not yield the same treatment results with the new NIST calibrated measurements results and 
therefore need adjustment. The conversion of the prescribed dose D is therefore defined as: 
 ( , ) ( , ) ( , )NIST i i ASMW i i i iD type z D type z F type z= ´  Equation I- 9 
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Table I- 6: Conversion factor F(type,z) depending on plaque type and distance z from the inner concave plaque 
surface along the central axis. 
 
It has been shown [47 ] that measurements using radiochromic films performed on a CCX plaque 
found a dose disagreement of 55%-110% with manufacturer specifications, equivalent to a depth 
displacement of up to 1.5 mm. This difference is clinically significant, since the dose fall-off is 
about 30% per millimeter, and the thickness of tumors treated is up to 5-6 mm. The center of the 
distribution was displaced by 3 mm from the central axis of the plaque. The measurements also 
show a steep dose decrease at the edges of the plaque, which should be accounted for when 
selecting the proper plaque diameter for treatment.  
Furthermore, the measurements performed for the Report 145 of the NCS commision on the 
recently calibrated sources are more consistent with the certificate, indicating that the new BEBIG 
standard is more accurate than the old standard. 
I.4. TREATMENT PLANNING USING PLAQUE SIMULATOR 
An existing 3D ophthalmic plaque dosimetry simulator [48 ][49 ][50 ], originally developed for 
modelling the dosimetry of ocular tumors using gold plaques using I-125 seeds, was modified to 
study the Ru applicators and their dosimetry [51 ]. This software is distributed under the title 
“Plaque Simulator” by BEBIG GmbH, and runs on Apple Macintosh personal computers under 
either OS-9 or OS-X. 
This treatment planning system is currently used in Centre Jean Perrin for the dosimetry involved 
by an ocular brachytherapy using 106Ru/106Rh ophthalmic applicators. 
This software is able to estimate dose to water by summing a “patch source” dose function (kernel), 
derived from a combination of Monte Carlo modeling and plastic scintillators measurements (points 
of measurements part of the BEBIG calibration sheet) over a discrete number of overlapping 
patches uniformly distributed over the active surface of the applicator. 
I.4.1. Positioning the plaque on the eye 
The position of the plaque during treatment is defined using a spherical projection of the eye. The 
ocular dimensions, the size of the tumor and its position in the eye can be specified from CT or MRI 
images (see Figure I- 21). The position of the geometrical centre of a plaque during treatment is 
specified by “grabbing” the image of the plaque on the screen using the mouse and “dragging” the 
plaque to the desired location. Alternatively, the plaque can be automatically centered over the 
tumour. 
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Figure I- 21: Eye contours, position and size determination on a CT image with Plaque Simulator.
 
I.4.2. Calculating and displaying the dose distribution 
Transverse, saggittal or coronal planar cross-sections may be requested, as well as any plane 
transecting the eye diametrically. This planar surfaces are displayed within a translucent eye. Dose 
calculation matrices ranging from 20´20 to 160´160 points may be selected. Bilinear interpolation 
is used to estimate isodose contours between the calculated points. Isodoses are displayed following 
a color scale. The display can be normalized to the dose at any location on the central axis or to the 
apex of the tumor. A table of dose values at 1 mm intervals on the central axis of the plaque is 
available. 
I.4.2.A. The patch source dose function 
The patch source dose function is not correlated to the point source dose function (calculated using 
Monte Carlo in Chapter IV for monoenergetic electrons and 106Rh polyenergetic point source) as it 
represents the macroscopic behavior of a small disk-like region of radionuclide. 
This function includes an anisotropy term to account for the angular variation in scatter and 
attenuation as particles traverse the 0.1 mm silver window. The near field of the plaque is modeled 
with patches that are assimiled to small disk and the farfield with patch as a point. 
Applicators are approximated using discrete number of overlapping patches (300 to 1000) 
uniformly distributed over the active area of the applicator. Patches are positioned 0.2 mm below 
the concave surface of the applicator in a 0.1 µm thick layer, 0.1 mm below the concave side of the 
applicator. The distance between patch centers is typically about 0.6 mm. 
The dose rate at a point P in water surrounding an applicator is estimated by summing the dose rate 
delivered to that point from all the patch sources. 
The dose rate from any individual patch source can be expressed in the same way as it is 
recommended in the AAPM’s TG43 report [52 ]: 
 ( , ) ( , ) ( ) ( ) ( , )D r S s t A g r G r F rf f= ´ ´ ´ ´  Equation I- 10 
where r is the distance between point p and patch s (estimation of the distance between the patch 
center c and the point P). f is the angle between a vector n normal to the patch and a vector from c 
towards P. S(s,t) is the source strength (Bq) of patch s at time t. A is a calibration constant for the 
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applicator, g(r) is a radial dose function in nGy/Bq-h, G(r) is a geometry function and F(r,f) is an 
anisotropy function.  
We will describe each term of the Equation I- 10 and the way they are calculated. 
 
Figure I- 22: Patches inside an ophthalmic applicator. 
 
 
 
 
 
 
 
 
 
 
 
Figure I- 23: The angle f used to calculate F(r,f) is 
defined as the angle between a vector n originating at 
the effective center c of a patch and directed towards 
the center of the sphere to which the applicator 
conforms, and a vector from c to the dose calculation 
point p. r is the distance between c and p. 
I.4.2.A.1. The source strength S 
The source strength of each patch is defined as the apparent total activity of the applicator (as 
specified by the manufacturer) divided by the number of patches. 
I.4.2.A.2. The calibration constant A 
The calibration constant A is an empirically dimensionless factor between 0.9 and 1.0 chosen to 
scale the calculation of the software to match the measurement dose rates on the central axis of the 
applicator at 5 mm in depth. 
I.4.2.A.3. The geometry factor G(r)  
As described in the TG43 report, the geometry factor accounts for the variation of relative dose due 
to the spatial distribution of activity within the source, ignoring photon absorption and scattering in 
the source structure. It is defined as in Equation I- 11: 
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Where r(r’) represents the density of radioactivity at the point p(r’)=p(x’,y’,z’) within the source 
and V denotes integration over the source core. dV’ is a volume element located at r’ in the source. 
When the distribution of the source can be approximated by a point source G(r,q) reduces to : 
 
2
1
( , )G r
r
q =  Equation I- 12 
where r is the distance between a calculation point and a patch. Equation I- 12 is used at large 
distance from the applicator for which each patch is considered as a point located at c. At low 
distance, near the surface of the applicator, the use of Equation I- 12 results in erroneously high 
values, especially near the concave surface. The limit between the nearfield and the farfield of each 
applicator has been determined to be a distance xn equal to 1.4 to 1.8 depending of the source 
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geometry for symmetric applicators. In the nearfield, patch sources are geometrically treated as 
small thin circular disk (r»1mm) with a uniform activity and a radius R, and a plane (r»0mm), 
Equation I- 13 evaluates this feature: 
 2( ) (( ( )) 1)/n nG r m x r x= - +  Equation I- 13 
 
Figure I- 24: Plotted equations of the geometry factor G(r) over the range 0 to 8mm. The solid line is the inverse 
square function (Equation I- 12) and the dashed line is the linear function (Equation I- 13) for the model CCB 
applicator with crossover distance xn=1.65 mm and slope m=2. 
Equation I- 13 best reproduces measured dosimetry. 
I.4.2.A.4. The radial dose function g(r)  
As described in the TG43 report, the radial dose function g(r) accounts for the effect of absorption 
and scatter in the medium along the transverse axis of the source, it is defined in Equation I- 14: 
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The radial dose function applies only to transverse axis, only for points with an angle of q0,  which is 
equal to p/2. This function defines the falloff of dose rate along the transverse axis due to 
absorption and scattering in the medium. 
For Plaque Simulator treatment planning, the radial dose function g(r) is estimated from a beta point 
source dose function which was calculated using a Monte Carlo model, results of Cross with 
ACCEPT code [53 ]. This approximation has been done by assuming that all of a patch’s activity is 
assigned to a point at its effective centre and so r is the distance between the point p and the 
effective centre c of each patch. 
A comparison between ACCEPT results and GATE calculations is done in Chapter IV concerning 
the beta point source dose kernel dosimetry. 
I.4.2.A.5. The anisotropy function F(r,j) 
Following the TG43 report, the anisotropy function accounts for the anisotropy of dose distribution 
around the source, including the effects of absorption and scatter in the medium. It is defined as: 
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Equation I- 15 describes the variation in dose as a function of polar angle relative to the transverse 
plane. F(r,q) is defined as unity on the transverse plane and his value off the transverse plane 
typically decreases as r decreases, as q approaches 0° or 180°, as encapsulation thickness increases 
and as particle energy decreases.  
Typically, for ophthalmic applicator sources, the scattering and absorption of beta particles 
emanating from the source are caused by the 0.1 mm silver window. 
The anisotropy function is managed by three parameters, a crossover distance xa (»2mm) which 
delineates between a nearfield and farfield, a bias parameter which governs the rate of transition 
from nearfield to farfield and an angular shift which is added to angle f to account for the 
manufacturing differences between individual applicators and applicators whose spherical radius of 
curvature is greater than 12 mm. In the nearfield of a patch, the anisotropy function is constrained to 
remain close to 1.0 at all angles. The anisotropy function is normalized to a value of 1.0 in the 
direction n which represents the minimum path through the applicator. 
I.4.2.B. Dosimetric calculations with Plaque Simulator in practice 
Protocol of measurements sheets provided by the manufacturer BEBIG are entered in the planning 
software. The required data consists of the nominal source activity (MBq), the calibration date, 11 
measurements at 0.6, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0 and 10.0 mm of central axis dose rate 
(mGy/min) and 33 points of measurements on a concentric sphere 1.0 mm above the plaque’s inner 
surface (those points are given in % and are normalized to the central point). 
 
 
Figure I- 25: Central axis measurements entered in the 
Plaque Simulator treatment planning system. 
 
Figure I- 26: Surface measurements entered in the 
Plaque Simulator treatment planning system. 
 
A scripted optimization process enables a fit to the central axis measurements (see ). The relative 
error associated is told to be under 2% in the majority of the cases. 
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Figure I- 27: Prescription window. The date of the 
plaque insertion and the date of the plaque removal are 
fixed to obtain 400 Gy at 1 mm in depth on the central 
axis using a CCA applicator. 
 
Figure I- 28: Isodoses obtained with Plaque Simulator 
with a CCA applicator.
As an example and following the ophthalmologist’s prescription for the treatment of a medium size 
ocular melanoma, 400 Gy are delivered at 1mm in depth on the central axis. The dates of the plaque 
insertion and removal are defined to fit the recommendation of the pratician. Dose to the apex and 
the duration of the irradiation are systematically checked. 
Figure I- 27 represents a typical ocular brachytherapy prescription entered in Plaque Simulator 
using a CCA applicator. The patient will have to keep the plaque during 117.4 hours to be treated 
with a dose of 400 Gy at 1 mm in depth on the central axis. Dose delivered to organs at risk such 
like the macula and the optic nerve are specified by the software depending of the position of the 
tumour in the eye. 
Two dimensional dose distributions are then available on the scleral and retinal surfaces (see Figure 
I- 28).  
CONCLUSION 
Ocular brachytherapy treatments using 106Ru/106Rh have proved there efficacy in the treatment of 
ocular melanoma and benign tumours. The utilization of such ophthalmic plaques is however a 
difficult task because of the high dose gradient delivered on very small size tissues. That’s why we 
have shown in this chapter that accurate measurements and dose calculations using treatment 
planning is of great importance in such treatment if we want to benefit of the special characteristics 
of a beta emitting radioactive source. 
With such preliminary explanations and observations, we make appear the fact that determining 
with high accuracy the dose distribution in a model eye is of necessary importance. Monte Carlo 
simulations are the key issue for dose calculations despite of their time consumming. In order to 
develop a convivial tool intended to medical physicists and ophthalmologists for their clinical 
routine dose calculation, we took advantage of a grid environment to parallelize Monte Carlo 
calculations on geographically distributed processors and store medical images with metadata on 
distributed storage resources. Description of the grid entity and its usage for treatment planning 
issues is detailed in the following chapter. 
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Chapter II.          
 
 
Grid technologies and health related 
applications 
 
 
INTRODUCTION 
Computers are still used much less extensively than they could be and it’s obvious to say that the 
average computing environment remains inadequate for computationally sophisticated purposes. To 
answer computational, large and distributed storage, and sharing datasets needs, the grid 
technologies appeared.  
From a technology point of view, radiotherapy is a highly complex procedure, involving a variety 
of computational operations for data gathering, processing and control. The modularity of the 
treatment process and the need of large data sets from different sources and nature (physics, 
mathematics, bio-statistics, biology, and medicine) make it a privileged candidate for healthgrid 
applications. In an enlarged Europe sharing data, expertise and computational resources will be a 
significant factor for a successful cost containment and improved access to a high overall quality of 
care in radiotherapy. It is an ideal tool for harmonising the cancer treatment as well as providing a 
common base for research collaboration.  
Adding the fact that Monte Carlo simulations are more and more integrated to the elaboration of 
accurate treatment planning for specific applications, such like ocular brachytherapy using 
106Ru/106Rh ophthalmic applicators, the grid could be a great alternative to reduce the computation 
time involved by such calculations. 
Based on the HealthGrid White paper published in 2005 [50 ], the first part of this chapter is 
dedicated to grid for health related applications. Issues concerning eHealth are described first; the 
healthGrid association federating a large community of researchers implied in grid improvements 
for health applications is detailed next, to finish with a description of what it has been envisaged to 
use grids for radiotherapy planning.   
After an overview of the grid computing projects that appeared in Europe over the last four years, 
the European DataGrid Project (EDG) intended to develop middleware of a grid infrastructure is 
described in a next part. A subparts is intended to achievements realized over the period of the 
project to build the grid infrastructure.  
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The third part describes the nature of the production grid infrastructure EGEE by highlighting the 
computing efficacy involved by using the grid. A discussion on the specific needs for the 
management of medical imaging and metadata on the grid with the first achievements performed in 
that domain is then done. 
II.1. GRID FOR HEALTH RELATED APPLICATIONS  
II.1.1. The challenges for eHealth 
eHealth is becoming the 3rd industrial pillar of healthcare after phramaceutical and medical imaging 
device industries. The eHealth retailers predict a benefit of more than $22B (US) for the year 2004. 
Most of the challenges encounter in eHealth applications must be overcome in the next year and can 
benefit of the grid technologies. 
§ First of all, the Health related data require long-term and large storage to store patient 
records comprising images, bio-signals, plain text, videos, photographs or other forms of 
digital data.  
§ The medical data (images, programs, etc…) must be linked with databases with medical 
information. Federated databases should then emerge between clinical centres, laboratories 
and hospitals. 
§ Medical information can require high bandwidth connections to meet minimum delay 
requirements for the pratician. That implies that technologies must converge to a high-
bandwidth communication networks between healthcare centres. 
§ Obtain the same degree of electronic management of patient data over healthcare centres. 
The Electronic Patient Record (EPR) enabling a coherent access to and the management of 
the complete patient information should achieve an easier access to data. The 
standardization of the data recording should also be reached in a near future to facilitate 
their management and utilization by each medical actors. 
§ Last but not least, the security is the most important issue. The access to the information 
must be performed only by authorized and authenticated persons and data must be encrypted 
to guarantee its confidentiality and integrity. Personal data are identified to be any piece of 
information in which its owner can be identified, either directly or in combination with 
information that is available or otherwise located. Furthermore, electronic archiving of 
personal data is strictly regulated by the European and national laws. 
 
Grids applied to health related applications must provide services or middleware components that 
deal with the specific problems arising in the processing of biomedical data. 
Although the ultimate goal for eHealth in Europe would be the creation of a single health grid, i.e. a 
grid comprising all eHealth resources, naturally including security and authorization features to 
handle subsidiarity of independent nodes of the healthgrid, the development path will mostly likely 
include a set of specific health grids with perhaps rudimentary inter-grid interaction/interoperational 
capabilities.   
The future evolution of grid technologies addresses most precisely problems that are very 
appropriate for healthcare. Health grid applications are oriented to both the individualized 
healthcare and the epidemiology analysis. Individualized healthcare is improved by the efficient and 
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secure combination of immediate availability of personal clinical information and widespread 
availability of advanced services for diagnostic and therapy. Epidemiology healthgrids combine the 
information from a wide population to extract the knowledge that can lead to the discovery of new 
correlations between symptoms, diseases, genetic features or any other clinical data. 
Facing to the growing of interest into providing grid tools for health related applications in the last 
Grid projects, the Healthgrid entity has born. In the following we will refer to the “Healthgrid white 
paper” [42 ] and to related work in the EDG [50 ] and EGEE project to describe what are the 
prospects and requirements to turn a grid to a health related grid. In the next part, we will focus 
especially on the computational models in medical imaging and therapy to be deployed in a grid 
environment. The Healthgrid white paper and all the information related to grid computing 
dedicated to health applications can be found on the healthgrid web site http://www.healthgrid.org. 
II.1.2. The HealthGrid association 
Over the last four years, a community of researchers working on Grid and High Performance 
Computing technologies started discussing the barriers and opportunities that grid technologies 
must face and exploit for the development of health-related applications. This interest lead to the 
first Healthgrid conference, held in Lyon, France, on January 16th-17th, 2003, with the focus of 
creating increased awareness about the possibilities and advantages linked to the deployment of grid 
technologies in health, ultimately targeting the creation of a European/international grid 
infrastructure for health. 
The topics of this conference converged with the position of the eHealth division of the European 
Commission, whose mandate from the Lisbon Meeting was “To develop an intelligent environment 
that enables ubiquitous management of citizens’ health status, and to assist health professionals in 
coping with some major challenges, risk management and the integration into clinical practice of 
advances in health knowledge.” In this context "Health" involves not only clinical procedures but 
covers the whole range of information from molecular level (genetic and proteomic information) 
over cells and tissues, to the individual and finally the population level (social healthcare). Grid 
technology offers the opportunity to create a common working backbone for all different members 
of this large "health family" and will hopefully lead to an increased awareness and interoperability 
among disciplines. 
The first HealthGrid conference led to the creation of the Healthgrid association, a non-profit 
research association legally incorporated in France but formed from the broad community of 
European researchers and institutions sharing expertise in health grids.  
After the second Healthgrid conference, held in Clermont-Ferrand on January 29th-30th, 2004, the 
need for a “white paper” on the current status and prospective of health grids was raised. Over fifty 
experts from different areas of grid technologies, eHealth applications and the medical world were 
invited to contribute to the preparation of this document. 
The association named Healthgrid [43 ] and governed by the French law of July 1, 1901 and the 
decree of August 16, 1901 has been founded in April 2003. 
The goal of the association is: 
§ to contribute to the structuring of the European Research Area for health, by, for example, 
favouring the use of grid technologies; 
Chapter II.Grid technologies and health related applications 
 46
§ to offer active support and guidelines for the extension of the association's members 
contribution to society; 
§ to supply information and other services relevant to the members of the association; 
§ to encourage co-operation between the members of the association, notably in the creation 
of effective networks of collaboration; 
§ create partnerships of benefit to both higher education and scientific research in the field of 
the health in its broadest sense, both within Europe and in the rest of the world. 
 
The HealthGrid is the coordinator of the SHARE project, part of the IST call 4, FP6 2004, intended 
to “Supporting and structuring HealthGrid Activities & Research in Europe: developing a 
roadmap”. The project will define a comprehensive and detailed European R&D roadmap, covering 
both technology and policy aspects, to guide and promote beneficial EU-wide uptake of HealthGrid 
technologies and applications into health research, and into health care service provision. 
II.1.3. Health grids: a grid scenario for radiotherapy planning (from the 
HealthGrid white paper [50 ]) 
II.1.3.A. Processing simulations in a grid environment 
Research communities in biocomputing or biomodelling and simulation have a strong need for 
resources that can be provided through the grid. Compliance with medical information standards is 
necessary for accessing large databases. There are many consolidated and emerging standards that 
must be taken into account. Complex and multimedia information such as images, signals, videos, 
etc. is clearly a target for grid and is more sensitive to data formats. 
Finally, flexibility is needed for the control of VOs at a large level. The management of resources 
should be more precise and dynamic, depending on many criteria such as urgency, users’ 
authorization or other administrative policies. 
Biocomputing medical applications are one of the family of healthgrid applications. The maturity of 
genetics and biomedical technologies brings them closer to medicine, and grand-challenge 
computing problems of biocomputing are currently being migrated to grid. Biomedical modelling 
and simulation is another important area for grid applications. For this second application, we will 
highlight in the following part the issues that have to reach to enable therapy planning in routine 
using a grid infrastructure. 
II.1.3.B. Issues for therapy planning 
Many human body models have been developed for therapy planning. Examples of numerical 
simulation used by health practitioners include radio-surgery/radio-therapy planning, 
electromagnetic source localisation (an inverse procedure to identify areas of disorder within the 
brain based on external EEG/MEG measurements), reconstructive maxillofacial surgery, etc. 
Today, most developments are in the transition between research use and clinical use.  Grid can be 
used to provide access to appropriate computational services and deliver these to medical users. 
Healthgrid would need large scale deployment studies to allow the evaluation of a wide range of 
requirements, including local deployment aspects and practical experience with production grid use. 
The major challenges will be to ensure that services can be delivered into the user’s workplace in an 
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appropriate, ergonomic manner and that security, policy and legal constraints related to the use of 
patient data are fulfilled. 
II.1.3.B.1. A grid scenario for radiotherapy planning and treatment  
Radiotherapy and Genes 
Presently patients are treated with standardised radiation doses. Gene profiling may enable an 
individualised adjustment of the dose so as to achieve tumour control in patients with a low 
radiosensitivity and avoid severe side effects in patients with above average sensitivity to radiation. 
In a first step a grid structure should allow research groups, each focusing on different molecular 
mechanisms, to access data in the distributed infrastructure for comparison studies.   
In a next step users should be able to submit the results of predictive tests for analysis to a shared 
software and expert platform for radiosensitivity grading. A similar approach can be followed for 
other aspects clinical decision making such as the assessment a tumour’s capacity for metastatic 
spread. For rapidly metastasising tumours, systemic (chemotherapy) treatment needs to be 
associated to the locally delivered radiotherapy. New tests now under development, predicting on 
the basis of gene profiling which tumours are most likely to metastasise, can make 60% of the 
chemotherapy currently administered e.g. for breast cancer, redundant. However, it takes a highly 
specialised team to interpret the results of these tests correctly. Grid-supported consultation of 
libraries of gene profiles or, alternatively, tele-consulting services offer also in these case excellent 
perspectives. 
Medical images for radiotherapy treatments 
Tissue electron density provided by CT scanning is still needed to calculate the dose delivered by 
photon and electron beams. To define the planning target volume (PTV) and organs-at-risk (OAR), 
new imaging modalities based on MR-imaging, MR-spectroscopy and PET are complementary to 
CT scans and become a requirement for high-precision high-dose radiotherapy. In contrast to CT 
scanning, the latter imaging modalities are available only in reference centres for reasons of cost 
and expertise. 
To secure access for all patients to optimal imaging for radiotherapy planning, the coordinating 
centre could perform a grid-mediated selection of an imaging centre, and the resulting 
complementary image acquisitions could be sent back through the grid.  
To reproduce the patient positioning and perform the complementary imaging in treatment-relevant 
conditions, the patient-individual immobilisation devices could be physically sent to the imaging 
centre. Alternatively, a retrospective registration grid service could be used to realign all the images 
in the relevant coordinate system. Many tools have been developed for computer-aided definition of 
PTV and OAR including anatomical atlases that can be warped to the patient-individual anatomy. A 
grid could make such tools and their upgrades in due time available to all groups involved in PTV 
and OAR definition. Nodes on the grid that provide expert help for patient-related problems in 
defining PTV and OAR are needed. 
Monte Carlo simulations for dose calculation 
Accuracy of Monte Carlo (MC) dose computation is excellent, provided that the computing power 
is sufficient to allow for enough runs to reduce the statistical noise. The grid is a natural alternative 
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to costly parallel computers. In this way, MC dose computations could become standard for 
radiotherapy quality assurance (QA), planning, and plan optimisation years before individual 
departments could afford a local investment that is capable to support MC. Requirements needed 
for such deployment include the existence of a service level agreement between the departments 
and the grid providers by which the grid level of performances in terms of security, stability and 
response time is guaranteed. Each delivery centre manages the commissioning of its own treatment 
units and incorporates both mechanical-physical and dosimetric parameters, including uncertainty 
flags, into an identity card that is accessible through the grid. This identity card will allow 
treatment-planning providers and computation services to establish, refine or fit their computational 
model of the linear accelerator. The identity card also contains the reference data so that periodical 
quality assurance (QA) procedures could make sure that the machine performs accordingly. One 
might expect that the cooperation through the grid between QA providers and delivery centres will 
streamline the QA procedures and harmonise the identity cards over the different accelerator types. 
The quality assurance of the treatment can also benefit from the grid, even if it is patient specific: 
once a treatment plan has been designed, some locations are selected to measure the dose level in a 
physical phantom that replaces the patient during the first treatment session.  
In parallel, the coordinating centre consults the grid for an independent dose computation service to 
compute the dose in the same set of points in the phantom. The comparison of the measured dose to 
the computed fractional dose is performed automatically at the delivery centre and will be submitted 
to the coordinating centre.  In case of violation of tolerances, the treatment plan will be recomputed 
in patient and phantom by a second dose computation service in the grid. Alternatively, the 
coordinating centre may consult the grid for a virtual treatment at another delivery centre. 
Conclusion 
Those previous requirements describe what should be enable in a near future to compute and 
manage radiotherapy treatments in a grid environment. The work to perform in order to achieve all 
those described aspects is still long but, in this thesis, we began to reflect and develop tools for 
ocular brachytherapy treatments using Monte Carlo. In the following parts of this chapter, we 
enumerate and discuss what are the grid functionnalities enabled at this date and argue about the 
grid computing efficacy and medical data management, the two main aspects involved in 
radiotherapy treatments nowadays. 
II.2. GRID COMPUTING IN EUROPE 
The computational grid can be associated by analogy to an electric power grid. Computation is 
equivalent to electricity and transmission and distribution technologies could be combined to grid 
capabilities. We talk about an infrastructure because computational grid is concerned by large-scale 
pooling resources but also by people, connections, data, etc. Different levels can be found for grid 
users: grid developers in charge of designing and implementing the basic services, tool developers 
who create the compilers, libraries that implement the programming models and services used by 
application developers, application developers who construct grid enabled applications and 
components, end users who will not write programs, but will use grid-enabled applications that 
make use of grid resources and services and finally system administrators who manage the 
infrastructure on which computational grids operate. All these features require a significant 
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hardware infrastructure for interconnections and software infrastructure to monitor and control this 
entity. Furthermore, grids have to develop a middleware layer capable of adressing application 
requirements coming from different scientific communities such as High Energy Physics, Earth 
Observation and Biomedical applications for which the requirements are surely the most complex 
and the most challenging for middleware developers. 
II.2.1. European and national grid projects 
Since 2000, the European Commission has been financing Grid research under the fifth research 
framework program (FP5) with more than 50 million Euros, as part of the European Union's 
Information Society Technologies (IST) research [1 ]. In FP5, the focus was mainly on technology 
development and application pilots. The main projects in FP5 were the European Data Grid [2 ], 
GridLab [3 ], EUROGrid [4 ], CROSSGrid [5 ] and DATATAG [6 ]. 
In FP6, beginning in 2002 and extending to 2006, the European Union is funding Grid research with 
more than 140 million Euros, following a technology push/application pull approach (i.e., 
developing the underlying technologies and Grid-enabling "real-world" applications). The crucial 
enabling infrastructure for the current research Grid projects is GEANT [7 ], the world's most 
powerful research network which links more than 3,000 research institutions across Europe. 
In the first phase, the European Union has launched several significant Grid initiatives which help 
structure the Grid infrastructures in Europe and build upon the already established GEANT 
infrastructure, most notably EGEE (Enabling Grids for E-Science) [8 ] [9 ] and DEISA (operating a 
distributed/Grid terascale supercomputing facility across Europe) [10 ] . 
In 2004, the EU has approved another 12 FP6 Grid projects, among them four major projects with a 
focus on Grid infrastructure technologies that will create a critical mass of expertise and resources 
from across Europe: 
 
§ CoreGrid is a "network of excellence" addressing longer term Grid research, creating the 
foundations for the next-generation Grids toward 2010 and beyond. The project brings 
together existing Grid research communities by creating virtual centers of excellence.  
§ NextGrid is an integrated project focusing on the underlying technologies of the Next 
Generation Grid, aiming to deliver a new Grid architecture by the end of the decade. The 
work addresses security and business models, taking into account requirements from sectors 
such as finance and media.  
§ Akogrimo is developing mobile Grid architectures and services. Building on Europe's 
strengths in mobile communications, the project will demonstrate a vision of dynamic 
virtual organizations in pilot applications in e-health and e-learning.  
§ SIMDAT is an integrated project developing generic Grid technologies for industry in the 
areas of data integration, collaboration and knowledge discovery. The focus is on the use of 
Grids to solve complex problems in important sectors such as aerospace, automotive, 
pharmacology and meteorology. 
In addition, seven smaller projects (K-WF Grid, UniGrids, HPC4U, inteliGrid, OntoGrid, 
DataMining Grid and Provenance) focus on specific targets, such as knowledge extraction, 
workflows, data mining, collaboration, trust and security. 
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With the UK e-Science projects (investments of more than 118 million pounds) a vast variety of 
Grid research, middleware, applications and industry projects born such as: DAME (Distributed 
Aircraft Maintenance Environment); GridCast (Grid for television/radio broadcasting); RiskGrid 
(for risk assessment calculations in financial services); GRIA (Grid Resources for Industrial 
Applications); MyGrid (a Grid portal for Bioinformatics research); and OGSA-DAI (Grid 
Resources for data access and integration). 
At GGF12 [11 ] in Berlin in the spring of 2004, the German Minister for Education and Research 
announced a five-year, 100-million-Euro e-Science program. Germany started as early as 1996 with 
the development of UNICORE [12 ], a uniform access infrastructure connecting German 
supercomputer and research centers. Germany is now investing a larger portion of the 100 million 
Euros in the development of D-Grid, a countrywide general Grid research infrastructure and Grid 
services initiative, along with several community Grids for community-specific middleware and 
Grid-enabled applications that focus on specific research areas. 
 
Other national and regional Grid initiatives are: the French Grid5000 project, the e-Toile projects 
the Instruire project (for the Auvergne region); the Italian GRID.IT; the DutchGrid and the 40-
million-Euro Dutch VL-e project to develop a virtual laboratory for e-Science in the Netherlands; 
the Grid-Ireland MarineGrid, CosmoGrid and WebCom-G projects; the NorduGrid with its 
Advanced Resource Connector (ARC) Grid middleware used by SweGrid, Estonian Grid, M-Grid 
in Finland, the Danish Production Grid and others; the Austrian Grid Initiative with focus on 
infrastructure, middleware and applications, and its ASKALON Grid application development and 
computing environment; Poland's PROGRESS Grid, combining resources in Krakow, Poznan, Lodz 
and other cities via its powerful PIONEER network; and the SEE-Grid for South Eastern European 
Grid-enabled e-Infrastructure Development, with partners from Greece, Bulgaria, Romania, Turkey, 
Hungary and Yugoslavia. 
Europe now has a long-term, coordinated and shared Grid R&D vision, mission, strategy, roadmap 
and funding, driven by the European Commission's IST Framework Programmes 5, 6 and 7 (the 
latter will start in 2007). 
II.2.2. The European Datagrid Project (EDG) 
The European Datagrid IST project [2 ] has came to completion at the end of March 2004 after a 
final review by the european commission. The main objective of the project was to develop a 
middleware layer capable of addressing application requirements coming from three different 
communities: High Energy Physics, Earth Observation, and Biomedical applications. Early in the 
project, two communities were identified inside the biomedical applications working group: the 
bioinformatics and the medical imaging communities in which GATE applications was implied. 
The DataGrid project was organized in working groups (or Work packages) dedicated to the 
middleware (5 WPs), the testbed infrastructure (2 WPs), the application communities (3 WPs) and 
the project management (2 WPs). 
II.2.2.A. Organization 
Grid Work scheduling (WP1): 
The objectives of this WP were: 
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§ The optimisation of the program executing location in function of the availability of data, 
computing power and network. 
§ The allocation of resources necessary to execute programs. 
§ The development of a common interface to access resource management systems available 
on the grid. 
§ The definition of priorities and rights to access resources. 
Data Management (WP2): 
The goal of this work package was to specify, develop, integrate and test tools and middleware 
infrastructure to coherently manage and share petabyte-scale information volumes in high-
throughput production quality grid environments. The main purposes of this WP were to: 
§ allow a secure access to massive amounts of data in a universal global name space, 
§ move and replicate data at high speed from one geographical site to another, 
§ manage synchronisation of remote replicas. 
§ Develop a generic interface to heterogeneous mass storage management systems to enable 
seamless and efficient integration of distributed resources.  
Information and monitoring services (WP3): 
The aim of this workpackage was to specify, develop, integrate and test tools and infrastructure to 
enable end-user and administrator access to status and error information in a Grid environment and 
to provide an environment in which application monitoring can be carried out.  
Fabric management (WP4): 
The objective of this WP was to develop tools enabling the installation and the automated 
management of the middleware components on computing resources (clusters). 
Mass Storage management (WP5): 
This WP was in charge of identify the different storage modalities used by the different scientific 
communities to develop a management file system. 
The Integration testbed and support WP (WP6) was in charge of testing the grid middleware.  
As a fully functional Data Grid depend critically on the nature and quality of the underlying 
network. Performance (bandwidth, latency), security, quality of service, and reliability are all key 
factors. Data Grid use the European (GEANT) and national research network infrastructures to 
provide a large set of network services between the computational and data resources that form the 
Data Grid testbeds thanks to the WP7 (Network services). This WP is in charge of four tasks:  
§ Planning for provisioning of infrastructure for testbed operation 
§ Network and Transport Services 
§ Network and Grid traffic monitoring 
§ Grid Security 
The last three WPs group the scientific applications: Particle physics (LHC experiments) was 
represented by the WP8, the Earth Observation by the WP9 and biomedical applications, grouping 
medical imaging, bioinformatics and radiotherapy planification treatments using Monte Carlo was 
represented by WP10. GATE Monte Carlo applications have been designed to be one of the 
demonstration application presented to the European Comission during the final review of the EDG 
project in February 2004. 
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II.2.2.B. Achievements and lessons learned 
The EDG project grouped more than 500 users under 12 organisations with more than 600 persons 
trained to use the Grid infrastructure. One million of lines of code have been produced under 7 
major middleware releases. Six High Energy physics experiments, ten biomedical applications and 
five Earth Observation institutes joined the project as applications. At the end of the project the 
application testbed was constituted of 20 sites representing 1000 CPUs and 6 Mass storage systems. 
 
The early distributed testbed was based on Globus 1 [13 ]; after having established the Certification 
Authorities (see description in II.3.1.c.1), the development of the higher grid middleware started 
with the workload management, the data management, the Information services and the Fabric 
management (see description in II.3.1.b.2). The first testbed was deployed in the middle of 2001 on 
five sites and the first application evaluation started in december 2001 with a first High Energy 
Physics job run. In September 2001, the CERN launched the LCG project [15 ]. 
After the first review successfully passed on March 1st 2002, the evaluation by end users revealed 
the need to focus on the stability of the middleware rather than on new functionality. An open 
source license was established in June 2002 and the tutorial program started in July of the same year 
during GGF5. The second testbed was delivered at the end of 2002 (release 1.4.x) and allowed first 
production tests for applications. The 2nd annual review was successfully passed in February 2003 
and the third testbed (release 2.x) enabling a better scalability and reliability was released at the end 
of August 2003, the release 2.1 was produced at the end of November 2003. Many components of 
the EDG 2.0 were deployed in the LCG-1 services (during summer 2003) and the EDG 2.1 largely 
influenced the LCG-2 components at the beginning of 2004. The final DataGrid review was 
presented in February 2004 and successfully passed, GATE applications was one of the 
demonstration presented to the European Comission as part of the biomedical applications.  
The main assets the DataGrid project developed are: 
§ A large scale testbed continuously available throughout the project duration 
§ The elaboration of 21 Certification Authority infrastructure 
§ An innovative middleware with all the components described here after in part II.3.1.b.2. 
§ A software released under OSI approved open source license that facilitates wide-spread 
usage and encourages feedback. 
§ Application groups that are an integral part of the project contributing to all aspects of work. 
Lessons learned are numerous, one of them is that application groups need to be involved in all 
phases of the decisions. The middlewere prototypes should have been available for application 
testing early. The cross activities between the WPs need to be coordinated. Furthermore, it has been 
highlighted that different testbeds should have been distributed: one to test bleeding edge software  
and an other one for the production infrastructure. Security services need to be an integrated part 
from the very beginning of the project to fit requirements of users, in particularly for the biomedical 
community.  
The EGEE project, intended to develop a production testbed has benefited of the gained experience 
in the EDG project and also of the developments performed in the LCG-2 middleware. The EGEE 
production testbed is described in the next part with a discussion concerning the current grid 
computing efficacy.   
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II.3. THE EGEE (Enabling Grid for E-sciencE) PROJECT 
II.3.1. Presentation 
The EGEE Grid will be built on the EU Research Network GÉANT [7 ] and exploit Grid expertise 
generated by many EU, national and international Grid projects to date.  
Funded by the European Commission, the EGEE project community has been divided into 12 
partner federations, consisting of over 70 contractors and over 30 unfunded participants covering a 
wide-range of both scientific and industrial applications.  
The work being carried out in the project is organised into 11 activities. Two pilot application 
domains have been selected to guide the implementation and certify the performance and 
functionality of the evolving infrastructure. One is the Large Hadron Collider Computing Grid 
supporting physics experiments and the other is Biomedical, where several communities are facing 
equally daunting challenges to cope with the flood of bioinformatics and healthcare data.  
With funding of over 30 million euros from the European Commission, the project is one of the 
largest of its kind. EGEE is a two-year project conceived as part of a four-year programme, where 
the results of the first two years will provide the basis for assessing subsequent objectives and 
funding needs.  
II.3.1.A.1. EGEE activities 
EGEE is organized into eleven activities which come under three main areas: 
§ Networking Activities (NA) which are the management and coordination of all the 
commmunication aspects of the project  
§ Specific Service Activities (SA) are the support, operation and management of the Grid as 
well as the provision of network resources  
§ Research Activities (JRA) concentrate on Grid research and development  
 
EGEE Networking activities (NA): 
 
§ Networking Activity 1 (NA1) is the overall management of the project.  
§ Networking Activity 2 (NA2) is Information Dissemination and Outreach and includes tasks 
such as running the external website, organising conferences and managing the distribution 
of publications.  
§ Networking Activity 3 (NA3) is User Training and Induction and includes tasks such as 
organising on-site training and producing training and course material.  
§ Networking Activity 4 (NA4) is Application Identification and Support and includes tasks 
such as supporting pilot applications and identifying new users. GATE applications are part 
of the NA4. 
§ Networking Activity 5 (NA5) is Policy and International Cooperation and includes tasks 
such as liaising with parties interested in the EGEE project on an international level.  
 
EGEE Specific Service Activities (SA): 
§ Specific Service Activity 1 (SA1) is European Grid Support, Operation and Management 
and includes tasks such as grid monitoring and control and resource and user support. 
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§ Specific Service Activity 2 (SA2) is Network Resource Provision and includes tasks such as 
policies and service level agreements.  
 
EGEE Joint Research activities (JRA): 
§ Joint Research Activity 1 (JRA1) is Middleware Re-engineering and Integration, it includes 
tasks such as re-engineering existing middleware, integrating middleware, testing and 
validation.  
§ Joint Research Activity 2 (JRA2) is Quality Assurance, it includes tasks such as ensuring 
that processes, products and operation services conform to project requirements, standards 
and procedures.  
§ Joint Research Activity 3 (JRA3) is Security, it includes tasks such as developing security 
frameworks and policies and designing security mechanisms.  
§ Joint Research Activity 4 (JRA4) is Network Service Development, it includes tasks such as 
developing interfaces to the network and advance reservations of network connectivity in 
terms of bandwidth, duration and quality of service.  
 
Biomed applications are part of the NA4. In the following section we will describe the goals of the 
NA4 and the biomed applications implied in it. 
II.3.1.A.2. The objectives of the NA4 
§ Support the deployment and running of many different applications from various fields. 
At this date, twelve applications are part of the Biomed Applications. Each of them are part of 
sub-groups corresponding to different categories of applications: 
ü "Pilot" applications will be used to test EGEE middleware and to evaluate 
performances. GATE (Geant4 Applications for Tomographic Emission), CDSS 
(Clinical Decision Support System) and GPS@ (Grid Genomic Web Portal) are part 
of this category. 
ü "Internal" applications will come from within the project in the sense that they 
involve EGEE partners in collaboration with institutes external to the project. SiMRI 
3D (Magnetic Resonance Image simulator), gPTM 3D (interactive radiological 
image visualization and processing tool), xmipp_Mlrefine (Macromolecular 3D 
structure analysis), GridGRAMM (Molecular Docking web), GROCK ( Mass 
screenings of molecular interactions web), WISDOM (grid-enabled docking 
platform for in sillico drug discovery) and Xmipp_assign_multiple_CTFs 
(Micrographia CTF calculation) are part of this category. 
ü "External" applications which come from collaborations external to the project and 
will need support for deployment on EGEE. SPLATCHE (genome evolution 
modeling) and the Mammogrid project whom aim is to develop a European-wide 
database of mammograms that will be used to investigate a set of important 
healthcare applications as well as the potential of this Grid to support effective co-
working between healthcare professionals throughout the EU. 
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§ Provide necessary feedback to Middleware and Operations, this particularly the case for 
pilot applications. 
§ Produce deliverables:  
All along the 2 years of the duration of the project, report (deliverables) have to be 
presented. Concerning NA4, for which GATE and biomedical applications in general are 
part, six deliverables must be produced: during the third month of the project, DNA4.1 
(Definition of Common Application Interface and Planning Document) elaborates the 
milestones of the NA4 applications; during the sixth month of the project, then follows 
DNA4.2 (Target Application Sector Strategy document) and for the ninth, fifteenth and 
twenty fourth month of the project, DNA4.3.1-3 concerning EGEE Application Migration 
Progress report are produced.  
II.3.1.B. The EGEE infrastructure 
II.3.1.B.1. The Grid middleware 
The LCG middleware 
As the EDG middleware isn’t upgraded any longer since the end of the project in February 2004 
(EDG 2.1.2). The first middleware that will be used on the "production" infrastructure is the LHC 
Computing grid [14 ] [15 ] [16 ] [17 ] LCG-2. LCG-2 has been derived from the EDG middleware 
but offers a few more facilities and has better documentation. 
The Large Hadron Collider (LHC), which is being constructed at the European Organization for 
Particle Physics (CERN), will be the world’s largest and most powerful particle accelerator. The 
accelerator will start operation in 2007, and the experiments that will use it will generate large 
amounts of data. The processing of this data will require enormous computational and storage 
resources. The job of the LHC Computing Grid Project [15 ] –LCG– is to prepare the computing 
infrastructure for the simulation, processing and analysis of LHC data for all four of the LHC 
collaborations: ALICE, ATLAS, CMS and LHCB.  
The LCG-1 middleware (first version) was based on Globus 2.2.4 and benefited of the work done in 
EDG WP1 concerning the Resource Broker [18 ] and the Workload Management System (WMS) 
[19 ] implementation, the EDG WP2 Replica Management tools and the Glue 1.1 [24 ] information 
schema. The LCG modifications focus on the job managers to avoid shared filesystems problems, 
MDS and BDII-LDAP, Globus gatekeeper enhancements and bug fixes to EDG and Globus/VDT 
[25 ]. 
The LCG-2 release was available at the beginning of 2004, LCG-2 expands the services of LCG-1, 
with enough resources and functionality for the 2004 Computing Data Challenge. The LCG-2 
middleware provides the experience on operating and managing a global grid service and benefits 
of a development program driven by data challenge experience: the data handling, the strenghtening 
of the infrastructure and the users and entity management (VO). 
The EGEE infrastructure was entirely based in April 2004 on the LCG-2 middleware to migrate in 
the middle of 2005 to a new one called gLite [26 ]. 
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The EGEE middleware gLite: Lightweight middleware for grid computing 
The architecture of the EGEE Grid middleware is called gLite [26 ]. This middleware is influenced 
by the requirements of Grid applications, the ongoing work in the Global Grid Forum on the Open 
Grid Services Architecture as well as previous experience from other Grid projects such as the EU 
DataGrid (EDG) [2 ], the LHC Computing Grid (LCG) [15 ], AliEn [27 ], the Virtual Data Toolkit 
VDT [25 ] (including Globus [13 ] and Condor [28 ] and NorduGrid [29 ]. 
Taking advantage of the large scale data handling of the LCG-2 middleware, the gLite service is 
focused on data analysis. Figure II- 1 represents a schema of the Grid middleware evolution until 
2007.  
After a testing phase of the gLite prototype, the new middleware is supposed to integrate the grid in 
september 2005. 
This migration was decided to answer specific needs of the different scientific communities. 
 
Figure II- 1: Evolution of the EGEE middleware 
 
The gLite service decomposition has been largely influenced by the work performed in the LCG 
project (the requirements and technical assessment group on an “architectural roadmap for 
distributed analysis” (ARDA) [30 ]). Figure II- 2 depicts the high level services, which can 
thematically be grouped into 5 service groups. The services and machines associated to are 
described in II.3.1.b.2. 
 
Figure II- 2: gLite services 
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All the services should be deployed and used independently, allowing their exploitation in different 
contexts. As the gLite grid services follow a Service Oriented Architecture, the interoperability 
among Grid services will be facilitated. 
II.3.1.B.2. Machines and services part of the EGEE infrastructure 
The User Interface 
The User Interface (UI) is the gateway to the EGEE grid services. This machine hosts personal user 
account and user’s certificate. From the UI, a user can be authenticated and authorized to use the 
EGEE Grid resources. This is the component that allows users to access the functionalities offered 
by the Information, Workload and Data management services. It provides the Commands Line 
Interface (CLI) to perform the Grid operations. 
The Computing Element and Storage Element 
A Computing Element (CE) is defined as a Grid batch queue and it is identified by a pair 
<hostname>:<port>/<batch queue name>. This is currently used to define different queues for jobs 
of different lengths. Examples of CE names in Clermont-Ferrand site: 
clrce01.in2p3.fr:2119/jobmanager-lcgpbs-long 
clrce01.in2p3.fr:2119/jobmanager-lcgpbs-short 
 
A Computing Element is built usually on a homogeneous farm of computing nodes called Worker 
Nodes (WN) and a node acting as a Grid Gate (GG) or front-end to the rest of the Grid. The GG 
runs a Globus gatekeeper, the Globus GRAM (Globus Resource Allocation Manager) [Ref], the 
master server of a Local Resource Management System (LRMS), together with the a local Logging 
and Bookkeeping server (see ). The types of LRMS supported are the Portable batch System (PBS), 
the Load Sharing Facility (LSF) and Condor. While all WNs need only outbound connectivity, the 
Gate node must be accessible from outside the site. The GG is responsible for accepting jobs and 
dispatching them for execution to the WNs. On the WNs, all commands and Application 
Programming Interface (API) for performing actions on Grid resources and Grid data are available. 
Each EGEE site runs at least one CE and a farm of WNs behind it. 
 
A Storage Element (SE) provides uniform access and services to large storage spaces. The Storage 
Element may control large disk arrays, mass storage systems (MSS) and the like. Almost EGEE 
sites provide one or more SEs. A site can include at least a classic SE, which has a GSIFTP server 
[31 ].The GSIFTP protocol offers basically the functionality of FTP, i.e. used for the transfers of 
files, but enhanced to use GSI security. It is responsible for secure, fast and efficient file transfer 
to/from the Storage Element. 
Thus, the main file access protocol in the Grid is GSIFTP [31 ], which is used for the transfering of 
files, and which will be always supported by any Grid storage resource. However, for the remote 
access (and not only copy) of files stored in the SEs, the protocol to be used is the Remote File 
Input/Output protocol (RFIO) [32 ]. 
The resources described up to now constitute the compute and storage power of the LCG-2 Grid. 
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Together with that infrastructure, additional services are provided to locate and report on the status 
of Grid resources, to access data on the Grid, and to find the most appropriate resources to submit 
user jobs. These are the Information System, the Data Management and Job Management services. 
The Information System 
Most grid services will publish or consume information. The information service should create the 
appearance of a single federated database covering all available information. 
The Information System (IS) provides information about the EGEE Grid resources and their status. 
In EGEE, the Monitoring and Discovery Service (MDS) from Globus [33 ] has been adopted as the 
provider of the Information Service. It implements the GLUE Schema using OpenLDAP, an 
opensource implementation of the Lightweight Directory Access Protocol (LDAP). 
Remark: GLUE (Grid Laboratory for a Uniform Environment) Schema defines a common 
conceptual data model to be used for Grid resources monitoring and discovery. The main 
components of the GLUE Schema describe the attributes and value of Computing Elements, Storage 
Elements and binding information for Computing and Storage Elements. 
Computing and storage resources at a site report (via the Grid Resource Information Servers, or 
GRISes) their static and dynamic status to the Site Grid Index Information Server (GIIS). 
If for some reasons, resources are unable to publish updated information to the GIISes, it could 
therefore involve a wrong information given to the end user. That’s why the Berkeley Database 
Information Index (BDII) is there. Each BDII contains information from the site GIISes defined by 
a configuration file, which it accesses through a web interface. In this way, each site can easily 
decide which information they desire to publish. 
The user can have access to site’s information and status by using command lines from the UI or 
web site. 
The data management 
The Data Management services are provided by the Replica Management System (RMS) of the 
European DataGrid Project (EDG) [2 ] and the LCG Data Management client tools.  
To have a large access to data, noway the submission is done, the data files can be replicated to 
many different sites of the Grid. As the users don’t matter to remember where the data are located, 
they use logical names for the files and the Data Management services are responsible for locating 
and accessing the data. 
The files in the Grid are referenced by different names: Grid Unique IDentifier (GUID), Logical 
File Name (LFN), Storage URL (SURL) and Transport URL (TURL). While the GUID or LFN refer 
to master files and not replicas, and say nothing about locations, the SURLs and TURLs give 
information about where a physical replica is located. 
In order to locate a Grid accessible file, the user will normally use a LFN. LFNs are usually more 
intuitive, human-readable strings, since they are allocated by the user as GUID aliases. Their form 
is: lfn:<any alias>. 
The SURL is used by the RMS to find where a replica is physically stored, and by the SE to locate 
it. Currently, the SURLs are of the form: sfn:<SE hostname>/<local string>, where <local string> is 
used internally by the SE to locate the file. 
The TURL gives the necessary information to retrieve a physical replica, including hostname, 
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path, protocol and port (as any conventional URL); so that the application can open and retrieve it.  
The Replica Location Service (RLS) and the Replica Metadata Catalog (RMC) are the two main 
services part of the RMS. 
The RLS maintains information about the physical location of the replicas (mapping with the 
GUIDs). Local Replica Catalogs (LRCs) which hold the information of replicas for a single VO are 
located on each SE and feed back information to the RLS. 
The RMC stores the mapping between GUIDs and the respective aliases (LFNs) associated with 
them, and maintains other metada information (sizes, dates, ownerships. . . ). 
The job management 
The services of the Workload Management System (WMS) are responsible for the acceptance of job 
submits and the dispatching of those jobs to the appropiate CE, depending on the job requirements 
and the available resources. The user’s interaction with the WMS is indeed limited to the 
description of the characteristics and requirements of the request via a high-level, user-oriented 
specification language, the Job Description Language (JDL) [34 ] [35 ] and to the submission of it 
through the provided interfaces. For that purpose, the WMS must retrieve information from the 
BDII, and the RLS.  
Job description files (.jdl files) are used to describe jobs for execution on Grid. The JDL adopted 
within EGEE (it was identical for the EDG project) is based on the Classified Advertisement 
(ClassAd) language [36 ] defined by the Condor Project [28 ], which deals with the management of 
distributed computing environments, and whose central construct is the ClassAd,  a record-like 
structure composed of a finite number of distinct attribute names mapped to expressions. A ClassAd 
is a highly flexible and extensible data model that can be used to represent arbitrary services and 
constraints on their allocation. The JDL is used to specify the desired job characteristics  and 
constraints, which are used by the match-making process to select the resources that the job will 
use. JDL files will be described for submissions of GATE jobs in Chapter III. 
A detailed description of the JDL syntax can be found in [34 ] and [35 ]. 
The Resource Broker (RB) is the machine where the WMS services run. These services are: 
§ The Network Server (NS), which accepts the incoming job requests from the UI, and 
provides support for the job control functionality. When the request from the UI (e.g. job 
submission, job removal) is valid, then it is passed to the Workload Manager. 
§ The Workload Manager, which is the core component of the system. Given a valid request, 
it has to take the appropriate actions to satisfy it. To do so, it may need support from other 
components, which are specific to the different request types. The decision of which 
resource should be used is the outcome of a matchmaking process between the submission 
requests and the available resources. The availability of resources for a particular task 
depends not only on the state of the resources, but also on the utilisation policies that the 
resource administrators and/or the administrator of the VO the user belongs to have put in 
place. 
§ The Resource Broker or Match-Maker, whose duty is finding the best resource matching the 
requirements of a job (match-making process using a JDL expression). 
§  The Job Adapter, which is responsible for making the final touches to the JDL expression 
for a job, before it is passed to CondorC for the actual submission. So, besides preparing the 
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CondorC submission file, this module is also responsible for creating the job wrapper script 
that creates the appropriate execution environment in the CE worker node (this includes the 
transfer of the input and of the output sandboxes). Then the job is passed to the Job control 
Service. 
§ CondorC is the module responsible for performing the actual job management operations 
(job submission, job removal, etc.), issued on request of the Workload Manager.  
§ Job Control Service (JCS), which finally performs the actual job management operations 
(job submission, removal. . . ) 
The Logging and Bookkeeping service (LB) is usually run on the RB machine. The LB logs all job 
management Grid events, which can then be retrieved by users or system administrators for 
monitoring or troubleshooting. 
All WMS components described before interact with the LB for logging information about the jobs 
they are handling and for querying information about them when needed. Moreover during the 
matchmaking phase the Resource Broker interacts with the Data Management Catalogs through the 
StorageIndex interface to resolve the locations of existing file names specified in the JDL Inputdata 
list, so that the submitted job would run on worker node, close to the used files. 
The WMS service also interacts with VOMS (see II.3.1.c.2) indirectly as it reads information about 
VO [38 ], groups and capabilities from the user’s proxy credentials issued by VOMS to enforce user 
authentication and authorization. The MyProxy service is contacted by the Proxy Renewal 
component of the WMS to renew automatically the credentials associated to long lived jobs. 
Last but not least the WMS interacts with the CEs for submitting jobs (this goes through CondorC) 
and for receiving synchronous/asynchronous notifications about resource status and characteristics. 
There could be configurations in which the WMS also interacts with the BDII to collect information 
about the whole resource pool available for a given VO. 
II.3.1.B.3. A typical job flow in EGEE 
Figure II- 3 illustrates the process that is followed by a job submitted to the Grid. The steps are 
defined as follow: 
 
1) The user logs to the UI machine and creates a proxy certificate that authenticates him in 
every secure interaction, and has a limited lifetime. The user submits the job from the UI to 
the WMS, where the job will be executed on a computing node. The user can specify in the 
job description file one or more files to be copied from the UI to the RB node; this set of 
files is called Input Sandbox. The event is logged in the LB and the status of the job is 
SUBMITTED. 
 
2) The WMS, and in particular the Match-Maker component, looks for the best available CE to 
execute the job. To do so, the Match-Maker interrogates the BDII to query the status of 
computational and storage resources and the RLS to find location of data. The event is 
logged in the LB and the status of the job is WAITING. 
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Figure II- 3: Job flow in EGEE 
 
3) The WMS Job Adapter prepares the job for submission creating a wrapper script that is 
passed, together with other parameters, to the JCS for submission to the selected CE. The 
event is logged in the LB and the status of the job is READY. 
 
4) The Globus Gatekeeper on the CE receives the request and sends the Job for execution to 
the Local Resource Management System (LRMS) (e.g. PBS, LSF or Condor). The event is 
logged in the LB and the status of the job is SCHEDULED. 
 
5) The LRMS handles the job execution on the available local farm worker nodes. User’s files 
are copied from the RB to the CE where the job is executed. The event is logged in the LB 
and the status of the job is RUNNING. 
 
6) While the job runs, Grid files can be accessed on a (close) SE using either the RFIO 
protocol, GSIFTP,  local access if the files are copied to the WN local filesystem or shared 
file system (e.g: afs, nfs, …). In order for the job to find out which is the close SE, or what is 
the result of the Match-Maker process, a file with this information is produced by the WMS 
and shipped together with the job to the WN. This is known as the .BrokerInfo file. 
Information can be retrieved from this file using the BrokerInfo CLI or the API library. 
 
The job can produce new output data that can be uploaded to the Grid and made available 
for other Grid users to use. This can be achieved using the Data Management tools described 
later. Uploading a file to the Grid means copying it on a Storage Element and registering its 
location, metadata and attribute to the RMS. At the same time, during job execution or from 
the User Interface, data files can be replicated between two SEs using again the Data 
Management tools. 
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If the job reaches the end without errors, the output (not large data files, but just small output 
files specified by the user in the so called Output Sandbox) is transferred back to the RB 
node. The event is logged in the LB and the status of the job is DONE. 
 
7) At this point, the user can retrieve the output of his/her job from the UI using the WMS CLI 
or API. The event is logged in the LB and the status of the job is CLEARED. 
 
Queries of the job status are addressed to the LB database from the UI machine. Also, from the UI  
it is possible to query the BDII for a status of the resources. If the site where the job is being run 
falls down, the job will be automatically resent to another CE that is analogue to the previous one, 
and following the same requirements the user asked for. 
In the case that this previous submissions are disabled (the user has the possibility to re-submit his 
jobs as he wants), the job will be marked as aborted. Users can get information about what 
happened by simply questioning the LB service. 
II.3.1.C. Requirements for a user to access the grid 
II.3.1.C.1. Obtaining a certificate 
The first requirement the user must fulfil is to be in possession of a valid X.509 certificate issued by 
a recognized Certification Authority (CA). The role of a CA is to guarantee that a user is who he 
claims to be and is entitled to own his/her certificate. In general CAs are organized geographically 
and sometimes by research institute. Each CA follows the European Policy for Management 
Authority for Grid Authentication (EU Grid PMA) [39 ]. It is a body to establish requirements and 
best practices for grid identity providers to enable a common trust domain applicable to 
authentication of end-entities in inter-organisational access to distributed resourceshas its own 
procedure to release certificates. 
II.3.1.C.2. Be part of a Virtual Organization (VO) 
The second requirement for a Grid user is to belong to a Virtual Organization (VO). A VO is an 
entity, which corresponds typically to a particular organization or group of people in the real world. 
The membership of a VO grants specific privileges to the user. For example, a user belonging to the 
ATLAS VO will be able to read the ATLAS files or to exploit resources reserved to the ATLAS 
collaboration. 
Remark: 
This last specification is not suitable for the BIOMED VO because of confidentiality problems 
between each application and between users of each application. This is one of the special 
requirement of the BIOMED VO for the EGEE middleware gLite. Each medical data must be 
anonym and the access to it should be with privileges. This point is discussed in the sub-section 
concerning VOMS. 
It is not possible to access the Grid without being member of any VO. Every user is required to 
select his/her VO when registering and the supplied information is forwarded to the VO 
administration and resource prividers for validation before the registration process is completed.  
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The biomed VO 
The BIOMED VO is supported by a large number of sites in EGEE. Table II- 1, Table II- 2 and 
Table II- 3 list the BIOMED VO resources for computing, storage and management (RB, RLS…). 
 
Table II- 1: Biomed CEs resources 
 
Table II- 2: Biomed SEs resources 
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Table II- 3: Biomed RBs, RLS and LDAP resources 
 
WMS are quite numerous and allow the user to have alternative. 
Proxy certificates 
When the user obtained the grid certificate under a .pem format (consisting of two files: the 
certificate file and the private key file) and is registered in a VO, he is able to generate a proxy 
certificate to launch jobs on the grid. A proxy certificate is a delegated user credential that 
authenticates the user in every secure interaction, and has a limited lifetime. For example when the 
User Interface passes a job to the Network Server, the UI authenticates using a proxy user credential 
(a proxy certificate) whereas the NS uses its own service credential. The same happens when the UI 
interacts with the Logging and Bookkeeping service. The UI uses a proxy user credential to limit 
the risk of compromising the original credential in the hands of the user. 
The command to create a proxy certificate is grid-proxy-init, which prompts for the user 
passphrase, as in the next example. By default, the proxy has a lifetime of 12 hours. It’s possible for 
the user to specify a different lifetime. 
Remark: If the job does not finish before the proxy expires, it is aborted. This is clearly a problem 
if, for example, the user must submit a number of jobs that take a lot of time to finish: he should 
create a proxy certificate with a very long lifetime, fact that would increase the security risks. 
To overcome this limit, a proxy credential repository system is used, which allows the user to create 
and store a long-term proxy certificate on a dedicated server (Proxy Server). The WMS will then be 
able to use this long-term proxy to periodically renew the proxy for a submitted job before it expires 
and until the job ends (or the long-term proxy expires). This technique will be use by the Genius 
web portal in the following section. The advanced proxy management offered by the UI through the 
renewal feature is available via the myproxy command suite. The user must know the host name 
of a Proxy Server (often referred to as MyProxy server). 
[UI] [maigne@clrglop208 maigne]$ myproxy-init –s grid001.ct.infn.it 
Your identity: /C=FR/O=CNRS/OU=LPC/CN=Lydia 
Maigne/Email=maigne@clermont.in2p3.fr 
Enter GRID pass phrase for this identity: 
Creating proxy .................................. Done 
Proxy Verify OK 
Your proxy is valid until: Tue May  3 11:12:36 2005 
Enter MyProxy pass phrase: 
Verifying password - Enter MyProxy pass phrase: 
A proxy valid for 168 hours (7.0 days) for user maigne now exists on 
grid001.ct.infn.it. 
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The user can destroy his myproxy using the command line myproxy-destroy. 
[UI] [maigne@clrglop208 maigne]$ myproxy-destroy -s grid001.ct.infn.it 
Default MyProxy credential for user maigne was successfully removed. 
Virtual Organization Membership Service (VOMS) 
The Virtual Organization Membership Service (VOMS) is a new service that will be used to 
manage authorization information in VO scope.  
VOMS is a service that keeps track of the members of a VO and grants users authorization to access 
the resource at VO level, providing support for group membership, roles (e.g. administrator,  
sofware manager, student) and capabilities. 
Those informations could be related to the file accesses on SE. This is particularly needed for the 
BIOMED users who should only have access to the medical data. That’s why user should be able to 
decide which information wants to publish. 
Each VO has its own server(s) containing groups membership, roles and capabilities informations 
for each member. The user contacts the server requesting his authorization info that send back the 
authorization info to the client. Then the client include it in a proxy certificate. 
These proxies will be said to have VOMS extensions. The user will utilize the voms-proxy-init 
command instead of the previously described grid-proxy-init, and a VOMS server will be contacted 
to check the user’s certificate and create a proxy certificate with VOMS information included. The 
VOMS certificate contains extra informations about the user and the VOs he belongs to. A practical 
example of the usage of VOMS proxy is that each user will have a restricted access to the files on 
the SE depending of their VO and their priority (identity).  
II.3.2. The grid computing efficacy 
II.3.2.A. Workload data analysis on computing resources 
Cluster resources are the final step of the Grid computing for a user’s job. So, the analysis of the 
cluster workload is essential to find the best scheduling policies for the users’ needs. A workload 
analysis of the LPC cluster part of the EGEE infrastructure have been performed by E. Medernach 
and published [40 ] to characterize and model users and groups behavior. This study enables to 
understand better what are the disadvantages of the grid computing until now and to suggest the 
possibility that a new architecture design should answer to the user’s needs. 
For instance the CE enqueues a job inside an appropriate batch queue chosen depending on the 
maximum CPU (running) time of the job. Obviously, the scheduler on the CE enables execution of 
jobs but has also to maximize job throughput and to maintain a good equilibrium between users in 
their usage of the cluster. In LPC site five batch queues are configured (see Table II- 4), each queue 
has its own limit in maximum CPU time (a maximum total time, the Wall time, is also associated to 
a queue to take into account the waiting time passed in the batch queue); if a job exceeds the 
duration of the queue time limit, it is automatically killed. For each queue, there is also a limit in the 
number of jobs that can be run at a given time to avoid that short jobs can’t be computed because of 
a lot of long jobs running since many hours. In the following Table II- 4 if a user launches 130 
infinite jobs on the LPC cluster, other users won’t be able to run anything until jobs are finished. In 
order to avoid such problems, site administrators should allocate different max jobs to be computed 
in a batch queue (more jobs for short or medium queues and less for the infinite one). 
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Table II- 4: Queue configuration at LPC site (maximum CPU time, Wall time and running jobs) 
The Running time 
It has been shown in [40 ] that the maximum CPU time was an unadapted variable to describe a job 
duration because it describes an upper limit for job duration to not exceed but can take any value 
below it. It has been shown by Medernach that jobs in shorter queues vary a lot in their duration 
compared to longer jobs. Table II- 5 shows for each queue the mean running time, its standard 
deviation and coefficient of variation (CV) which is the ratio between standard deviation and the 
mean. 
 
Table II- 5: Queue mean running time in seconds at LPC, corresponding Standard Deviation and Coefficient of 
Variation. 
The waiting time 
In order that the user finds the best scheduling policies for his jobs, it has been shown in [40 ] that 
the user has to launch not too short jobs compared to their waiting factor and has to send jobs not 
very often in order that they all wait together in a queue. In addition, the execution of long jobs is 
delayed by the scheduler to run shorter jobs before if possible. Table II- 6 shows the mean waiting 
time per jobs for different queues. 
 
Table II- 6: Queue mean waiting time in seconds at LPC, corresponding Standard Deviation, Coefficient of 
Variation and number of jobs. 
We have to notice that the more a job is splitted the more it will wait in total. 
Arrival time 
Concerning the job arrivals per time of day at the LPC cluster, there is an activity peak around 
midday, 2pm and 4pm, less jobs are submitted during night. In addition, the moments of interrarival 
time for each group of users are very irregularly distributed and do not correspond to Poisson 
processes, Table II- 7 shows that the Coefficient of Variation is much higher than 1 for all the 
groups and especially for the biomed group. 
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Table II- 7: Group interarrival time in seconds, corresponding Standard Deviation and 
Coefficient of Variation. 
II.3.2.B. Job requirements  
The only way to obtain the best access to resources on the EGEE grid infrastructure was to define 
requirements in the JDL file describing the job’s characteristics: the application software tag 
published on each site of the grid where the software is installed and the job maximum run time 
(MaxCPUTime). 
Like it was shown in II.3.2.a, the MaxCPUTime variable defined in the JDL file is inaccurate to 
optimally schedule jobs on grid sites. A better concept has to be found to manage in a better way the 
job flows on each site. It has been proposed to look at the relative urgency of a job. The urgency 
parameter should define for example the user’s level. For instance, each user responsible of the 
management of an application (software managers) may be regarded as a non-prioritary user 
compared to others in the case that there is an installation or an update of the software used. The 
urgency parameter should also be defined in collaboration with the site administrators to promote 
some specific applications hosting by a laboratory or to provide a quality of service for jobs 
requiring real time interaction, for example a critical medical application. 
The user has the possibility to know at each time the number of jobs currently running or waiting on 
each site hosting his VO thanks to the Information System. 
lcg-infosites --vo biomed ce 
 
**************************************************************** 
These are the related data for biomed: (in terms of CPUs) 
**************************************************************** 
 
CPU Free Total 
Jobs 
Running Waiting Computing Element 
168 144 0 0 0 ce01.pic.es:2119/jobmanager-lcgpbs-biomed 
22 22 9 0 9 lcgce.psn.ru:2119/jobmanager-lcgpbs-biomed 
5 4 0 0 0 ce00.inta.es:2119/jobmanager-lcgpbs-biomed 
4 4 0 0 0 rhodes.cines.fr:2119/jobmanager-torque-biomed 
20 13 0 0 0 grid1.irb.hr:2119/jobmanager-lcgpbs-biomed 
110 110 6 0 6 clrce01.in2p3.fr:2119/jobmanager-lcgpbs-day 
84 37 0 0 0 clrce02.in2p3.fr:2119/jobmanager-lcgpbs-day 
1 1 0 0 0 lcgce02.ifae.es:2119/jobmanager-lcgpbs-biomed 
14 14 0 0 0 cclcgceli02.in2p3.fr:2119/jobmanager-bqs-long 
110 110 15 0 15 clrce01.in2p3.fr:2119/jobmanager-lcgpbs-long 
110 110 4 0 4 clrce01.in2p3.fr:2119/jobmanager-lcgpbs-test 
84 37 0 0 0 clrce02.in2p3.fr:2119/jobmanager-lcgpbs-long 
16 16 0 0 0 mallarme.cnb.uam.es:2119/jobmanager-pbs-biomed 
50 46 2 2 0 mu6.matrix.sara.nl:2119/jobmanager-pbs-biomed 
64 64 0 0 0 cclcgceli02.in2p3.fr:2119/jobmanager-bqs-short 
5 5 0 0 0 ce001.imbm.bas.bg:2119/jobmanager-lcgpbs-biomed 
56 54 2 2 0 ce1.egee.fr.cgg.com:2119/jobmanager-pbs-biomed 
110 110 2 0 2 clrce01.in2p3.fr:2119/jobmanager-lcgpbs-short 
84 37 1 1 0 clrce02.in2p3.fr:2119/jobmanager-lcgpbs-short 
52 52 0 0 0 cclcgceli02.in2p3.fr:2119/jobmanager-bqs-medium 
5 5 0 0 0 ce001.grid.bas.bg:2119/jobmanager-lcgpbs-biomed 
16 16 0 0 0 grid10.lal.in2p3.fr:2119/jobmanager-pbs-biomed 
84 80 3 2 1 gridba2.ba.infn.it:2119/jobmanager-lcgpbs-long 
20 19 1 1 0 ramses.dsic.upv.es:2119/jobmanager-pbs-biomed 
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6 3 0 0 0 ce01.grid.acad.bg:2119/jobmanager-lcgpbs-biomed 
84 80 0 0 0 gridba2.ba.infn.it:2119/jobmanager-lcgpbs-short 
972 416 0 0 0 lcgce01.gridpp.rl.ac.uk:2119/jobmanager-lcgpbs-S 
20 19 0 0 0 ramses.dsic.upv.es:2119/jobmanager-pbs-biomedg 
25 25 0 0 0 ce2.egee.cesga.es:2119/jobmanager-lcgpbs-biomed 
110 110 9 0 9 clrce01.in2p3.fr:2119/jobmanager-lcgpbs-infinite 
84 37 0 0 0 clrce02.in2p3.fr:2119/jobmanager-lcgpbs-infinite 
28 28 0 0 0 egeece.ifca.org.es:2119/jobmanager-lcgpbs-biomed 
244 207 4 4 0 tbn20.nikhef.nl:2119/jobmanager-pbs-qlong 
40 40 0 0 0 epgce1.ph.bham.ac.uk:2119/jobmanager-lcgpbs-short 
54 45 6 6 0 grid012.ct.infn.it:2119/jobmanager-lcglsf-long 
244 207 0 0 0 tbn20.nikhef.nl:2119/jobmanager-pbs-qshort 
64 56 0 0 0 ce01.isabella.grnet.gr:2119/jobmanager-pbs-short 
26 25 11 0 11 ce101.grid.ucy.ac.cy:2119/jobmanager-lcgpbs-biomed 
40 40 0 0 0 epgce1.ph.bham.ac.uk:2119/jobmanager-lcgpbs-biomed 
22 20 0 0 0 grid002.ca.infn.it:2119/jobmanager-lcgpbs-grid 
54 45 0 0 0 grid012.ct.infn.it:2119/jobmanager-lcglsf-short 
84 80 4 4 0 gridba2.ba.infn.it:2119/jobmanager-lcgpbs-infinite 
972 416 1 0 0 lcgce01.gridpp.rl.ac.uk:2119/jobmanager-lcgpbs-bioL 
64 56 0 0 0 ce01.isabella.grnet.gr:2119/jobmanager-pbs-biomed 
22 17 1 1 0 griditce01.na.infn.it:2119/jobmanager-lcgpbs-grid 
14 11 0 0 0 node001.grid.auth.gr:2119/jobmanager-lcgpbs-biomed 
20 16 1 1 0 pccmsgrid08.pi.infn.it:2119/jobmanager-lcgpbs-grid 
100 0 22 0 22 prod-ce-01.pd.infn.it:2119/jobmanager-lcglsf-grid 
28 24 4 4 0 scaicl0.scai.fraunhofer.de:2119/jobmanager-lcgpbs-
biomed 
56 56 0 0 0 ce01-lcg.cr.cnaf.infn.it:2119/jobmanager-lcglsf-
biomed 
9 9 0 0 0 testbed001.grid.ici.ro:2119/jobmanager-lcgpbs-biomed 
54 45 3 3 0 grid012.ct.infn.it:2119/jobmanager-lcglsf-infinite 
8 5 1 0 1 gridit-ce-001.cnaf.infn.it:2119/jobmanager-lcgpbs-
grid 
76 69 0 0 0 zeus02.cyf-kr.edu.pl:2119/jobmanager-lcgpbs-biomed 
66 65 0 0 0 lcg00125.grid.sinica.edu.tw:2119/jobmanager-lcgpbs-
biomed 
24 18 0 0 0 marseillece01.mrs.grid.cnrs.fr:2119/jobmanager-pbs-
biomed 
3 2 0 0 0 node03.datagrid.cea.fr:2119/jobmanager-lcgpbs-biomed 
 
The CPU and Free variables correspond to the total CPU and total free CPU allocated for each site. 
It appears that those parameters are not very relevant for an optimal usage of the grid resources. 
First of all, the information related to those variables refer to the totality of CPU resources on each 
site and do not take into account the user’s VO membership. Effectively, as it is shown in Table II- 
8, only a percentage of resources are allocated to each VO according to each site adminitrator 
policy. In a second time, we can see in this same table that each site should refer to a normalized 
CPU and not only to the total number of CPUs. That’s why, two sites referring to the same number 
of resources could not have the same efficacy in terms of computing flow rate capacity depending 
of the type of processors used. The South West EGEE resources make reference to a 2.8 GHz for 
their normalization, as a consequence, for the CIEMAT-LCG2 cluster made of 40 CPUs, the 
normalized CPUs are equivalent to 52.0 which implies that the mean processor efficacy is better 
than a cluster made of only 2.8 GHz processors. On the contrary, the USC-LCG2 site composed of 
72 processors is in reality equivalent to 41 normalized CPU. 
So, if the input job rates are higher than the capacity of the grid sites, then, the sites are overloaded 
and the global performances are low due to jobs waiting in order to be processed. 
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Table II- 8: EGEE South West Resources. 
 
We could think about defining a computing flow rate requirement in the JDL file in addition of the 
other parameters used. The site managers remain the more appropriate person to contact to deal 
needs and resource requirements for each application. 
An attempt to model the job arrival rate has been proposed by E. Medernach [40 ] and we can thing 
about modelling the entire job computing on each site to understand better the computational flow 
rate on each site depending of the VO, the applications and the number of users. 
In addition to a better information given to the user concerning the computing resources for their 
submissions, the Grid should allow the migration of jobs between sites if one of them is saturated 
by a vast number of jobs. A local site flow control should maintain a non-saturation of the grid 
computing resources.  
For instance, the LCG middleware with the Resource Broker collects user requests and distribute 
jobs on the grid resources, but we have to keep in mine that the matching of available resources and 
the balancing in function of the job submittal requests shouldn’t be performed over a centralized 
machine. First of all, even if the Resource Broker are numerous now for each VO (it was not the 
case in the DataGrid project for which one Resource Broker was defined), it still remains a 
bottleneck that used to shutdown if the job flows are important. Even if a job has been well finished 
on a computing resource, if the Resource Broker fails, the user is incapable of retrieving results on 
the user interface machine and the job is lost. The data have to be globally distributed as stated by 
Dmitry Zotkin and Peter J. Keleher [41 ]: 
“In a distributed system like Grid, the use of a central Grid scheduler may result in a performance 
bottleneck and lead to a failure of the whole system. It is therefore appropriate to use a 
decentralized scheduler architecture and distributed algorithm”. 
II.3.2.C. Managing medical data in a grid environment 
II.3.2.C.1. Storage and retrieval 
Healthgrids are more closely related to data, but hospitals are reluctant to let information flow 
outside hospital bounds. For a large-scale deployment of healthgrids, and thus for opening an 
attractive business, it is important to leverage security up to a trustworthy level of confidence that 
could release a generalized access to data from the outside (see also below). Although data storage 
remains the responsibility of the hospital, many business opportunities can arise from data sharing 
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and processing applications. Federation of databases requires computing effort and complex 
structures. 
All the medical data files provided by healthcare centres are mainly produced using the Digital 
Image and Communication in Medicine (DICOM) standard [44 ]. DICOM describes an image 
format, a communication protocol between an image server and its clients, and other image related 
capabilities. A more detailed definition of the DICOM image format is given in Chapter IV. 
On top of such a standard, Picture Archiving and Communication Systems (PACS) [45 ] are 
deployed to manage data storage and data flow inside hospitals.  
In addition to the image content, medical metadata carrying additional information on the images 
(disease) of the patient are mandatory for the pratician in order to provide a diagnosis. The metadata 
(image related, pathology, follow-up, etc…) are contained in the Radiological Information Systems 
(RIS). For that purpose, no open standards exist for the data structure and the communication 
between services. 
A system taking into account larger data sets with the integration of an other component (such as 
computation and/or storage grid resource) must be deployed by taking care of the security and 
privacy requirements. To detail the interfacing of DICOM medical data, we take as example a 
storage interface to DICOM medical servers which was developped during the EDG project by the 
biomedical grid users from CREATIS to easily manipulate medical images from the EDG testbed. 
 
Figure II- 4: DM2 interface between medical imagers and the grid 
 
Figure II- 4 shows the Distributed Medical Data Manager (DM2) [46 ] [47 ] that has been 
developped during the EDG project and now on the EGEE one. The DM2 splits raw data from 
metadata part of the DICOM slices, the metadata are then stored in a relational database to ease 
query on them. The raw images are stored on the grid storage resources and one or several GUID 
are associated to virtual image files. A link between each image GUID, the composing DICOM 
slices, and the associated metadata are stored in the same database. 
 
An other tool, developed by the WP2 in the EDG project, named Spitfire [48 ], has been used to 
access relational database containing information on medical data used for GATE Monte Carlo 
computations on the grid infrastructure. The entire processing of GATE Monte Carlo simulations 
won’t be discussed here but in Chapter III, we will focus now on the utilization done with this 
software on medical data. 
The Spitfire software consists of the Spitfire Server module, the Spitfire client libraries and a 
Browser or command line executables. It is a very thin layer on the top of a Relational Database 
Management System (by default MySQL was used) that provides a Java Database Connectivity 
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driver. It’s using Web Service technology (Jakarta Tomcat) to provide connections to a few user-
definable database operations. Spitfire gives a quick an easy access to data, but it is not supposed to 
be used as a full-fledged Data Management System. The access patterns have to be simple: single or 
few row lookups and inserts, updates and deletes and information on the tables. Spitfire makes use 
of the Grid Authentication (X.509 certificates) and an additional authorization. 
 
Furthermore, management of distributed databases and data mining capabilities are important tools 
for many biomedical applications in fields such epidemiology, drug design or even diagnosis. 
Expert system services running on the grid must be able to interrogate large distributed databases to 
extract such knowledge as may lead to the early detection of new sources of diseases, risk 
populations, evolution of diseases or suitable proteins to fight against specific diseases.  
II.3.2.C.2. Security and privacy 
Security in grid infrastructures is currently adequate for research platforms, but it must be improved 
in the future to ensure privacy of data in real healthgrids.  
In order to convince physicians and patients to use grids for their data storage and processing needs, 
many functionalities need to be provided such as: 
§ Reliable authentication of users 
§ Secure transfer of data between grid elements 
§ Secure storage of data on a grid element 
§ Anonymization of medical records 
§ Access control for resources (data, storage space or computing power) 
§ Tamper-proof logging of operations performed on medical files 
§ Robustness against denial-of-service attacks 
The grid infrastructure is able now to answer some requirements for a biomedical usage of the 
resources, we will detail below what is the status of the grid technologies. 
 
Concerning the authentication of users: This subject is well adressed in grid environment. The use 
of a public key infrastructure (PKI) with certification authorities (CA) and X.509 certificates are 
sufficient to access the grid resources. The EGEE middleware relies on Globus [13 ] and its public 
key-based infrastructure [38 ] to answer those needs. 
Concerning the secure transfer of data: the grid benefits of well researched area such as SSL/TLS, 
IpSec or SSH and GridFTP for data transfers [49 ]. The EGEE middleware uses this last technology 
but not yet the encrypted protocol included in. 
Concerning the secure storage of data: Encrypted storage systems exist but fail to adhere to the 
dynamic nature of grid access permissions. Mechanisms have to be elaborated to share the 
decryption keys between users authorized to access data. A solution has been deployed by Seitz et 
al. [46 ] to provide access to decryption keys based on access permissions. 
Concerning anonymization: Failure on privacy in biomedical personal information causes 
irreparable damage, since there is no way to retrieve the situation. Even if the name and address of 
the patient are removed on the medical file, it is still possible to re-identified the patient using 
secondary information. A promising approach to deal with anonymisation is described in [50 ]. 
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Concerning Authorization and access control: In addition to the cross-organizational nature of grid 
access permissions, the medical field adds other inherent problems, the confidentiality and a 
restricted access to data for users part of the same VO. Effectively, the membership of users within 
those groups must be clarified to have a restricted access to data. 
Concerning traceability: The grid must provide a log-keeping system enabling the update of 
information about access requests on the medical data located on the storage element. 
Concerning the availability of services: measures to prevent denial-of-service attacks are not 
specific to grid architectures. One thing to keep in mind is that the security services shouldn’t be 
relied on a single centralized service. Grid technologies can ease the access to replicated resources 
and information, just requiring the user to have a permanent Internet connection. 
CONCLUSION 
The EDG project was a pioneer in identifying the biomedical domain as a relevant area of 
application for grid technologies. Conferences and workshops organized in the biomedical domain, 
with the creation of international entities such as the HealthGrid association or the GGF Life 
Science research group [52 ] aim to federate research projects and communities in this field. 
The EGEE project hosts a lot of biomedical applications in which GATE is a pilot deployment, 
benefiting of the experience gained in the EDG project. 
As we described it, the functionalities of the Grid are numerous but remain often unadapted to a 
usage of the grid in clinical routine in addition to the biomedical research needs.  
The best usage of the grid capabilities has to be found to obtain a sufficient gain in time for the 
computation of GATE treatment plannings.  
In the following chapter, we will concentrate on the set up of GATE applications in such Grid 
infrastructure and the convenient tools developed to enable an inexperienced grid user (physician, 
medical physicist…) to use the Monte Carlo accuracy in medical treatment planning. The  
parallelisation of the simulations associated to computing time tests, the data management 
associated to the usage of medical images in treatment planning, the outputs analysis and a web 
portal user interface are one of the fields treated. A joint submission between two grid 
infrastructures, the DEISA and EGEE projects is the next issue to test advantage of supercomputing 
calculations in medical physics treatment planning. 
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Chapter III.  
 
 
The GATE Monte Carlo simulation 
platform for dosimetric applications 
 
 
 
INTRODUCTION 
GATE (Geant4 Application for Tomographic Emission) is born in December 2001 thanks to a joint 
effort between the University of Lausanne (Christian Morel and Daniel Strul), the University of 
Geneva (Giovanni Santin) and the LPC of Clermont-Ferrand (Vincent Breton and Delphine 
Lazaro). Since, OpenGATE meeting occur three times per year to discuss about the validations and 
the new  developments of the platform. The OpenGATE collaboration published a joint paper in the 
journal Physics in Medicine in Biology [1 ] in 2004 relating all the implementations and features of 
the platform. 
At this date, three sub-working groups have been created inside the OpenGATE collaboration to 
focus on special fields related in particularly to dosimetric applications: the optimisation of the 
code, the parallelization of simulations on cluster and/or grid environment and the customization 
and validation of the platform for dosimetric studies. Effectively, in addition to an ease of use, a 
Monte Carlo code has to offer a compromise between time consuming and precision of the 
calculations in order to be used in clinical routine. Furthermore, the Monte Carlo code must be 
validated for dosimetric applications using in particularly electrons in water equivalent medium and 
in heterogeneous media (body and tumour volumes reconstructed using CT data). As the definition 
of the GATE platform has been widely described in some publications and thesis [2 ], we will 
discuss in a first part on the current functionalities and the requirements necessary to enable the use 
of GATE for dosimetric applications. A second part is intended to current and future developments 
enabling: 
§ an efficient usage of the code infrastructure with the implementation of variance reduction 
techniques, 
§ the convivial visualization of CT data imported in the simulation, 
§ an extended usage of the platform for dosimetric applications involving dose calculations 
based on voxelized volumes (CT data). 
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§ The validation of the GEANT4 electromagnetic processes implying electrons is detailed in a 
third part. 
III.1. GATE: A MONTE CARLO PLATFORM FOR DOSIMETRY 
III.1.1. Functionalities available and requirements for dosimetry applications 
GATE (Geant4 Application for Tomographic Emission) has been released for the first time in May 
2004, with the production of the first open source package of the platform. The last version 
available is 1.1.0 compatible with GEANT4 version 6.2.p02. Version 1.2.0 compatible with 
GEANT4 version 7.0.p01 is under test at this date. The platform is encoded in C++ langage on the 
top of the GEANT4 software. The Scientific Linux 3.0 is the operating system used.  
The ease of use of the platform is enabled thanks to a scripted interface, all the encoding 
functionalities of GATE have been transcripted in command lines. The user only needs to call the 
script line related to the creation of a geometry, output format chosen, etc, to create his simulation.  
III.1.1.A.  Geometry and Systems 
III.1.1.A.1. Existing functionalities 
A lot of functionalities in the code are intended to nuclear medicine simulations, for example PET 
and SPECT system validations and image processing. Creation and definition of geometry (shape, 
dimensions, material allocated to, translation and rotation, repeaters) are very easy using the GATE 
command lines.    
In addition, predefined detector geometry systems are there  to facilitate the hierarchical description 
of a tomograph. Each system can be described by components organized in a tree level structure, 
each component having its own specific role or ordering. As for an example of the cylindricalPET 
scanner system, the geometrical volumes containing crystals are grouped in matrices, themselves 
assembled in submodules and modules. At the top level of this structure, the sectors composed of 
modules are “repeated” on a cylindrical surface to build up the whole device.  
The main property of a system is that its geometry description is supported by specific list-mode or 
histogrammed (sinogram or projection) data output formats. Currently there are five systems 
available in GATE: one for SPECT, three for PET and a generic system appropriate to model novel 
tomographic paradigms. 
III.1.1.A.2. Needed functionalities 
To create specific geometry, for example an iodine brachytherapy source for wich rounded tips are 
positionned on each side of its cylinder shape, the user has to combine a cylindrical shape and two 
hemispherical tips joined to it by taking care that volumes don’t overlap between each other. In the 
same way, ophthalmic applicators with notches are impossible to create using this technique. GATE 
don’t integrate yet in its functionalities boolean operations that allow the creation of a new volume 
by the association of two others, nor the BREPS (Boundary Represented Solids) that enables the 
definition of volumes by describing their boundaries. Both topics are available in the GEANT4 
software. 
Even if the creation of geometry is simple using command lines, GATE has to provide facilities to 
create complex geometry shapes for radiotherapy and brachytherapy experiments in order to be 
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used for clinical routine treatments.In the case of dosimetry studies using linear accelerators or 
brachytherapy sources, the current system used is the generic system “scanner”. Five level 
components are associated to this system with no geometry fixed as it is the case for example with 
cylindricalPET system for which a box is allocated to each system components. 
As no system has been specifically created for linear accelerator nor for brachytherapy geometry 
building, the user has to post-analyze information concerning interactions occuring in each medium 
of interest which involves a considerable loss of time. 
Because geometrical concepts are common to many different linear accelerators, we could imagine 
to prefine a system for their hierarchical description. We could envisage the same for iodine 
brachytherapy sources and 106Ru/106Rh ophthalmic applicators. 
III.1.1.B. Voxelized sources and phantoms: GATE calculations based on CT data 
The current GATE versions enable the simulation of dosimetric studies in voxelized volumes such 
like CT data. The way to transcript the medical data to insert it in the simulation is quite simple. 
Two files are needed for the transcription of the medical data in the simulations: a binary file 
(image.raw) grouping the CT slices and a transcription file (range.dat) to assign to each voxel or, to 
a range of voxels material characteristics. In the following subparts we will talk about the medical 
images format that we have to deal with to perform Monte Carlo simulations with voxelized media: 
the DICOM and Interfile formats. 
III.1.1.B.1. Definition of DICOM and Interfile formats 
The DICOM standard 
Medical images provided by hospitals or clinical centres are defined in the DICOM standard. 
DICOM, “Digital Imaging and Communication in Medicine” is a norm defining communication 
methods for the different medical imaging equipments. This norm has been developed to: 
§ Promote communication of digital image information, regardless of device manufacturer 
§ Facilitate the development and expansion of Picture Archiving and Communication Systems 
(PACS) that can also interface with other systems of hospital information. 
§ Allow the creation of diagnostic information data bases that can be interrogated by a wide 
variety of devices distributed geographically. 
 
DICOM has been emitted by the American College of Radiology (ACR), American College of 
Cardiology (ACC), American Society of Echocardiography (ASE), European Society of Cardiology 
(ESC), and American Society of Nuclear Cardiology (ASNC) in association with the NEMA 
(National Electrical Manufacturers Association) in 1984, and it was originally called the 
ACR/NEMA standard. This norm is currently updated by those two comittees with the help of 
international experts like the Japaneese Industry Association for Radiation Apparatus (JIRA) in 
Japan, and the Committé Européen de Normalisation (CEN TC 251) under the name MEDICOM in 
Europe. ACR is responsible for technical and medical instructions, whereas the role of the NEMA 
is dedicated to publications and legal issues to avoid infractions against anti-trust laws. 
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The first version of DICOM norm was introduced to the RSNA (Radiological Society of North 
America) in 1985 under the name ACR-NEMA 300-1985 (also called ACR-NEMA Version 1.0); 
the official version was available in 1993. 
In addition to the interoperability of medical equipments and data transfer improvements, the 
DICOM norm enable to obtain medical image and information concerning the patient, data 
acquisition, date, examination, etc..  in the same format. 
DICOM is used for image management, network image transfer, network printing and media 
interchange/archiving. The networking support is based on the TCP/IP (Transmission control 
Protocol/Internet protocol). DICOM is an object oriented standard. 
The goal here is not to define entirely the DICOM standard, the reader can find full documents 
describing the DICOM standard status [4 ]. We will highlight the main characteristics of DICOM 
standard and the encoding of pixels data to extract the Hounsfield units information for our 
simulations. 
 
Network Image Transfer provides the capability for two devices to communicate by sending objects 
such as images or radiotherapy plans, querying remote devices, and retrieving these objects. 
Network transfer is currently the most common connectivity feature supported by DICOM 
products. Since 1993, all the images types can be transferred (CT, MRI, PET, SPECT….) but also 
other files like CT angiography, X-ray intra oral for dentistery, radiotherapy portal imaging, etc. 
Figure III- 1 shows the principle of network used in radiology and care units with a cluster 
archiving. Modern MRIs, X-rays, ultrasounds, and CT and PET scans are stored and moved as 
digital images. Studies can be huge. Typical MRIs contain 10 files of 20 to 30 megabytes (MB) 
each. Therefore, DICOM images are important and must traverse the healthcare network 
dependably and consistently. 
 
Figure III- 1: Network image transfer with the DICOM standard 
 
In DICOM, each entity becomes an information object and its attributes correspond to data 
elements, as described by the information-object definition.  
DICOM names the object (for example, the ultrasound multiframe object) and uses the attributes or 
data elements that describe the object. The attributes that are used frequently together to describe a 
given type of object have been collected in modules for the sake of convenience. The DICOM 
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information object answers the question, “What is it that I want to communicate?”. Figure III- 2 
shows the different type of information that can be communicate: patient information, study 
information, series information and Image information. 
 
Figure III- 2: Image Information Object Definition 
 
Service classes are made up of message service elements. These are of two types: composite 
services (store, find, get, move, cancel, and echo) and normalized services (those that let the system 
know that a file was created or that a value is to be set). There are also two service roles in DICOM, 
since a device can use a service class or provide it (or both, as an archive does). 
The service class, answers the question, “What do I want to do with the information?” This can 
apply to a function to be performed, such as sending an image to an archive, or notification about 
events that occur, such as the archive’s acknowledgment of the receipt of that image. 
All DICOM Applications are implemented through Service Class functionality. For example, an 
Application sends or receives images through Storage Service Class. It may also print images 
through the Print Service Class. All Service Classes are specified by the Standard as a group of SOP 
(Service Object Pair) Classes. SOP is the combination of an Information Object Definition (IOD) 
and a DICOM Message Service Element (DIMSE). 
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Table III- 1: Service Object Pair classes 
 
A DICOM image is made of data corresponding to pixels in the image (usually those data are 
located at the end of the file), they are preceded by technical and demographic data. 
Information is organised in a sequential form, each elementary information is made of three data 
fields: 
§ The first field is coded under 8 bytes, and represents a tag listed in the DICOM dictionnary, 
it indicates the type of information following.  
§ The second field of 8 bytes indicates the length of the information contained in the third 
field. 
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§ The third field is of variable length, and is determined by the previous field corresponding to 
the information identified by the first field. 
The organisation of the data flow is detailed in Table III- 2, Figure III- 3 shows a real data flow that 
can be read in a DICOM file. 
 
Table III- 2: Organisation of DICOM flow 
 
Figure III- 3: Real data flow that can be read in a 
DICOM file
The Interfile format 
The DICOM format is not compatible with GATE simulations. To enter CT data in our simulations 
the DICOM images have to be converted into Interfile formats. The conversion is realized using the 
commercial software Pixies [5 ]. 
 
Interfile is a file format for the exchange of nuclear medicine image data. It has been created first to 
satisfy the needs of the European COST B2 Project for the transfer of images of quality control 
phantoms, and incorporates the AAPM (American Association of Physicists in Medicine) Report 
No. 10, and has been subsequently used for clinical work.  
It specifies a file format composed of ascii "key-value" pairs and a data dictionary of keys. The 
binary image data may be contained in the same file as the "administrative information", or in a 
separate file pointed to by a "name of data file" key. Image data may be binary integers, IEEE 
floating point values, or ascii and the byte order is specified by a key "imagedata byte order". The 
order of keys is defined by the Interfile syntax which is more sophisticated than a simple list of 
keys, allowing for groups, conditionals and loops to dictate the order of key-value pairs.  
Conformance to the Interfile standard is informally described in terms of image data types, pixel 
types, multiple windows, special Interfile features including curves, and restriction to various 
maximum recommended limits.  
Interfile is specifically not a communication protocol and strictly deals with offline files. There are 
efforts to extend Interfile to include modalities other than nuclear medicine, as well as to keep 
ACR/NEMA and Interfile data dictionaries in some kind of harmony.  
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Figure III- 4 shows a sample of Interfile 3.3 key-value pairs describing the binary image data.  
 
 
Figure III- 4: Interfile 3.3 key-value pairs describing a binary image data. 
 
The more relevant fields that appear in this file (i.e. that are more relevant for GATE simulations) 
are: 
§ The name of the data file (image.raw), in this case, the description file and the binary image 
are dissociated. 
§ The number of images (CT slices) converted are mentioned 
§ The image data byte order BIGENDIAN or LITTLEENDIAN is specified (see remark 
below). 
§ The matrix size in the two dimensions are mentioned in number of pixels 
§ The number format in each pixel is described (signed or unsigned integer..) 
§ The scaling factors represent the size of the pixels in X and Y dimensions 
§ The slice thickness has also to be mentioned 
All these fields are read by the GateToInterfile classes in the GATE source code.  
 
Image data can be encoded in different bytes during the acquisition on CT scan (16 bytes is 
generally the encoding used for the DICOM data). The adjectives big endian and little endian refer 
to which bytes are most significant in multi-byte data images. 
To understand better what we want to say by naming a byte order by little endian or big endian, we 
will write in binary mode the decimal value 12. We can convert it in two different ways like it is 
shown in Figure III- 5. 
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Figure III- 5: Bytes encoding for Little and Big Endian modalities. 
 
For the Big Endian encoding the column 8 represents the Most Significant Bit (MSB), the column 1 
represents the Least Signifiant Bit (LSB). 
As example, we will compare a Little Endian and a Big Endian byte order. 
§ In the case of a Little Endian byte order: 
If we consider this 16-bit binary value read from a DICOM file as is: 11111111 00000000 
                                                                                                                             (first byte)       (second byte) 
this would tempt us the value to be 65280 (that’s the decimal equivalent of the binary 
number). But it’s not the correct value should be interpreted as second byte first and then the 
first byte; 000000 11111111, the decimal value would be 255. Little Endian is the default 
Transfer Syntax. 
§ In the case of a Big Endian byte order: 
Opposite of Little Endian. Most Significant Byte is  on the left and the Least Significant byte 
is on the right. The Decimal equivalent of 11111111 00000000 is therefore 65280. 
Transcription of DICOM CT data into Interfile format 
As an example, images taken at CHU of Clermont are in DICOM3 Little Endian, the number of bits 
allocated is 16, the number of bits stored is 16 and the highest bit is 15.  
The DICOM format provides a great flexibility regarding the organization and the structure of the 
pixel data; every pixel is made of one or more samples, each one of them is described by a number 
of bits (the “Bits Stored”) and is packed in a cell that can use and even greater number of bits (the 
“Bits Allocated”) allowing the user to include overlay data within each sample or simply pad each 
sample in a multiple of 8 bits. 
The way to save the pixels can vary a lot depending of the manufacturer and the users. The common 
way to store pixels value is not to compress data, for example one pixel of 12 bits is saved in a word 
of 16 bits. Figure III- 6 shows some examples of allocation and storage of data in the DICOM3 
standard. 
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Figure III- 6: Allocation and storage of data in pixels in DICOM3 standard 
 
We can see that we have to deal with the complexity of all possible combinations of allocated, 
stored and high bits. The translation of DICOM format in raw format enable to not include any 
information except the “cleaned” and “padded” pixel data.  
By making this conversion: 
§ The data others than pixels are not stored 
§ Samples made of more than 8 bits are stored ("padded") in a word (2 bytes) otherwise in a 
byte, so that each sample starts at the beginning of a word (respectively a byte).   
§ The structure of every sample is "cleaned", so that the least significant bit starts at bit 0 
(High Bit = Bits Stored - 1).   
§ Unused bits are set to 0 (unused bits are found according to the value of Bits Stored and Bits 
Allocated). Overlay data are lost.  
§ The binary syntax may be chosen (Little or BigEndian) when samples are stored in a word 
(2 bytes).  
§ The raw conversion performs faster when the pixel cell and the pixel sample have the same 
size and is a multiple of 8 bits. 
 
Hounsfield units allocated to pixel in the DICOM3 format are defined in the range –1024 to +3071 
(4096 values), the water has the value 0 and the air has the value –1000. To this range of Hounsfield 
units is associated a range of values coming from 16 bits or 8 bits encoded images. 
In the case of medical images taken at the CHU of Clermont-Ferrand, 16 bits are allocated to the 
pixels with 16 bits stored, that means the image is composed of 216 (65536) different values. 
To understand better how is done the reading of Interfile image in GATE, an example of an 
insertion of a medical image in GATE simulations is defined below: 
Chapter III. The GATE Monte Carlo simulation platform for dosimetric applications 
 85
The image can be issued from a single DICOM CT slice or from the association of multiple slices to 
obtain a voxelized matrix representing a part of the body of a patient. 
First, the user has to create a replicaMatrix (see 
definition in III.1.1.b.2), then he has to define a 
reader describing the type of data used, in our 
case we will always use an interfile reader (the 
image can also be entered as ASCII data instead 
of Interfile); finally the user specifies that he 
translates the binary image using ranges defined 
in the file range.dat, see beside an example of 
range.dat file that read a binary image encoded 
in 12 bits, 212 different values defined the voxels 
CT numbers. To each range of bits is associated 
a material (for which the composition is defined 
in the GateMaterials.db file). On the first line, 
the number of ranges is defined. 
 
Figure III- 7:File range.dat defining the transcription 
of  binary number ranges into materials. 
III.1.1.B.2. Needed functionalities 
By allowing simulations on voxelized phantoms (i.e on CT data), GATE simulations can be used to 
quantify dose deposited in heterogeneous media such as a human body. To enable the user creating 
easily parameters of his simulation, a visualization of the medical data (the voxelized volumes) 
should be available. But, for the versions of the GATE platform used for this work (versions 1.0.2 
to 1.2.0), the voxelized images are integrated in the code using the replication of volumes. The use 
of this method involves frequent dynamic memory allocations due to the fact that each voxel is 
created as a single volume (GateBoxCreator). Figure III- 8 shows the different C++ classes 
implied in the creation of a ReplicaMatrix (name given to the matrix created after the replication of 
the voxels) and Figure III- 9 shows the classes implied in the visualisation of such matrix. 
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Figure III- 8: Schema of the classes implied in the 
creation of a ReplicaMatrix 
 
Figure III- 9:Schema of the classes implied in the 
visualisation of the ReplicaMatrix
 
The creation of voxelized phantoms and sources from ASCII or Interfile files by associating to each 
voxel of the image a box is thus very time consuming. Therefore, we implemented a visualization 
tool (see description in III.1.2.b) to enable the user to position radioactive sources or beams in 
function of the voxelized phantom, to rotate and translate easily voxelized volume in the simulation 
using the mouse, to colour the gray scaled voxelized images in function of the transcription of 
Hounsfield units into tissue parameters (density and atomic weights), this feature is very interesting 
to visualize different part of the anatomy of the patient (bone, muscles, tumoral tissues).  
 
As explained before, GATE enables the definition of voxelized sources inside human body CT data, 
this feature is particularly interesting for dosimetric studies in nuclear medicine for which the 
radioactive source is injected in the patient body. 
For sealed radioactive sources inserted in the patient body such like iodine-125 sources introduced 
in the prostat or ophthalmic applicators positioned on the eye, the voxelization of the source is a 
hard task because of the shape of the sources (rounded shape comparing to squared shape of the 
voxels) and because of their small size (0.8 mm in diameter for an iodine-125 cylindrical source 
comparing to 0.6 to 1 mm for the voxel size). For these kind of sources, it is necessary to develop 
functionalities in the GATE platform to insert them as part of a voxelized phantom. 
 
Furthermore, the particle transport in voxelized phantoms or sources defined using replication 
matrices is slowed down because each voxel is identified as a unique volume.  The tracking of 
particles is difficult (position of the particle in a voxel, calculation of the distance between voxel 
boudary and particle interaction, etc..) and the dynamic assignment of material density is very long 
as each voxel is an individual entity. To overcome those difficulties, new developments in GATE 
are focussed on parameterised volumes [6 ] to optimize the use of the platform for dosimetric 
studies in human body. Parameterised volumes are described in III.1.2.c. 
III.1.1.C. Source and detector movements, source decay 
III.1.1.C.1. Existing functionalities 
One of the distinctive features of GATE is the management of time-dependent phenomena. To 
introduce a source into a GATE simulation, the user needs first to define the properties of the 
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activity distribution, then the geometry and specify the start and stop times of the acquisition (which 
are equivalent to the start and stop times in a real experiment). GATE can model complex activity 
distributions. For each new event, the source manager randomly decides, based on total source 
activities, how the source decays. The Geant4 “General Particle Source” is used to shoot particles of 
a given type to a given direction with a given kinetic. 
A source is defined by its name, its activity, its type (ion, positron, electron, gamma), its energy 
(type and amount), its distribution of emission (defined with angular span), its shape (point, beam, 
plane, surface, volume) for surface and volume the type of geometry can be defined (Circle, 
annulus, ellipsoid, square, cylinder, …), its placement in the experiment building and its 
confinement which allows the emission of particles from complex geometry and when the source is 
in movement during the simulation. 
By choosing to emitt an ion, the Radioactive Decay Module (RDM) part of the GEANT4 software 
is used. It enables to simulate the entire radioactive decay of an ion but slows down the simulation. 
That’s why the generation of positrons or electrons particle can be simulated by pre-defining and 
storing the emission spectra of most often used radioactive sources: fluorine-18, oxygen-15, carbon-
11 for PET acquisitions or rhodium-106 for ocular brachytherapy (see Chapter I). Those sources 
decay meanwhile the time start and the time stop defined by the user. 
So, concerning source definitions, nothing is needed in addition, the current implementations allow 
an acceptable definition of source decay meanwhile the experiment. 
III.1.1.D. Information on interactions in media and output data 
III.1.1.D.1. Existing functionalities 
In order to record interactions within regions of the experiment, portions of the scanner geometry 
are designated as sensitive detectors. GATE only stores hits for those volumes that have a sensitive 
detector attached. Two types of sensitive detectors are defined in GATE: the crystal sensitive 
detector (crystalSD) is used to generate hits from interactions that occur inside the detector portions 
of the scanner. The phantom sensitive detector ( phantomSD) is used to detect and count the 
Compton and Rayleigh interactions occurring within the scanner’s field-of-view (FOV). In addition 
to other information concerning hits, for dosimetry studies, the crystalSD is used to recover 
information concerning the energy deposited at each interaction with their spatial position in the 
media (edep, posX, posY, posZ) in order to calculate the dose in volumes of interest. Those output 
data are available under ASCII and ROOT formats. 
III.1.1.D.2. Needed functionalities 
Dose calculations in volumes of interest should be available as a direct ASCII or ROOT output 
data. As explained before, for the moment, the user is required to analyze information concerning 
interaction by implementing his own program to obtain dose calculations. In homogeneous 
phantoms, the user should be able to locate where the dose has to be calculated, for example small 
cylinders on the central axis of a “water eye” or dose on the transverse and on the longitudinal plane 
of a water cistern, and obtain as a final output, directly from the simulation the calculated dose in 
Gray at each point of interest. 
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III.1.2. Platform improvements for dosimetric applications 
In the following parts are discussed the first improvements currently performed to improve GATE 
functionalities for dosimetric applications. In a first part is described the variance reduction 
technique added to the code to speed up Monte Carlo calculations. In a second part, our 
visualization tool for voxelized data is detailed to finish with the implementation of parameterised 
volumes described in a third part. 
III.1.2.A.  Variance reduction techniques implementation in GATE  
Several techniques are used to speed up the simulation, they are known as variance reduction 
techniques and, are inspired on the fact that only few particles are appropriate for data analysis. For 
example, in SPECT applications few photons are actually appropriate to form projection data. It is 
the same in radiotherapy for which interactions of particles occuring in some parts of the linear 
accelerator are useless to simulate for the dosimetric analysis. 
Some variance reduction techniques have been incorporated recently in the GEANT4 code: the 
geometrical importance sampling (that combined the geometrical splitting and the Russian 
Roulette) and the weight roulette. The technique that is incorporated into GATE is the geometrical 
importance sampling. The group of research Medical Image and Signal Processing (MEDISIP) part 
of the University of Ghent is in charge of the implementation of variance reduction for SPECT 
applications, their work presented at the EMBS conference in 2004 [3 ] is described below. 
III.1.2.A.1. The geometrical importance sampling 
The idea is to avoid the simulation of photons that do not contribute to the physical quantified 
output. For example, many particles are tracked in vain by GATE because halfway the material (in 
our case the human body), they lose their energy due to attenuation effects and are unable to 
contribute to projection data. In the same way, the tracking of photons travelling in the wrong 
direction with no chance of reaching detector seems also to be futile.  
First, to allow a higher chance of survival to photons in an attenuating medium, particle splitting at 
certain intervals in the geometry of the experiment is achieved. Then, to keep attenuation physically 
modeled, one needs to divide the weight of those photons by a splitting factor.  
Secondly, to avoid the tracking of photons that will never reach the detector, the Russian Roulette is 
used. Photons are submitted there to a game of chance where they can be deleted or increase their 
weight. 
 
 
Figure III- 10: Principle of geometrical importance sampling: the cells on the left have half  importance the cells 
on the right. Figure (a): the track is splitted in two tracks with half the weight. Figure (b): The track is either 
deleted or its weight is doubled after surviving Russian Roulette. 
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Figure III- 10 shows the simple case of two cells, where the cells on the left have imprtance value I1 
while those on the right have importance value I2= 2 ´ I1. 
Figure III- 11 shows the principle for a simple water phantom and a single SPECT detector head. 
The importance map geometry is defined by a set of concentric cylinder segments, with each 
cylinder doubling the importance value of the previous (inner) cylinder. The innermost cylinder has 
an importance value I1=1 and contains a point source, while the last two outer cylinders have equal 
importance. No splitting will occur in the collimator or crystal, as the outer cylinder covers the 
SPECT detector head. 
 
Figure III- 11: Simple importance map configuration for a water phantom and a single SPECT detector head. 
III.1.2.A.2. Pulse height tallies 
Pulse height tallies are commonly used in medical imaging. These tallies correspond to the 
frequency of detected pulses in distinct energy bins, covering a relevant energy spectrum. Since 
each pulse is the combination of different detector hits, the tally bin is not known until the end of an 
event history. In an analog simulation (without variance reduction) this poses no problems as each 
detected hit can be stored and the pulse can be calculated at the end of each event. Geometrical 
importance sampling combined with russian roulette however introduces branches into the particle 
history, which results in a much more complicated pulse calculation. Simply adding all hits in a 
detector crystal would lead to a completely wrong energy spectrum. 
Figure III- 12 shows a single photon event that encounter a collimator and makes a collision. We 
can observe backscatter of splitted track and track cut by the Russian Roulette. 
For the special case of SPECT simulations (without using variance reduction), each detected hit in 
the crystal is stored and the pulse is calculated at the end of each event. But, when we used 
geometrical importance sampling with Russian Roulette, new branches are introduced in the 
particle history which results in a much more complicated pulse calculation. Simply adding all hits 
in the detector crystal would lead to a completely wrong energy spectrum.  
That’s why a new track history has been developed in GATE by keeping a log of all tracks and their 
weights generated by GEANT4. At the same time, a track history tree is built by adding tracks 
where necessary to accommodate splitting and Russian Roulette. 
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Figure III- 12: Visualization of the collision of a photon with the collimator and the backscatter particles created. 
 
In Figure III- 13 track one represents the original photon. It may be subjected to Compton 
interactions and at some point it is split up by geometrical importance sampling. It should be noted 
that only one new track t2 is generated by this process. Tracks t1 and t2 have now half the weight of 
the original track t1. Track t2 is later split up as a result of a photoelectric effect. The rest of the 
diagram follows the same principles. In order to retain physically meaningful pulses, one needs to 
extract all the physically possible passes and assign a weight to them.  Each geometrical importance 
split introduces a new possible path. Figure III- 14 and Figure III- 15 show the possibilities for the 
diagram of Figure III- 13. Each path is assigned a weight according to the deconvolution approach. 
Starting at the “leaf nodes” of the tree, we work our way up and follow each of the paths in Figure 
III- 14 and Figure III- 15. Whenever a geometrical importance split is encountered, we multiply the 
weight of the path by the splitting ratio 1/n, with n the number of tracks splitted into. Results for the 
five paths are shown in Table III- 3. 
 
 
Figure III- 13: Simple particle history with branching: “v” indicates a geometrical importance split while “p” 
indicates a physical split. All tracks are numbered according the numbering rules in GEANT4 
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Figure III- 14: Two physically possible branches from 
the right side of Figure III- 13. 
 
 
Figure III- 15: Three physically possible branches 
from the left side of Figure III- 13. 
 
It is now possible to group crystal hits together by simply looking up if they belong to the same 
”physical” path and thus form an actual pulse. In this case it could be that only paths 1, 2 and 4 
result in actual pulses, but not paths 3 and 5 in Table III- 3 if there are crystal hits tied to paths 1, 2 
and 4, but not to paths 3 and 5. Note that the sum of weights of all paths in a track history tree 
equals 1, thus the total weight is conserved. A track can increase its weight by surviving Russian 
Roulette. In this case it could be scattered towards a region of higher importance and be subjected to 
geometrical importance splitting. Figure 6 shows how this is dealt with. The track history adds the 
same track t1 with its new weight 1 - as it is doubled by Russian Roulette - as a physical  branch. 
This ”new” track acts as a parent for the tracks produced by the splitting which follows in this case 
and represents in fact the same physical track t1 but with a doubled weight. By adding the track in 
the history tree in this way, we make sure that a parent track t1 with the appropriate weight can be 
located for any subsequent tracks. 
 
Table III- 3: The five paths with their respective weight. The sum of weights: 0.25+0.25+0.125=1. 
III.1.2.B. Visualisation of medical images in 3 dimensions 
The solution was found to create an external module to enable the visualisation of medical images 
described as Interfile format. The C++ langage has been chosen for the module encoding, the 
OpenGL has been used for the visualisation part and the display management. This module is 
compatible with a Linux system (Xlib library). 
The input data necessary for the visualisation are:  
- a file describing the image (info.visu);  
- the binary image (image.raw);  
- an ASCII transcription file (range.dat) 
Figure III- 16 represents an example of “info.visu” file to describe the medical data to be visualised. 
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Figure III- 16: File “info.visu” describing the medical data: name of the image,transcription file, number of 
voxels and their dimensions 
All the parameters described in this file are mandatory to visualise the medical data to use in GATE 
simulations. 
§ The fichierRAW parameter defines the binary image (CT slices) to use. 
§ The fichierRange parameter defines the transcription of the ranges of voxels. 
§ The fichierSortieRAW parameter defines the resulting binary image, after the user 
modifications. 
§ The fichierObjets parameter is a file describing the geometries to insert near or inside the 
voxelized medical slices. 
§ The fichierSortieObjets parameter is the file created after modifications of the user. 
§ The numCoupe parameter is for describing the number of slices part of the medical binary 
image 
§ The numPixelX, numPixelY parameters describe the number of pixels in the X and Y 
dimensions in the binary file. 
§ The sizePixelX, sizePixelY, sizePixelZ parameters define the voxel dimensions in the binary 
file. 
The module is composed of two parts:  
§ A dialogue screen describing all the functionalities available: zoom, translation of the slices, 
rotation of the slices, coordinate axes, moving on the different slices, adding of a slice, 
remove of a slice, registration, creation and insertion of volumes. 
§ A visualisation screen that shows the voxelized slices to the user. 
 
Figure III- 17 represents a screenshot of the C++ module. 
Thanks to this visualization tool, we are able to quantify the range of voxels for which we have 
defined a tissue associated to. Effectively the particularity of the viewer is to enable the coloring of 
voxels following some range values. The file table.visu allows the user to fix colours to visualize 
voxels ranges by describing them with a Red Green Blue (RGB) encoding. 
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Figure III- 17: Screenshot of the C++ module enabling the visualisation of medical data. On the left part, the 
dialogue screen enable the user to manage the image. On the right part the creen of visualisation 
 
Table III- 4: File table.visu. The color Red (255 0 0) 
has been assigned to the material Mat19-80 (for 
Hounsfield number between 19 and 80 H) 
 
 
Figure III- 18: Range of materials between 19 and 80 
H visualized in red color by the Linux viewer. 
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III.1.2.C. The parameterised volumes in GATE simulations 
III.1.2.C.1. Particle transport in Geant4 
Several levels occur in the particle transport : run (initialization, termination, and overall control of 
running a pre-defined number of histories), event (simulation of one history), track (an intermediate 
level between event and step), step( advancing one step). 
The unit of particle propagation is step, i.e, relocation of the particle from the current position to the 
next position. The G4SteppingManager class is responsible for the management of the particle 
transport. The GetPhysicalInteractionLength (GPIL) functions of all registered processes for the 
current type of particle in transport are invoked, and the travelling distance by every process is 
calculated (for G4Transportation) or sampled (for physics processes). The process with the 
minimum step length will be selected to be the one to constrain the step size; next, the 
AlongStepDoIt method of all continuous and continuous-discrete process with the minimum step 
length and the processes whose PostStepDoIt method will be executed no matter their step length 
will be invoked. The states of the particle (spatial position, energy, direction, spin, traveling 
time,etc) are updated during and at the end of each step.  
The step size is critical for computational efficiency. Due to the continuous energy loss, the step 
size should be small so that the difference of the cross sections at the beginning and at the end of the 
step is small enough. On the other hand, the step size cannot be too small in order not to increase 
the computing time too much. 
III.1.2.C.2. Parameterised volume 
In GATE (GEANT4) the best volume type for hosting up to tens of millions of CT voxels is a 
parameterised volume. Parameterised Volumes are repeated volumes in the case in which the 
multiple copies of a volume can be different in size, solid type, or material. Therefore for CT voxels 
defined in a parameterised volume, the dimensions and materials can all be different (even if the 
dimensions of the voxels are the same in CT images, the material allocation can be different for 
each voxel). A great advantage of parameterised volume is the high efficiency in memory usage. 
Effectively, in the case of ReplicaMatrix, each rectangular voxel is defined as a single volume (an 
object of G4Box), therefore the total memory is much larger since we have to save information 
concerning the mother volume, the name of the voxels and assign material density and composition. 
For a parameterised volume, although the volume is functionally divided into a certain number of 
daughter volumes (e.g, CT voxels), there is always only one volume object existent at any given 
time. This volume is used to represent all the daughter volumes by dynamically changing its 
properties of volume type, dimensions, location, and material. 
Each time when a particle encounters the boundary of the current volume, the properties of this 
volume will be refreshed to reflect those of the next daughter volume the particle will enter. The 
memory saving with parameterised volume for CT data is tremendous. 
 
To define a parameterised volume, the optimized direction X, Y, Z or all three directions have to be 
chosen to group the voxels in order to improve the transport efficiency. During optimization, the 
spatial span of each daughter volume along the designated optimization direction in the 
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parameterised volume is determined. The parameterised volume is then sliced with a thickness of 
one half of the minimum span. Each daughter volume (CT voxels) in a parameterised volume is 
given an exclusive index number (copy number) as the identifier, and this number is stored in the 
corresponding slice vectors. When a particle reaches the parameterised volume from outside, this 
copy number stored in the slice vector will be examined to find the daughter volume the particle 
will go into. In the case of the particle is already in the parameterized volume, when a particle 
arrives at the boundary of a voxel, a new voxel is searched from the vector of the current slice or 
one of its neighboring slices. 
When a particle goes from one voxel to another, we have to search the voxel where the particle will 
enter in. To improve the search mechanism of the voxel without modiying the Geant4 code, is to 
use one parameterised volume for one CT slice. The selected optimization axis should be parallel to 
the CT slice. For the case of  512 ´ 512 voxels per slice, the maximum number of voxels searched 
each time is 1024. 
III.2. VALIDATION OF GEANT4 ELECTROMAGNETIC PHYSICS FOR 
ELECTRONS 
III.2.1. Interactions of electrons 
Any energy loss process must calculate the continuous and discrete energy loss in a material. Below 
a given energy threshold the energy loss is continuous and above it the energy loss is simulated by 
the explicit production of secondary particles. Hard ionisation events generate secondary electrons 
and hard bremsstrahlung collisions generate secondary photons. The energy loss of the primary and 
the phase state of the secondary particles is generated by sampling from the appropriate probability 
density functions decribing the processes. 
Two processes play an important role in electron interactions with matter: 
§ Inelastic collisions of electrons with atomic electrons: the Möller cross section 
§ Inelastic interaction of electrons with nuclei: Bremsstrahlung 
III.2.1.A.  Inelastic interaction with atomic electrons: ionization process 
When an electron gets inside a medium, interactions with atomic electrons occur. Each of this 
interaction involves an energy loss Q that can take the value 0 to the cinetic energy of the electron 
t.  An incident electron is subjected to a lot of interactions before being stopped. This slowing down 
is caracterised by the linear energy transfer which is the mean energy transferred to the medium 
(dE) by the electron per unit of length. 
The Bethe-Bloch formula, caracterising the energy loss per length unit, must be modified in order to 
take into account the low electron mass involving that the mass of the incident particle (electron) is 
equal to the mass of the target particle (atomic electron) and the fact that the electrons aren’t 
distinguishable. 
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t :the cinetic energy of the electron, 
me: masse of an electron, 
/ cb u= , 
ck is a correction parameter that depends of energy and of the atomic number Z, 
I: mean ionisation potential. This quantity is difficult to calculate as it groups the global atomic 
properties (excitation levels and relative differential cross sections of those excitations). It has been 
measured for different materials and parameterised in function of Z. 
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III.2.1.B. Inelastic interaction of electrons with nuclei: Bremsstrahlung 
The interaction of a fast electron impiging on a neutral atom involves the curving of the trajectory 
of the electron under the coulombian force effect; the energy transfered is practically nul. The 
electron submitted to this acceleration radiates energy by the production of a photon with an energy 
E deducted from the kinetic energy of the electron. 
The radiative energy loss is given by 
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Bombarding electrons can also eject electrons from the inner shells of the atoms of the metal target, 
and the quick filling of those vacancies by electrons dropping down from higher levels gives rise to 
sharply defined characteristic x-rays. 
The energy loss by inelastic collisions is the major process involves in water at the energies used in 
brachytherapy treatments using electrons. The Bremsstrahlung process is predominant at high 
energy and for high Z media (approximatively 100 MeV in water and 10 MeV in lead). 
III.2.1.C. Electron stopping powers and ranges 
§ The maximum range, Rp, is the thickness of absorber at which the recorded transmission 
reduces to an undetectable level. To measure, it is therefore a rather arbitrary quantity 
depending on the threshold sensitivity of the detector. Usually it will be larger than the 
extrapolated range. 
§ The extrapolated range Rex, is determined by extrapolation of the linear portion of the 
transmission curve to the abscissa. For low-energy electrons, because of the occurrence of 
large energy transfers and angular deviations, Rex is the quantity which, on the available 
experimental evidence, most closely corresponds to the theoretical RCSDA range in the 
continuous slowing down approximation (CSDA). The continuous slowing down 
approximation (CSDA) range represents the path length that an electron would traverse 
when slowing down from its original energy E to a stop, if its rate of energy loss along the 
track were equal to the mean rate of energy loss. 
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§ The median range, Rm, is the thickness of absorber at which the transmitted fraction is 
reduced to 50%. 
 
 
 
Figure III- 19: Range definition 
 
 
 
 
 
 
Kinetic   Collision Radiative Total     D. Effect 
Energy    Stp. Pow. Stp. Pow. Stp. Pow. Parameter 
MeV       MeV cm2/g MeV cm2/g MeV cm2/g 
 
1.000E-02 2.256E+01 3.898E-03 2.256E+01 0.000E+00 
5.000E-02 6.603E+00 4.031E-03 6.607E+00 0.000E+00 
1.000E-01 4.115E+00 4.228E-03 4.119E+00 0.000E+00 
5.000E-01 2.034E+00 7.257E-03 2.041E+00 0.000E+00 
1.000E+00 1.849E+00 1.280E-02 1.862E+00 2.428E-01 
1.500E+00 1.822E+00 1.942E-02 1.841E+00 5.437E-01 
2.000E+00 1.824E+00 2.678E-02 1.850E+00 8.218E-01 
2.500E+00 1.834E+00 3.468E-02 1.868E+00 1.069E+00 
3.000E+00 1.846E+00 4.299E-02 1.889E+00 1.288E+00 
3.500E+00 1.858E+00 5.164E-02 1.910E+00 1.484E+00 
4.000E+00 1.870E+00 6.058E-02 1.931E+00 1.660E+00 
4.500E+00 1.882E+00 6.976E-02 1.951E+00 1.821E+00 
5.000E+00 1.892E+00 7.917E-02 1.971E+00 1.967E+00 
 
Figure III- 20: ESTAR: Stopping Powers and Range Tables 
for Electrons
 
The stopping power of matter for penetrating charged particles is a quantity of central significance 
in all physics experiments involving accelerated particles and in numerous applications such as 
radiation diagnostics and therapy, materials analysis and modification, etc.  
The stopping power is conventionally defined as the mean energy loss per travelled pathlength, -
dE/dx , the average being taken over a large number of trajectories sampling both the penetrated 
material and the beam. 
The database ESTAR [7 ] calculates stopping-power and range tables for electrons according to 
methods described in ICRU Reports 37 [8 ] (see Figure III- 20). Stopping-power and range tables 
can be calculated for electrons in any user-specified material. 
III.2.2. Geant4 electromagnetic physics packages 
The GEANT4 elctromagnetic packages handle the electromagnetic interactions of leptons, photons, 
hadrons and ions. In particular they include multiple scattering, ionization, bremsstrahlung, positron 
annihilation, photoelectric effect, Compton and Rayleigh scattering, gamma conversion, 
synchrotron, transition radiation, Cerenkov effect, refraction, reflection, absorbtion, scintillation, 
fluorescence, Auger effect, Particle induced X-ray Emission (PIXE). Three electromagnetic 
packages are available in GEANT4: 
§ Standard Package for which the physical processes of GEANT3 have been used but are not 
reliably modelled below 1 keV for ionization and bremsstrahlung processes. 
§ Low Energy Package, based on the Livermore Data libraries [9 ][10 ][11 ][12 ]which 
extends the reliable coverage of electromagnetic interactions down to 250 eV (and can be 
used up to approximatively 100 GeV). 
§ Low energy Package, based on Penelope analytical approach [13 ][14 ]. 
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III.2.2.A.  The Standard package 
The standard package [15 ] provides a variety of models based on  an analytical approach to 
describe the interactions of electrons, positrons, photons and charged hadrons in the enrgy range 
between 1 keV and 100 TeV. The models assume that the atomic electrons are quasi-free (i.e, their 
binding energy is neglected except for photoelectric effect) while the atomic nucleus is fixed (i.e., 
the recoil momentum is negelected). 
III.2.2.A.1. The ionization process in the standard package 
The  G4eIonisation class provides the continuous and discrete energy losses of electrons and 
positrons due to ionization in a material 
GEANT4 uses the Möller differential cross section, sM, to treat inelastic collisions of electrons with 
atomic electrons (e-e-) above a given threshold energy.  
The Möller cross section, which was derived for collisions with free electrons at rest, is given by 
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The direction of the ejected electron is generated with respect to the direction of the incident 
particle. The azimuthal angle f is generated isotropically and the polar angle q is calculated from 
energy-momentum conservation. This information is used to calculate the energy and momentum of 
both the scattered incident particle and the ejected electron, and to transform them to the global 
coordinate system. 
III.2.2.A.2. The bremsstrahlung process in the standard package 
The G4eBremsstrahlung class  provides the energy loss of electrons and positrons due to the 
radiation of photons in the field of a nucleus. Above a given threshold energy the energy loss is 
simulated by the explicit production of photons. Below the threshold the emission of soft photons is 
treated as a continuous energy loss. The parameterisation of the energy loss and the total cross 
section is given in the GEANT4 Physics Reference Manual [16 ]. 
III.2.2.B. The Low Energy package: evaluated data driven approach 
The Low Energy package extends the range of accuracy of electromagnetic interactions down to 
lower energy than the Standard package. The Low Energy package exploits evaluated data libraries 
(EPDL97 [9 ], EEDL [10 ], EADL [11 ]) that provide data for the calculation of the cross-sections 
and the sampling of the final state for the modeling of photon and electron interactions with matter. 
The current implementation of low energy electron and photon processes can be used down to 250 
eV. 
For now, GATE involves the use of the standard and low energy electromagnetic packages for the 
photon processes and the standard electromagnetic package only for the processes implying 
electrons. It adopts different models depending on the energy range and the particle charge. In the 
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high energy domain (> 2 MeV) the Bethe-Bloch formula, while in the low energy one (< 1 keV for 
protons) the free electron model are applied respectively. In the intermediate energy range 
parameterized models based on experimental data from Ziegler [17 ] and ICRU reviews are 
implemented; corrections due to the molecular structure of materials and the effect of the nuclear 
stopping power are taken into account. 
III.2.2.B.1. The ionization process in the Low Energy package 
The sampling method is based on energy spectra of delta rays contained in the EEDL, and the 
process is treated as a number of discrete interactions. The energy spectrum data are available as a 
function of sub-shell. Subsequent fluorescence is treated. 
The class G4LowEnergyIonisation calculates the continuous energy loss due to electron ionisation 
and simulates d-ray production by electrons. The d-electron production threshold for a given 
material, Tc, is used to separate the continuous and the discrete parts of the process. The energy loss 
of an electron with the incident energy, T, is expressed via the sum over all atomic shells, s, and the 
integral over the energy, t, of d-electrons. 
The d-electron production cross-section is a complimentary function: 
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where Tmax=0.5T is the maximum energy transfered to a d-electron, ss(T) is the total cross-section 
for the shell, s, at a given incident kinetic energy, T, and 0.1 eV is the low energy limit of the EEDL 
data. 
The probability of emission of a d-electron with kinetic energy, t, from a sub-shell, s, of binding 
energy, Bs, as the result of the interaction of an incoming electron with kinetic energy, T, is 
described by:  
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 Equation III- 6 
where the parameter x is varied from min (0.1 )/( )s sx eV B T B= + + to 0.5. The function, P(x), is 
parameterised differently in 3 regions of x: from xmin to x1 the linear interpolation with linear scale 
of 4 points is used; from x1 to x2 the linear interpolation with logarithmic scale of 16 points is used; 
from x2 to 0.5 the following interpolation is applied: 
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 Equation III- 7 
where A is a fit coefficient, g is expressed via the gamma factor of the incoming electron: 
 2(2 1) /g g g= -  Equation III- 8 
For the high energy case (x >> 1) the formula of P(x) is transformed to the Möller electron-electron 
scattering formula.  
The value of the coefficient, A, for each element is obtained as a result of the fit on the spectrum 
from the EEDL data for those energies which are available in the database. The values of x1 and x2 
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are chosen for each atomic shell according to the spectrum of  d-electrons in this shell. Note that x1 
corresponds to the maximum of the spectrum, if the maximum does not coincide with xmin. The 
dependence of all 24 parameters on the incident energy, T, is evaluated from a logarithmic 
interpolation.  
The sampling of the final state proceeds in three steps. First a shell is randomly selected, then the 
energy of the d-electron is sampled, finally the angle of emission of the scattered electron and of the 
d-ray is determined by energy-momentum conservation taken into account electron motion on the 
atomic orbit.  
The interaction leaves the atom in an excited state. The deexcitation of the atom is simulated. 
Sampling of the excitations is carried out for both the continuous and the discrete parts of the 
process.  
III.2.2.B.2. The Bremsstrahlung process in the Low Energy package 
The class G4LowEnergyBremsstrahlung calculates the continuous energy loss due to low energy 
gamma emission and simulates the gamma production by electrons. The gamma production 
threshold for a given material wc used to separate the continuous and the discrete parts of the 
process. The energy loss of an electron with the incident energy T re expressed via the integrand 
over energy of the gammas. 
The angular distribution of the emitted photons with respect to the incident electron can be sampled 
according to three alternative generators described below. The direction of the outcoming electron 
is determined from the energy-momentum balance. These generators are currently implemented in 
G4ModifiedTsai, G4Generator2BS and G4Generator2BN classes. 
III.2.2.C. The Low Energy package: analytic approach 
The physics models developed for the Penelope Simulation Toolkit (PENetration and Energy Loss 
of Positrons and Electrons) [13 ] have been implemented in GEANT4 as an alternative and 
independent set of processes in the Low Energy Package. The models, specifically developed for 
Monte Carlo simulation, are based on an approach which combines numerical databases with 
analytical cross section models for the different interaction mechanisms. In particular, they include 
low-energy and atomic effects (e.g. Doppler broadening, shell effects) and can be applied to 
energies from a few hundred eV to about 1 GeV [14 ]. 
 
The G4PenelopeIonisation class calculates the continuous energy loss due to electron and 
positron ionisation and simulates the d-ray production by electrons and positrons. The electron 
production threshold Tc for a given material is used to separate the continuous and the discrete parts 
of the process. 
The simulation of inelastic collisions of electrons and positrons is performed on the basis of a 
Generalized Oscillation Strength (GOS) model [18 ]. It is assumed that GOS splits into 
contributions from the different atomic electron shells.  
The total cross section s -(E) for the inelastic collision of electrons of energy is calculated 
analytically. It can be split into contributions from distant longitudinal, distant transverse and close 
interactions,  
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III.2.2.D. Specification of the GEANT4 physic processes in GATE 
In GATE, the physical processes specified for electrons and positrons transport are hard coded in 
the software and can not be altered. User can define the photon processes list (photo-electric effect, 
Compton scattering, Rayleigh effect and gamma conversion); and for each process, the user can 
select the specific energy model (standard electromagnetic physics, low energy electromagnetic 
physics or do not simulate the interaction). For electrons and positrons, the standard 
electromagnetic package is used.    
Charged particles are tracked to the end of their range. A cut allows the user to suppress particles 
whose range would be less than a user defined value that we name the range cut. As a consequence, 
there is no tracking cuts but only production thresholds. For photons the absorption length defines 
the cut. GATE allows the choice of three types of cut: the cut concerning secondary electrons 
(setElectronCut), the cut concerning the delta rays (setDeltaRayCut) and cut for X-rays 
(setXRayCut). 
The cuts concerning delta rays and X-rays production are always applied using the low-energy 
electromagnetic package. 
III.2.3. Multiple scattering implementation in GEANT4 
In GEANT4, the electron step algorithm is modelled in the multiple scattering process. A brief 
discussion follows concerning the implementation of the process and the corrected parameters 
concerning the angular distribution between 5.2.p02, 6.2.p02 and 7.0.p01 GEANT4 versions and 
the different dosimetric studies obtained as a consequence of these modifications. 
Multiple Scattering (MSC) simulation algorithms can be classified as either "detailed" or 
"condensed". In the detailed algorithms, all the collisions/interactions experienced by the particle 
are simulated. This simulation can be considered as exact; it gives the same results as the solution of 
the transport equation. However, it can be used only if the number of collisions is not too large, a 
condition fulfilled only for special geometries (such as thin foils), or low enough kinetic energies. 
For larger kinetic energies the average number of collisions is very large and the detailed simulation 
becomes very inefficient. In all condensed history Monte Carlo programs, the effect of the large 
number of elastic interactions which occur over a given pathlength is modelled by means of a 
multiple scattering theory; the global effects of the collisions are simulated at the end of a track 
segment.  
The global effects generally computed in these codes are the net displacement, energy loss, and 
change of direction of the charged particle.  
Most particle physics simulation codes use the multiple scattering theories of Molière [18 ], 
Goudsmit and Saunderson [20 ] and Lewis [19 ]. The theories of Molière and Goudsmit-
Saunderson, which are exact if the cross section remains constant over a step, describe the angular 
deflection of electrons after travelling a given pathlength. The Lewis theory computes the moments 
of the spatial distribution as well. None of these MSC theories gives the probability distribution of 
the spatial displacement. Therefore each of the MSC simulation codes incorporates its own 
algorithm to determine the spatial displacement of the charged particle after a given step. These 
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algorithms are not exact, and are responsible for most of the uncertainties in the MSC codes. 
Therefore the simulation results can depend on the value of the step length and generally one has to 
select the value of the step length carefully.  
A new class of MSC simulation, the "mixed" simulation algorithms, appeared in the literature 
recently. The mixed algorithm simulates the "hard" collisions one by one and uses a MSC theory to 
treat the effects of the "soft" collisions at the end of a given step. Such algorithms can prevent the 
number of steps from becoming too large and also reduce the dependence on the step length.  
As it was stated before, for the majority of photon and electron interaction processes, there are three 
implementations available: Standard, Low-energy and Penelope. The charged particle multiple 
scattering process is an exception in which alternative models are not available.  
The MSC model used in GEANT4 belongs to the class of condensed simulations, class II. The 
model is based on Lewis' MSC theory and uses model functions to determine the angular and 
spatial distributions after a step. The functions have been chosen in such a way as to give the same 
moments of the (angular and spatial) distributions as the Lewis theory. This theory is applicable for 
all scattering angles, and it allows electron step sizes to be arbitrarily small.  
III.2.3.A.  The angular distribution 
The angular distribution is approximately Gaussian for small scattering angles in both versions, but 
the width of the distribution has been changed between the versions; the Highland formula has been 
corrected for the central part of the distribution. There are differences in the tail of the distribution 
as well.  
III.2.3.A.1. The tail of the distribution 
GEANT4 version 5.2.p02 
In the Geant4 version 5.2.p02, the angular distribution u=cosq is sampled according to a model 
function g(u). The functional form of the function is  
 [ ]1 3 2( ) ( ) (1 ) ( ) (1 ) ( )g u p qg u q g u p g u= + - + -  Equation III- 10 
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where a>0, c>0 and u0 are model parameters, Ci normalization constants. For small scattering angle 
q, g1(u) is close to the Gaussian 2 20exp( / 2 )q q-  with 
2
0 1/ aq = , while g(u) has a Rutherford-like tail 
for large q, if c is not far from 2. 
GEANT4 version 6.2.p02 
In the 6.2.p02 version, the g2(u) function as the form 
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 with b>0 
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It involves a modification in the Rutherford-like tail for large q. 
GEANT4 version 7.0.p01 
Nothing has been modified in this version concerning the tail of the distribution. 
III.2.3.A.2. The width of the angular distribution: correction of the Highland formula 
GEANT4 version 5.2.p02 
In the 5.2.p02 version, the original Highland-Lynch-Dahl formula is used and give the 
parameterisation of the central part of the distribution as 
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where q0 is the width of the approximate Gaussian projected angle distribution, p, bc and z are the 
momentum, velocity and charge number of the incident particle, and x/X0 is the thickness of the 
scattering medium in radiation lengths. 
GEANT4 version 6.2.p02 
In this version, for electrons and positrons, the width given by the Highland formula was bigger 
than the value observed by Hanson (with 10% of differences at small angles). Therefore, a modified 
correction term was introduced: 
The original correction term 
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for x/X0 <1. 
The constants c1 and c2 were chosen in such a way that the Hanson data is reproduced in the 
simulation. 
GEANT4 version 7.0.p01 
The width of the central part of the distribution has been modified, the modified formula for q0 is 
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 Equation III- 12 
This formula gives much smaller step dependence in the angular distribution and describes the 
available electron scattering data better than the Highland form. 
III.2.3.B. The path length correction PLC 
In every electron step, a path length correction (PLC) is performed to calculate the energy loss 
along the step. The PLC refers to the transformation between the electron geometrical path length 
and the true path length. 
The geometrical path length is defined as the straight-line distance of the step and the true path 
length takes into account the path curvature and so, is longer than the geometrical path length. After 
the electron is transported along its initial geometrical path, the code samples the mean lateral 
displacement and the scattering angle. 
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The mean lateral displacement accounts for the lateral deflection of the electron along the step, 
whereas the scattering angle determines the direction vector of the next step. 
These two quantities are not correlated in the GEANT4 model. 
To prevent the step to cross a boundary, a safety radius that corresponds to the distance to the 
closest boundary, from all directions is compared to the lateral displacement. If the safety radius is 
smaller, the electron is relocated laterally to a distance equal to the safety. 
The PLC is not correlated to the scattering angle,  and the lateral displacement is switched off when 
the electron stops at the interface. 
III.2.4. The step control and boundary crossing parameters in GEANT4 
The particle step length is determined by the volume boundaries, thresholds for secondary particle 
production and the location of the discrete interaction site. For electrons, the production threshold is 
specified in terms of range which is then internally converted to energy for every material. 
The following lines represent the standard output generated by a GEANT4 execution. Production 
cuts have been fixed to 10 µm for electrons, 1 mm for positrons and 1 µm for photons. The 
conversion of range in energy is given for the materials used in the simulation, here, there’s Air, 
Water and Silver materials. 
========= Table of registered couples ============================== 
 
Index : 0     used in the geometry : Yes     recalculation needed : No  
 Material : Air 
 Range cuts        :  gamma 1 mum    e- 10 mum    e+ 1 mm 
 Energy thresholds :  gamma 990 eV   e- 990 eV    e+ 990 eV 
 Region(s) which use this couple :  
    DefaultRegionForTheWorld 
Index : 1     used in the geometry : Yes     recalculation needed : No  
 Material : Water 
 Range cuts        :  gamma 1 mum    e- 10 mum         e+ 1 mm 
 Energy thresholds :  gamma 990 eV   e- 6.44974 keV    e+ 338.695 keV 
 Region(s) which use this couple :  
    DefaultRegionForTheWorld 
Index : 2     used in the geometry : Yes     recalculation needed : No  
 Material : Silver 
 Range cuts        :  gamma 1 mum    e- 10 mum         e+ 1 mm 
 Energy thresholds :  gamma 990 eV   e- 61.9458 keV    e+ 1.37814 MeV 
 Region(s) which use this couple :  
    DefaultRegionForTheWorld 
 
All particles created in the simulation are tracked down to zero kinetic energy. The user is able to 
fix step size constraints using three parameters: 
The Maximum step size can be specified for any given volume thanks to the G4UserLimits class. 
A step function with the arguments dRoverRange and finalRange. The dRoverRange variable refers 
to the fractional range reduction, which is the maximum fraction of the stopping range that an 
electron can travel in a step. The step size decreases gradually until it is smaller than finalRange. 
The Step control near interfaces is determined by fr. When an electron crosses an interface, the step 
size is reduced such that it stops at the boundary first. As it gets transported away from a boundary 
into a new volume, the step length s is controlled by a parameter known as fr, 
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where r is the particle range and l is the transport mean free path that determines the mean particle 
scattering properties. The fr parameter is 0.2 by default, and can be changed to any value between 0 
and 1. The maximum number of steps per boundary crossing, n, restricted by this approach is  
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III.2.5. Evaluations and comparisons of stopping power and CSDA range for 
electrons 
The behavior of electromagnetic models for electrons in water was studied and compared to the 
reference data of ICRU. In fact, GEANT4 (version 6.2.p02) data were compared with ESTAR [7 ] 
database that generates stopping powers and CSDA ranges for electrons which are the same as 
those tabulated in ICRU report 37 [8 ].  
Electrons are generated with a chosen energy from the center of a box, filled with liquid water. The 
multiple scattering and the energy loss fluctuations are not active, in agreement with the stopping 
power and CSDA range definitions. 
Comparisons between reference data and Geant4 simulations obtained by means of the specific 
electromagnetic Packages have been performed by means of a Goodness-of-Fit Statistical Toolkit 
[21 ], specialised in the comparison of data distributions. Among the ones available in the 
Goodness-of-Fit Statistical Toolkit, the Chi-squared test was selected, as this is the only Goodness-
of-Fit algorithm including data uncertainties in the computation of the test statistics. The Goodness-
of-Fit Statistical Toolkit returned the computed Chi-squared value together with the number of 
degrees of freedom and the p-value of the comparison. 
The p-value represents the probability that the 
test statistics has a value at least as extreme as 
that observed, assuming that the null hypothesis 
is true. Obviously p-values higher than the 
confidence level a = 0.05 set a priori led to the 
acceptance of the null hypothesis, stating the 
equivalence between reference data and Geant4 
simulations.  
The validation test exhibited that all the three 
Geant4 physics models are in excellent 
agreement with the NIST reference data; the test 
has not pointed out any particular difference 
among the three approaches. 
 
Figure III- 21: Goodness-of-Fit test results concerning 
the electron stopping power plotted as a function of 
the atomic number Z of the selected elements 
(Standard: black diamonds, Low Energy EPDL: black 
squares, Low Energy Penelope approach: empty 
circles). All the p-values obtained are higher than the 
confidence level set (a = 0.05). 
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III.2.6. Beta ray point source dose distributions 
III.2.6.A.  Introduction 
Radial distributions of dose around isotropic point sources of electrons or beta emitters in an infinite 
water medium, or dose-point-kernels are the basis of many dosimetry problems for medical 
applications. This calculation is the basis for calculate doses from extended source distributions in 
homogeneous media or for averaging doses over finite volumes. In ocular brachytherapy, dose 
deposited from 106-Ru ophthalmic applicators of a given shape and of a given dimension can be 
derived from the calculation of dose point kernels. 
Analytical methods fail to account for the 3D nature of radiation transport and all relevant energy 
deposition processes. Monte Carlo simulations of dose point kernels is the only practical method for 
calculation that can consider all interactions of importance for the transport of secondary particles. 
III.2.6.B. Monte Carlo calculation details 
In Monte Carlo simulations, the dose around a point source is obtained by scoring the energy 
deposited in thin concentric spherical shells around the source per particle decay. Dose estimation 
techniques have been developed for photons, the linear track length kerma estimator of Williamson 
[22 ] that estimates the kerma by scoring tracks crossing a volume is widely used now, but there are 
no alternatives for electrons. 
In Monte Carlo calculations, the energy scored in a spherical shell delimited by the radii R1 and R2 
divided by the shell mass is taken as the dose at some effective radius of the shell R1<Reff<R2. The 
effective radius Reff is actually the distance of a hypothetical zero thickness scoring shell from the 
source that would yield the same result as the finite thickness scoring shell delimited by R1 and R2 
used in the calculations. 
The energy deposited in spherical shells has been scored to obtain dose point kernels in water for 50 
keV, 100 keV, 200 keV, 1MeV and 4 MeV monoenergetic electron point sources and for 106-Rh 
beta sources. To model the beta sources we generated electrons following the spectrum from the 
ICRU Report 56 [23 ]. 
A cut-off of 2 keV have been chosen for the simulations. 
The dose distribution is converted into a dimensionless quantity as suggested by Cross [24 ] to 
become a slowly varying quantity with energy, making interpolation in energy more accurate with 
relatively wide energy intervals. This dimensionless quantity is defined as  
 2( / , ) 4 ( , ) /E Ej r r E r D r E r Epr=  Equation III- 13 
with r being the radial distance to the middle of the spherical shells, rE the nominal CSDA range 
(see Table III- 5 for the values of the CSDA range for the different electron energies, values have 
been taken from the NIST web database ESTAR [7 ]), r the density of the medium, and D(r,E) the 
dose per incident particle at distance r. The quantity defined in Equation III-13 represents the 
fraction of emitted energy that is deposited in a spherical shell of scaled radius r/rE to r/rE + d(r/rE). 
                                                         Chapter III. The GATE Monte Carlo simulation platform for dosimetric applications 
107 
 
Table III- 5: Electron CSDA ranges, rE, in water 
for electrons with initial energies E. 
A spherical water phantom of 400 mm in diameter contains 22 spherical shells each of thickness of 
0.05 rE. This selection was made for comparison with the results by Cross who used this thickness. 
III.2.6.B.1. Uncertainties evaluation  
Uncertainties associated to Monte Carlo results have been calculated by doing a quadrature sum of 
the statistical uncertainty and the total cross sections uncertainty.  
The results presented are affected by a total Monte Carlo uncertainties % stot calculated as the 
quadrature sum of the statistical uncertainty %sµ and the cross section uncertainty %sC.S: 
 
2 2
.% % %tot µ C Ss s s= +  
Equation III- 14 
 
Statistical uncertainties don’t overlapp 0.016%, 0.02%, 0.013%, 0.01%, 0.09% and 0.08% 
respectively for 50 keV, 100 keV, 1 MeV, 2 MeV, 3 MeV and 4 MeV electron dose point kernels. 
Stopping powers implying electrons (ionisation, …) obtained with the standard energy package of 
Geant4 version 6.2.p02, have been compared to the ESTAR database given by NIST [7 ] for an 
energy spectrum going from 1 keV to 10 MeV. The relative deviation between NIST and Geant4 
values is below 5% between 1 keV and 10 MeV.  
As no evaluation concerning electron cross sections have been performed between the GEANT4 
electromagnetic standard package and the NIST database, the total cross section uncertainty 
concerning electrons .% C Ss  is evaluated to be 5%. It results that the uncertainties allocated to dose 
point kernels don’t overlapp 5% for all distances. 
III.2.6.C. Results 
III.2.6.C.1. Monoenergetic beta point source dose kernels 
Figure III- 22 to Figure III- 27 include comparison of the dimensionless quantity j(r/rE,E) obtained 
using the GEANT4 versions 5.2.p02, 6.2.p02 and 7.0.p01 (standard electromagnetic package) with 
several calculations reported in the literature for 50 keV, 100 keV, 1 MeV, 2 MeV, 3 MeV and 4 
MeV monoenergetic electron sources. The curves calculated by Simpkin & Mackie with EGS4 [25 
], by Cross et al. [24 ] with the 2.1 1988 version of ITS/ACCEPT code, a derivative of ETRAN, by 
Schaart (work specially performed for this comparison and not published) with the MCNP4c code 
and by Mainegra et al. [26 ] with EGSNrc are shown.  
Since 1973, a number of improvements have been made in the ETRAN code. In particular, electron 
stopping powers [27 ][28 ][29 ] and bremsstrahlung cross sections [30 ][31 ][32 ][33 ] were revised 
and an error in the Landau/Blunck-Liesegang [34 ] distribution of energy losses was corrected [35 
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][36 ][32 ][33 ]. Using these improvements Berger and Seltzer recalculated the kernels for 
monoenergetic electrons in 1990. In addition the EGS4 code which has been extensively used for 
electron beam calculations [37 ][38 ][39 ] was used by Simpkin and Mackie [40 ] who have 
published point source dose kernels for monoenergetic electrons and for eight beta-ray emitters. 
For the GATE calculations the energy deposited in each of the spherical shells was scored. Figure 
III- 28 to Figure III- 37 show the relative errors calculated between the GEANT4 versions and 
between GEANT versions and MCNP4c code. A fairly good agreement can be found between 
EGS4 and EGSNRc calculations. While MCNP4c and ETRAN are in well agreement and differe 
from the results obtained with EGS codes. ACCEPT results are in disagreement with those codes. 
After comparisons of the three GEANT4 versions, it appears that the version 6.2.p02 is in far better 
agreement with MCNP4c results than the other GEANT4 version with discrepancies less than 10% 
until 1 MeV and near 1% at higher energy. 
 
Figure III- 22: Comparison of GATE_G4 versions calculated dose point kernels for 50 keV electrons with 
EGSnrc (Mainegra), EGS4 (Simpkin and Mackie), ACCEPT (Cross) and MCNP4c. 
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Figure III- 23: Comparison of GATE_G4 versions calculated dose point kernels for 100 keV electrons with 
EGSnrc (Mainegra), EGS4 (Simpkin and Mackie), ACCEPT (Cross) and MCNP4c. 
 
Differences between ACCEPT and other Monte Carlo codes at the origin is explained by the fact 
that Cross et al. used an unrestricted collision-stopping power at this point arguing that the mean 
energy deposited per source electron in a shell of thickness dr is Spcolldr, where Spcoll is a 
restricted collision-stopping power that relects the fact that knock-on electrons (delta rays) have not 
yet built up to equilibrium with the source electrons. The relative dose contribution from 
backscattered electrons becomes negligible as r approaches zero. The unrestricted collision stopping 
power is expressed by the following Equation III- 15: 
 
(0, ) E
coll
rdE
j E
dx E
æ ö= ´ç ÷
è ø
 Equation III- 15 
A cubic interpolation on a linear scale was used to join this point smoothly to the calculated values 
at r/rE³0.125. stopping powers and ranges were taken from Berger and Seltzer (1982). 
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Figure III- 24: Comparison of GATE_G4 versions calculated dose point kernels for 1 MeV electrons with 
EGSnrc (Mainegra), EGS4 (Simpkin and Mackie), ACCEPT (Cross) and MCNP4c 
 
The largest differences occur near the maxima of the distributions (r/rE=0.625), where they amount 
to 6%, 2% and 2.3% for 4 MeV electrons respectively between GEANT4 version 5.2.p02, version 
6.2.p02 and 7.0.p01 and MCNP4c. Near the end of the ranges differences are larger between the 
code (see Figure III- 28 to Figure III- 37). The 6.2.p02 is the version for which less differences are 
observed with MCNP4c calculations. 
 
Figure III- 25: Comparison of GATE_G4 versions calculated dose point kernels for 2 MeV electrons with EGS4 
(Simpkin and Mackie), ACCEPT (Cross), ETRAN (Seltzer) and MCNP4c 
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Figure III- 26: Comparison of GATE_G4 versions calculated dose point kernels for 3 MeV electrons with EGS4 
(Simpkin and Mackie), ETRAN (Seltzer) and MCNP4c 
 
Figure III- 27: Comparison of GATE_G4 versions calculated dose point kernels for 4 MeV electrons with 
ACCEPT (Cross), ETRAN (Seltzer) and MCNP4c 
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Figure III- 28: Relative errors calculated between 
GEANT4 versions for 100 keV electron dose point 
kernel 
 
Figure III- 29: Relative errors calculated between 
GEANT4 versions and MCNP4c (Schaart) for 100 keV 
electron dose point kernel 
 
Figure III- 30: Relative errors calculated between 
GEANT4 versions for  1 MeV electron dose point 
kernel 
 
Figure III- 31: Relative errors calculated between 
GEANT4 versions and MCNP4c (Schaart) for 1 MeV 
electron dose point kernel 
 
Figure III- 32: Relative errors calculated between 
GEANT4 versions for  2 MeV electron dose point 
kernel 
 
Figure III- 33: Relative errors calculated between 
GEANT4 versions and MCNP4c (Schaart) for 2 MeV 
electron dose point kernel
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Figure III- 34: Relative errors calculated between 
GEANT4 versions for  3 MeV electron dose point 
kernel 
 
Figure III- 35: Relative errors calculated between 
GEANT4 versions and MCNP4c (Schaart) for 3 MeV 
electron dose point kernel 
 
Figure III- 36: Relative errors calculated between 
GEANT4 versions for  4 MeV electron dose point 
kernel 
 
 
Figure III- 37: Relative errors calculated between 
GEANT4 versions and MCNP4c (Schaart) for 4 MeV 
electron dose point kernel 
The large discrepancies obtained with the different GEANT4 versions, less than 10% before 
r/rE=0.625 and a relative error that could approach 100% at large distances from the source 
(r/rE»0.825), involved a precise study of the differences occuring in the GEANT electromagnetic 
physics implementation since version 5.2.p02 to version 7.0.p01. 
 
In order to remove doubts that we had concerning our GATE simulations, we reproduced in a first 
time, the analysis of a 4 MeV electron dose point kernel with a GEANT4 program (calculations 
performed by Michel Maire, part of the GEANT4 collaboration). Calculations were performed 
using a cut value of 1 keV in water for electrons. 
Results observed were the same as with the GATE calculations except at a distance near 0 for 
which j(r/rE,E) is about 0.85 instead of 0.65 with GATE calculations and MCNP4c. This difference 
is explained by the fact that GEANT4 results have been reproduced using a cut value of 1 keV in 
water for electrons. 
The current GEANT4 version (7.1.p01) gives the same results as the 7.0.p01. 
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Figure III- 38: Comparisons of the GEANT4 versions concerning calculations of a 4 MeV dose point kernels 
using GEANT4 programs. 
 
Comparison of the Standard and Low Energy packages 
In order to highlight differences between the Standard Electromagnetic package and the Low 
energy one, we reproduce the simulation of a 4 MeV electron dose point kernels using the GEANT4 
version 5.2.p02. This comparison will allow to define if the differences obtained between GATE 
simulations and other Monte Carlo is related to the implementation of the ionization process in 
GEANT4. 
Results show discrepancies between the two packages but results obtained with the Low Energy 
package isn’t in better agreement with other Monte Carlo calculations (neither with MCNP4c nor 
with ETRAN and ACCEPT codes). The shape of the curves is the same between the two packages 
with a displacement to longer distances for the Low Energy processes. 
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Figure III- 39: Comparison of the GEANT4 electromagnetic packages on 4 MeV electron dose point kernels. 
 
As the Low Energy package doesn’t give results in better agreement with the other Monte Carlo 
calculations, we try to find how the geometry boundaries and cuts could influence results. 
Influence of cuts and geometry boundaries 
We reproduced dose point kernels calculations by comparing results obtained using a large volume 
of water (in this configuration, the dose deposited is calculated in virtual spherical shells in a ROOT 
program) and using spherical shells modelled in the simulation for the recovering of hits. For both 
comparisons we fix different energy cuts on electrons: 2 keV, 6 keV and 10 keV in water. 
By considering a large volume of water we remarked that the cut values have a non negligeable 
influence on the dose deposited (see Figure III- 40). On the contrary, by choosing to model the 
spherical shells in the simulation, the changes occuring on the cut values have no influence on dose 
deposited (see Figure III- 41).  
Results obtained with a cut value of 2 keV in a large volume of water give comparable results to 
those obtained by modelling spherical shells in the simulation. 
With low cut values, the user is sure to reproduce the maximum of electron interactions occuring in 
a medium and obtain more precise results. By splitting the medium in thin parts (such like the 
spherical shells), the step length is adapted to the boundaries in the simulation. The step of the 
particle will be stopped at the boundary, an energy loss is allocated to this step in the volume, then a 
new step is created and the tracking of the particle continue. 
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Figure III- 40: Influence of the cut value on 4 MeV electron dose point kernels calculated in a large volume of 
water. 
 
 
Figure III- 41: Influence of the cut value on 4 MeV electron dose point kernels calculated in spherical shells. 
 
By the way, this behavior of the code can’t explain the discrepancies obtained with other Monte 
Carlo calculations and between the GEANT4 versions. 
By analysing the electromagnetic physics processes, we remark that the multiple scattering 
implementation was the only process common to all the GEANT4 package. Differences in the 
implementation of the MSC along the GEANT4 version could explain discrepancies in the results. 
Influence of the angular distribution implementation for the different GEANT4 versions on electron 
MSC 
In order to test the differences occuring in the MSC implementation (the angular distribution) 
between the GEANT4 version 6.2.p02 and 7.0.p01, we ran the fifth example concerning 
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electromagnetic processes (TestEm5). We studied the transmission of electrons through a thin layer 
of water. The layer made of water is located at 1.273 cm from the monoenergetic electron source in 
a world filled with air. The energy of electrons is 4 MeV. One million of electrons have been 
generated. We plotted the space angle of transmitted electrons at the exit of the water layer and the 
projected angle on the y and z direction of the same scattering angle. The cut-off value in range for 
electrons is 0.0043 mm, equivalent to 1 keV in air and 2 keV in water medium. 
 
 
Figure III- 42: OpenGL view of the setup and particles simulated to study the Multiple Scattering in GEANT4. 
 
 
Figure III- 43: Angular distributions of 4 MeV 
electrons transmitted through a water foil of 1.02 mm. 
Comparisons between 6.2.p02 and 7.0.p01 versions. 
 
Figure III- 44: Angular distributions of 4 MeV 
electrons transmitted through a water foil of 1.02 mm 
represented with a logarithmic scale. Comparisons 
between 6.2.p02 and 7.0.p01 versions. 
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Figure III- 45: Projected angle on the y direction of 4 
MeV electrons transmitted through a water foil of 1.02 
mm. Comparisons between 6.2.p02 and 7.0.p01 
versions. 
 
Figure III- 46: Projected angle on the y direction of 4 
MeV electrons transmitted through a water foil of 1.02 
mm represented with a logarithmic scale. 
Comparisons between 6.2.p02 and 7.0.p01 versions. 
 
Distribution is roughly Gaussian in shape and centered at zero. The spread in scattering angles is 
significantly wider for the 7.0.p01 version than for the 6.2.p02 version whereas the peak is higher 
for the 6.2.p02 version. To quantify better the differences between the two versions we fitted with a 
standard Gaussian curve (see Equation III- 16), the projected angles. 
 2
1
0
2
( ) exp 0.5
x p
f x p
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æ öæ ö-
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 Equation III- 16 
A difference of 10.8% on the FWHM has been found between the two fits. 
 
Figure III- 47: Transmitted energy spectrum of 4 MeV electrons through a 1.02mm water foil. Comparisons 
between 6.2.p02 and 7.0.p01 versions. 
 
                                                         Chapter III. The GATE Monte Carlo simulation platform for dosimetric applications 
119 
Figure III- 47 presents a comparison between 6.2.p02 and 7.0.p01 versions concerning the energy 
spectrum of transmitted electrons at the exit of the thin water foil. As it can be shown, no 
differences have been found between the two versions. 
III.2.6.C.2. Beta dose point kernels for 106Rh polyenergetic source 
We have calculated the dose point kernel for the 106Rh beta source, using spectrum from ICRU 
Report 56 [23 ]. This spectrum has been modelled in the simulation like it was explained in Chapter 
I. The dose rate per unit activity times the distance squared is plotted in order to be compared with 
Cross et al. calculations (ACCEPT version 2.1 and version 3.0 have been compared). The results by 
Cross et al. show significant discrepancies near the origin for the 2.1 version where they use the 
unrestricted collision stopping power approximation (Equation III- 15) to estimate the dose at the 
origin. A good agreement between the different GEANT4 code versions is found. 
 
Figure III- 48: Dose rate in water per distance squared from a 106Rh beta spectrum as calculated with the 
GATE_G4 versions and compared with ACCEPT (Cross). 
 
At distances between 0.016 and 1.1 cm, GEANT4 version values agree within 2% or better. The 
major discrepancy occur at low radial distance with ACCEPT_3 results.  
Differences between GEANT4 versions have also been modelled by plotting j(r/rE,E) (see Figure 
III- 49). Relative errors don’t overlapp 2% and 5% respectivelly between 5.2.p02 and 6.2.p02 and 
6.2.p02 and 7.0.p01 versions. These results make appear far less discrepancies between the 
GEANT4 versions with the 106Rh point source than with monoenergetic point source. 
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Figure III- 49: Comparison of GATE_G4 versions calculated dose point kernels for 106Rh point source. 
 
 
Figure III- 50: Relative errors calculated between GEANT4 versions for  106Rh dose point kernel. 
Influence of the angular distribution implementation for the different GEANT4 versions on electron 
MSC 
In the same manner as for the monoenergetic dose point kernels, we tested the differences occuring 
in the MSC implementation (the angular distribution) between the GEANT4 version 6.2.p02 and 
7.0.p01 for polyenergetic sources. We kept the same geometry configuration as for monoenergetic 
electrons, but this time the source is composed of a distribution in electron energy, the energy 
spectrum was assumed to be Gaussian with a mean energy of 2.0 MeV and a sigma equal to 1.27 
MeV that is equivalent to a FWHM equal to 3.0 MeV. One million of electrons have been 
generated. We plotted the space angle of transmitted electrons at the exit of the water layer and the 
projected angle on the y and z direction of the same scattering angle. The cut-off value in range for 
electrons is 0.0043 mm, equivalent to 1 keV in air and 2 keV in water medium. 
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Figure III- 51: Angular distributions of electrons 
emitted following a Gaussian spectrum transmitted 
through a water foil of 1.02 mm. Comparisons 
between 6.2.p02 and 7.0.p01 versions. 
 
Figure III- 52: Angular distributions of electrons 
emitted following a Gaussian spectrum transmitted 
through a water foil of 1.02 mm on. Comparisons 
between 6.2.p02 and 7.0.p01 versions on a logarithmic 
scale. 
 
 
Figure III- 53: Projected angle on the y and z direction 
of electrons emitted following a Gaussian spectrum 
transmitted through a water foil of 1.02 mm. 
Comparisons between 6.2.p02 and 7.0.p01 versions 
 
Figure III- 54: Projected angle on the y and z direction 
of electrons emitted following a Gaussian spectrum 
transmitted through a water foil of 1.02 mm. 
Comparisons between 6.2.p02 and 7.0.p01 versionson 
a logarithmic scale. 
 
We can note differences between versions for the angular deviation at the exit of the water foil. The 
energy spectrum of electrons transmitted after the foil has also been plotted (see Figure III- 55). We 
can remark higher differences between the versions than for monoenergetic electrons. 
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Figure III- 55: Transmitted energy spectrum of electrons emitted following a Gaussian through a 1.02mm water 
foil. Comparisons between 6.2.p02 and 7.0.p01 versions. 
 
CONCLUSION 
After the large usage of the GATE platform for SPECT and PET applications, it is now being 
customized to face the problematics encountered for dosimetric studies. The possibility offered by 
the platform to read and convert CT images for the calculation of dose deposited in reconstructed 
tissues, make it very attractive for treatment planning with real patient data. 
In addition, the implementation of the variance reduction technique coupled with the splitting of the 
simulation on cluster and/or grid environments would give great assets to the platform for a soon 
optimized usage in clinical applications. 
However, new developments need to be implemented in the code to face the requirements of 
dosimetry applications, such like geometry and system facilities, output data directly defining the 
dose deposited in tissues. 
Furthermore, GATE calculations based on the GEANT4 physics have proved to give reliable results 
for simulations implying photons. As electrons are the final particles implied in the dose deposited 
at the millimeter scale (voxel size) and as beta sources and radiations are also particularly used in 
radiotherapy treatments, it has been of high importance to validate the GEANT physics for such 
particles. 
Differences occuring between GEANT4 versions for the simulation of electron dose point kernels 
have been explained by changes occuring in the Multiple Scattering implementation between the 
versions. As the 6.2.p02 version gives more reliable results with other Monte Carlo codes and as the 
simulation of Rh106 dose point kernel don’t make appear large differences between the GEANT4 
versions, the choice have been made to use the 6.2.p02 version for the simulation of 106Ru/106Rh 
ophthalmic applicators dosimetry in water medium presented in Chapter IV. It is expected that the 
Multiple Scattering encoding will change completely in the GEANT4 version 8 to fit results obtain 
with EGSnrc code in particularly for dosimetric applications. 
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Chapter IV.  
 
 
106Ru/106Rh ocular brachytherapy 
treatment planning using GATE. 
Preliminary studies using CT images. 
 
 
 
INTRODUCTION 
The integration of point kernels is used in some hospitals and laboratories for calculating dose in the 
eye and elsewhere. In Centre Jean Perrin the analytic software Plaque Simulator (version 5.3.2) uses 
a cruder method that consists into summing over some hundreds of individual point sources to 
estimate the dose rates in a modelled eye. 
The goal is to quantify how accurately eye applicator doses can be calculated by different methods 
using Monte Carlo, integration of point kernels or analytic calculations. We compare in a first part 
our GATE Monte Carlo results using the GEANT4 version 6.2.p02 with measurements and the 
previous cited three calculation methods. Doses are calculated in water on the central axis and on 
the median plan of the beta emitter ophthalmic applicators. 
After a validation in aqueous media, the ambition is to use GATE Monte Carlo platform on 
voxellized images described by CT slices. In order to perform such treatment planning with GATE, 
in a second part, we study the impact of the translation of CT numbers on tissue parameters (density 
and atomic composition of human tissues) on the dose deposited by photon and electron beams.  
Soft and bone tissues described by a gray scale in CT slices are identified to be well translated by 
colouring the corresponded Hounsfield units in voxels using the tool in Chapter IV.  Then, the 
influence of the translation of tissue parameters on the dose deposited by electron and photon beams 
is studied. 
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IV.1. 106Ru/106Rh OCULAR BRACHYTHERAPY TREATMENT PLANNING 
USING GATE 
IV.1.1. Theoretical calculation of the beta point source dose function for 
106Ru/106Rh eye applicators, comparisons 
The beta point kernels for radionuclides can be obtained from theoretical calculations. Loevinger [1 
] proposed in 1956, a function describing the b  emission of radionuclides based on the data 
available at that time. Two types of measurement can be performed. First, the measurements can be 
performed using extrapolation chambers on extended plane sources; an homogeneous medium and 
dimensions of the beta plane source larger than the diameter of the chamber have been chosen for a 
reliable measurement. A second method is to measure the dose distribution around a point source of 
a b-emitting radionuclide in air (isodoses in air are sufficiently extended to allow the usage of large 
size detectors). The air must be free and the scattering produced by objects must be negligible. 
Then, dose distributions in tissue are derived from dose distributions in air by applying corrections 
concerning the differences in medium composition and density [2 ][3 ]. 
From these types of measurements, the beta point source dose function can be derived using 
mathematics. By taking into account more recent experimental data (those of Cross in 1967) [4 ], 
and the theoretical studies of Berger [3 ][5 ], a new function has been established. 
IV.1.1.A. The function of Loevinger 
IV.1.1.A.1. Definition 
 The function proposed by Loevinger is the following: 
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 Equation IV-1 
[ ] 0with for cruxº ³  
where 
J(x) is the absorbed dose rate at a distance x (in cm) from the point source (in Gy MBq-1h-1) 
u is an apparent absorption coefficient (in cm2 g-1) 
r  is the density of the homogeneous medium (in g cm-3) 
c  is a dimensionless parameter, which gives the value of the first term inside the curly bracket at  x 
= 0 and also the value rux at which this term becomes and remains zero, 
B  is a normalising constant, evaluated by the requirement that the total energy absorbed in avery 
large sphere must just be the energy emitted. 
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with  1 2 23 ( 1)c c ea - = - -  
To match accurately the Berger and Cross data, the following expression has been proposed by 
Vynckier and Wambersie [6 ]: 
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A new dimensionless parameter f has been introduced with a modified expression of a: 
1 2 23 ( 1) (3 )exp(1 ) 4exp(1 /2)c c e f f fa - = - - + + - - -  
The values of the different parameters corresponding to the 106-Rh radionuclide are the following: 
c=0.939, f=5.26, u=3.62 cm2/g for a mean beta energy of 1.41 MeV. The water density is used for 
r. 
The dose rates inside the eye are calculated by integrating the beta point source function over the 
plaque. We reproduced the work of Hokkanen et al. [7 ] by using the software MATHEMATICA 
for the applicators CCA, CCB, CCX and CCZ (the published work of Hokkanen was done only for 
the CCB plaque). 
The dose rate can be expressed as: 
 
2
1 1( ,0, ) ( ) sinD x z J r drd dl q q j
·
= ò  Equation IV-4 
 
Following the Figure IV- 1, the spherical coordinates is at the centre of curvature of the plaque. 
Point r is on the plaque and the dose rate is measured at r1, with l=|r1-r|. 
We used a constant r in the calculations, [ ]max0,q qÎ , where qmax determines the size of the plaque, 
and [ ]0,2j pÎ . The dose rates have been calculated for the plane y1=0. 
The plaque was assumed to be spherically symmetric and consists of radioactive material only. For 
practical eye applicators, we have to keep in mind that homogeneity is spoiled by the metal source 
window and the metal backscatterer. This can result in erroneous modellisation of dose 
distributions. 
Comparisons concerning depth dose on the central axis and isodoses are presented in sections 
IV.1.2.b and IV.1.2.c. 
 
Figure IV- 1:The coordinate system used in the calculations. 
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IV.1.2. Monte Carlo calculations of ocular brachytherapy treatments using 
106Ru/106Rh ophthalmic applicators, comparisons 
IV.1.2.A. GATE Monte Carlo calculation details 
Physics concerning electron dose point kernels have been studied in the previous chapter. The 
GEANT4 versions fail to give homogeneous results for monoenergetic electrons but show that the 
6.2.p02 version is in better agreement with MCNP4c calculations. By taking into account that 
calculations concerning 106Rh point kernels show less discrepancies between GEANT4 versions, the 
6.2.p02 version of GEANT4 was chosen to simulate dose distributions for ophthalmic applicators. 
IV.1.2.A.1. Description 
GATE calculations are based on the 1.1.0 version of the platform that is compatible with the 
GEANT4 version 6.2.p02. The cut value on electrons has been chosen to be of 2 keV in water. 
Ophthalmic applicators in silver and radioactive source layer have been modelled in the simulation 
using the angles q and j which describe respectively the angle from the central axis to the 
applicator and the angle from the x axis (see Figure IV- 2 and Table IV- 1). 
 
 
Figure IV- 2: Coordinate system used in 
GATE calculations. 
 
 
Table IV- 1: q and j angles defining the ophthalmic plaques.
 
The radioactive source has been modelled to be of 0.2 mm in thickness and emitting the 106Rh beta 
spectrum described in Chapter I.  
Hits representing the deposited energy are collecting in a large volume of water (sphere of 30 cm in 
diameter). 
The dose deposited on the central axis of the applicators are collected in small cylinders of 1 mm in 
diameter and 0.5 mm in height to reproduce the same dimensions of the plastic scintillator used for 
the calibration measurements performed by BEBIG on the plaques. 
The dose deposited in the 3 dimensions to obtain isodoses are calculated in small voxels of 1 mm3. 
In this section, dose distributions calculated by Monte Carlo codes (ACCEPT, GATE, …), 
theoretical calculations using the modified Loevinger function, analytic software (Plaque Simulator 
version 5.3.2) and measurements (plastic scintillator calibrations and other measurement results 
published by Soares et al. [8 ]) are compared with each other. 
The depth dose variation on the central axis of the applicator is particularly studied because this 
quantity is one of the most often measured and is of practical importance since the source axis is 
usually positioned to intersect the region of most clinical interest. Isodoses on the median plan are 
also presented and have been compared to Plaque Simulator calculations and theoretical 
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calculations following the modified Loevinger function. A special comparison with ACCEPT 
results are obtained for the CCB plaque. 
IV.1.2.A.2. Uncertainties evaluation  
Uncertainties associated to Monte Carlo results have been calculated by doing a quadrature sum of 
the statistical uncertainty and the total cross sections uncertainty. In order to take into account 
discrepancies between the GEANT4 physics (concerning Multiple Scattering implementation) 
obtained in Chapter IV for dose point kernels, we compared the GEANT4 versions for dose 
deposited for an ophthalmic plaque and allocated the larger mean relative difference obtained 
between the GEANT4 versions to the cross section uncertainty term %sG4. Uncertainties 
concerning the geometry of the applicators haven’t been taken into account nor the source energy 
spectrum as explained in the update version of the AAPM Task Group No.43 Report 4-5 [9 ]. 
The results presented are affected by a total Monte Carlo uncertainties % stot calculated as the 
quadrature sum of the statistical uncertainty, the cross section uncertainty and GEANT4 
uncertainty.  
 
2 2 2
. 4% % % %tot µ C S Gs s s s= + +  Equation IV- 5 
§ Statistical uncertainties don’t overlapp 0.40%, 0.53%, 0.34% and 0.33% respectively for 
CCA, CCB, CCX and CCZ applicators. 
§ The total cross section uncertainty concerning electrons .% C Ss  is evaluated to be 5% (same 
explanation as in Chapter IV).  
§ The GEANT4 uncertainty is evaluated by the mean relative differences calculated between 
versions of the code for the simulation of the dose deposited by a CCB applicator on the 
central axis of a virtual eye until 1.2 cm in depth. We lead to a maximal mean difference of 
2.3% between 6.2.p02 and 7.0.p01 version. 
It implies that the total uncertainty on results don’t overlapp 5.5%  for CCA, CCB, CCX and CCZ 
applicators in the following parts. 
IV.1.2.B. Dose distribution on the central axis 
IV.1.2.B.1. Influence of the cut value on electrons 
The choice of the cut value allocated to particles is evaluated by the user in order to find a 
compromise between the time of the simulation and the precision required. In the case of the dose 
deposited by ophthalmic applicators, we performed some tests to see the impact of the cuts on the 
dose deposited at the scale of an eye dimension (24 mm in diameter). 
Figure IV- 3 represents the impact of different cut values on electrons emitted from a CCA 
applicator. The more the cut value is high, the more we can see fluctuations on the dose deposited. 
Figure IV- 4 focuses on the dose deposited between 0 and 2 mm in depth. For the shortest cut value 
(0.01 mm in range), the dose deposited is well simulated by a constant decreasing along the two 
first millimeters. 
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Figure IV- 3: Impact of the cut in range on the relative depth dose on the central axis of a CCA applicator, 
normalized at 100% at 1 mm. 
 
 
Figure IV- 4: Impact of the cut in range on the relative depth dose on the central axis of a CCA applicator, 
normalized at 100% at 1 mm. Zoom between 0 and 2 mm in depth. 
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IV.1.2.B.2. Evaluation of the impact of gamma rays on the dose deposited 
As the 106Rh/106Ru source emitts also gamma rays (see Chapter I for the description of the source), 
we made appear the differences observed on the dose deposited on the central axis of a CCA 
applicator by simulating or not the three principle gamma rays. 
 
Figure IV- 5: Impact of the simulation of the 3 principle gamma rays on the depth dose distribution of a CCA 
applicator. 
Results are presented in Figure IV- 5 on a logarithmic scale to show the impact of gammas at high 
distances for which the relative dose is below 1%. Differences observed don’t overlapp 0.2% at 12 
mm. As the dose deposited inside the eye is not affected by the simulation of gamma rays, in the 
following studies, we consider that the 106Rh/106Ru sources emitt only betas following the ICRU 
spectrum encoded (see Chapter I). 
IV.1.2.B.3. Comparisons and results 
GATE using the GEANT4 version 6.2.p02 has been compared to: 
§ analytic integration of point kernel using the Hokkanen method [7 ], 
§ the analytic software Plaque Simulator (version 5.3.2) used in the Centre Jean Perrin of 
Clermont-Ferrand to planify the dose deposited for routine clinical treatments of ocular 
tumours, and  
§ Plastic scintillator measurements for the calibration of the applicators (BEBIG calibration), 
uncertainty allocated to those measurements are evaluated to be ± 20%. 
Figure IV- 6, Figure IV- 7, Figure IV- 10 and Figure IV- 11 show the comparisons respectively for 
the CCA, CCB, CCX and CCZ applicators. Results are normalized at 100 % at 2 mm in depth on 
the central axis of the applicator. 
Differences between GATE calculations and integration of point kernels, Plaque Simulator and 
measurements have been calculated. Table IV- 2, Table IV- 3, Table IV- 4 and Table IV- 5 
represent the ratios of normalized doses on the central axis from the previous described methods to 
GATE, respectively for CCA, CCB, CCX and CCZ applicators. 
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The numerical integration of the expression of Vynckier and Wambersie calculated using the 
Hokkanen et al. [7 ] method, is in well agreement with GATE calculations, except at larger distance 
(³1 cm for CCA and CCB, ³0.9 cm for CCX and ³0.7 CCZ) for which differences overlap 10%. 
The differences between the two calculated data sets arise from the fact that the source 
encapsulation is not taken into account in the numerical integration comparing to GATE 
calculations. 
Cross et al. have shown that the comparisons between a bare concave source simulated with 
ACCEPT 3.0 and a numerical integration of point kernel differ less than by simulating the silver 
encapsulation of the applicators. At 6 mm in depth, 2% of difference is observed between a bare 
concave source and integration against 30% for an encapsulated concave source. 
Measurements with plastic scintillator provide lower dose values than GATE calculations on the 
central axis but are in agreement within the 20% errors associated to those measurements.  
Plaque Simulator calculations give results in very good agreement with GATE except at distances 
higher than 1.0 cm for which differences remain important. 
For distances equal or smaller than 0.1 cm, GATE calculations are in bad agreement with other 
methods. For the comparison with measurements GATE results still remain inside relative error 
bars allocated to measurements and differ by 10% with the integration and Plaque Simulator. 
 
 
Figure IV- 6:Comparison of calculated and measured relative doses on the axis of a CCA applicator in water. All 
the doses are normalized to the axial value at a depth of 2 mm. 
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Figure IV- 7: Comparison of calculated and measured relative doses on the axis of a CCB applicator in water. 
All the doses are normalized to the axial value at a depth of 2 mm. 
 
As the CCB applicator has been widely simulated using Monte Carlo codes and has also benefited 
of accurate measurements of the dose deposited by Soares et al., we compare our simulations with 
those added results. Figure IV- 8 represents the comparisons of GATE calculations with other 
Monte Carlo codes, using EGS4 (Sipliä) [10 ], ACCEPT3.0 (Cross) [10 ], MCNP4B (Mourtada) [10 
], GEANT3 (Taccini at al.) [11 ] and the code of Davelaar et al. [12 ] . In four of these the doses 
were calculated in water. The calculations of Taccini et al. were for PMMA plastic and their 
distribution has been scaled to water using the scaling factor h=0.949 and specific gravity 1.19. 
Figure IV- 8 shows a lack of agreement between the codes that can be due to the fact that the ways 
in which the concave applicators has been defined by the users are significantly different. Average 
measurements of Soares et al. fit well the ACCEPT 3.0 results and GATE calculations agree with 
ACCEPT 3.0 calculations within 2% out to depth of 1 cm. Major differences between GATE and 
ACCEPT 3.0 calculations are found at low distance from the CCB applicator, they can lead to 18% 
at 0.05 cm in depth and 7 % at 0.1 cm. 
Figure IV- 9 shows specifically the comparison between the average measured values of Soares et 
al. [8 ] that have been fitted by the following function and the GATE results that have been fitted 
using the same method: 
 [ ] 2 3 4 50 0 0( , ) / ( , ) exp( )s s s s s sD z r D z r a b z c z d z e z f z= + + + + +  Equation IV- 6 
with as=0.108 949 658, bs=-0.054 575 73, cs=-0.063 052 45, ds=0.008 861 022 3, es=-0.000 785 280 
71, fs=2.589 042 3 ´ 10-5 for Soares et al. (results of the fit are multiplied by 100) and as=4.88219, 
bs=-0.286467, cs=0.0133814, ds=-0.00293989, es=0.000119082, fs=-3.348 ´ 10-6 for GATE 
calculations. 
The fit function provide us a comparison at 0.0 mm in depth for which Monte Carlo calculations as 
measurements are very difficult to obtain. At 0.0 mm, difference is of 20% between the two fitted 
values. Between 1 and 12.0 mm differences don’t overlap 5.7%.  
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Figure IV- 8: Comparison of GATE calculations with other Monte Carlo codes and measurements concerning 
relative doses on the axis of a CCB applicator in water. All the doses are normalized to the axial value at a depth 
of 1 mm. 
 
 
Figure IV- 9: Comparisons of fitted GATE results with average measured values in water (Soares et al.) 
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Figure IV- 10: Comparison of calculated and measured relative doses on the axis of a CCX applicator in water. 
All the doses are normalized to the axial value at a depth of 2 mm. 
 
 
Figure IV- 11: Comparison of calculated and measured relative doses on the axis of a CCZ applicator in water. 
All the doses are normalized to the axial value at a depth of 2 mm. 
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Table IV- 2: Ratios of normalized doses on the central 
axis of a CCA plaque. 
 
Table IV- 3: Ratios of normalized doses on the central 
axis of a CCB plaque.
 
 
Table IV- 4: Ratios of normalized doses on the central 
axis of a CCX plaque. 
 
Table IV- 5: Ratios of normalized doses on the central 
axis of a CCZ plaque.
 
IV.1.2.C. Isodoses on the median plan 
GATE results have been compared to Hokkanen’s integration of the analytical point kernels and to 
the Plaque Simulator tables. Figure IV- 12, Figure IV- 15, Figure IV- 19 and Figure IV- 22 show 
the calculated results obtained with GATE. Doses are normalized to 100% at 1 mm in depth on the 
central axis of the plaques. 
Differences between GATE calculations and analytical integration from Hokkanen method in water 
have been calculated. Table IV- 6, Table IV- 8, Table IV- 10, Table IV- 12 show respectively ratios 
of normalized doses from GATE to integration of point kernels from Hokkanen method for CCA, 
CCB, CCX and CCZ applicators. Figure IV- 13, Figure IV- 16, Figure IV- 20 and Figure IV- 23 
show the isodose curves from GATE and point kernel integration calculations. 
Table IV- 7, Table IV- 9, Table IV- 11 and Table IV- 13show respectively ratios of normalized 
doses from GATE to Plaque Simulator for CCA, CCB, CCX and CCZ applicators. Figure IV- 14, 
Figure IV- 17, Figure IV- 21 and Figure IV- 24 show the isodose curves from GATE and Plaque 
Simulator calculations. 
Figure IV- 18 represents a comparison between GATE and ACCEPT 3.0 [10 ] Monte Carlo code 
for a special CCB plaque of 21 mm in active diameter and 12.1 mm of curvature radius instead of 
the standard size (18.6 mm in active diameter and 12 mm for the curvature radius). 
We don’t present comparisons with measurements for the two-dimensional distributions. 
Effectively, radiochromic film measurements are the only data available at this date for two-
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dimensional dose distribution evaluation. The measurement uncertainty is estimated to be about 
7.5% for the absorbed dose due to the variations occuring in the thickness of the sensitive emulsion 
coating and therefore is not accurate enough for reliable comparisons. 
 
 
Figure IV- 12: Relative doses in water for a CCA applicator calculated using GATE. 
 
 
Table IV- 6: Ratio of doses from GATE to analytical point kernels from Hokkanen method for a CCA 
applicator. 
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Figure IV- 13: Comparison of isodose contours for doses in water from a CCA applicator between GATE 
calculations (dashed curves) and theoretical calculations based on the Hokkanen study (solid curves). Doses have 
been normalized to 100% at 1mm. 
 
 
Table IV- 7: Ratio of doses from GATE to Plaque Simulator calculations for a CCA applicator. 
 
 
Figure IV- 14: Comparison of isodose contours for doses in water from a CCA applicator between GATE 
calculations (dashed curve s) and Plaque Simulator analytic calculations (solid curves). Doses have been 
normalized to 100% at 1mm. 
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Figure IV- 15: Relative doses in water for a CCB applicator calculated using GATE. 
 
 
Table IV- 8: Ratio of doses from GATE to analytical point kernels from Hokkanen method for a CCB 
applicator. 
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Figure IV- 16: Comparison of isodose contours for doses in water from a CCB applicator between GATE 
calculations (dashed curves) and theoretical calculations based on the Hokkanen study (solid curves). Doses have 
been normalized to 100% at 1mm. 
 
 
Table IV- 9: Ratio of doses from GATE to Plaque Simulator calculations for a CCB applicator. 
 
 
Figure IV- 17: Comparison of isodose contours for doses in water from a CCB applicator between GATE 
calculations (dashed curves) and Plaque Simulator analytic calculations (solid curves). Doses have been 
normalized to 100% at 1mm. 
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Figure IV- 18: Comparison of isodose contours for doses in water from a CCB applicator between GATE 
calculations (dashed curves) and ACCEPT 3.0 calculations from Cross et al. (solid curves). Doses have been 
normalized to 100% at 1mm. 
 
 
Figure IV- 19: Relative doses in water for a CCX applicator calculated using GATE. 
 
Chapter IV. 106Ru/106Rh ocular brachytherapy treatment planning using GATE. Preliminary studies using CT images. 
 142
 
Table IV- 10: Ratio of doses from GATE to analytical point kernels from Hokkanen method for a CCX 
applicator. 
 
 
Figure IV- 20: Comparison of isodose contours for doses in water from a CCX applicator between GATE 
calculations (dashed curves) and theoretical calculations based on the Hokkanen study (solid curves). Doses have 
been normalized to 100% at 1mm. 
 
 
Table IV- 11: Ratio of doses from GATE to Plaque Simulator calculations for a CCX applicator. 
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Figure IV- 21: Comparison of isodose contours for doses in water from a CCX applicator between GATE 
calculations (dashed curves) and Plaque Simulator analytic calculations (solid curves). Doses have been 
normalized to 100% at 1mm. 
 
 
Figure IV- 22: Relative doses in water for a CCZ applicator calculated using GATE. 
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Table IV- 12: Ratio of doses from GATE to analytical point kernels from Hokkanen method for a CCZ 
applicator. 
 
 
Figure IV- 23: Comparison of isodose contours for doses in water from a CCZ applicator between GATE 
calculations (dashed curves) and theoretical calculations based on the Hokkanen study (solid curves). Doses have 
been normalized to 100% at 1mm. 
 
 
Table IV- 13: Ratio of doses from GATE to Plaque Simulator for a CCZ applicator. 
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Figure IV- 24: Comparison of isodose contours for doses in water from a CCZ applicator directly against the 
“eye” between GATE calculations (dashed curves) and Plaque Simulator analytic calculations (solid curves). 
Doses have been normalized to 100% at 1mm. 
 
The theoretical integration of point kernels obtained with the Hokkanen method is in far bad 
agreement with GATE calculations, especially far off the central axis, near eye boundary.  
The shape of the Plaque Simulator isodoses is in better agreement with GATE calculations. 
To consider better the differences between results from GATE with point kernel integration and 
Plaque Simulator calculations on an ocular treatment, we compare in Table IV- 14 the doses at 2 
mm and 4 mm off the central axis at 3 mm in depth, which represent typically the approximate 
distance from an ophthalmic applicator of the centre of a 6 mm in thickness medium size ocular 
melanoma. 
We can remark that point dose kernels is in better agreement with GATE close to the central axis (2 
mm off) than Plaque Simulator, except for the CCX plaque. But for distances larger from the central 
axis point kernel integration fail to give reliable results comparing to our Monte Carlo calculations, 
especially for small plaques CCX and CCZ. A difference on the dose deposited higher than 2 % 
lead to very different treatments, for all the plaques, Plaque Simulator and point kernels 
overestimate dose distributions comparing to GATE. In conclusion, the time duration of ocular 
brachytherapy would be longer by using GATE instead of the Plaque Simulator treatment planning. 
 
 
Table IV- 14: Comparisons of relative differences between GATE with Plaque Simulator and point kernel 
integration at 2 mm and 4 mm off the central axis and 3 mm in depth. 
IV.1.2.D. Conclusion 
The agreement between Monte Carlo calculations of dose distributions and those calculated by 
integration of point kernels is not good for an encapsulated applicator, especially in the median plan 
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of the applicators and at large distance from the central axis, as shown in Table IV- 6, Table IV- 8, 
Table IV- 10, Table IV- 12 and Figure IV- 13, Figure IV- 16, Figure IV- 20, Figure IV- 23. 
It seems also quite difficult to add in the numerical integration inhomogeneities involved by the 
silver window of the plaques. It has been shown by Cross et al. that a layer of silver of 0.1 mm thick 
hasn’t the same effect on beta radiation than a layer of water of 1.34 mm in particularly because of 
the betas transmitted by the Ag window have a significantly harder spectrum than those transmitted 
by water windows of various density and thicknesses. The angular distribution of the betas 
transmitted remains virtually the same. That’s why we can’t expect better results from integration of 
point kernels than those presented here by adding a virtual layer of 1.34 mm thick to take into 
account attenuation of the silver window.  
Despite the lack of measurements for the two-dimensional dose distributions, we can conclude that 
ACCEPT 3.0 and GATE agree with one another within 8% out to depth of 1 cm. Values calculated 
by GATE agree with measurements within the experimental errors (<5.7%), out to a depth of 12 
mm. At shorter distances measured values are lower than those calculated. 
Plaque Simulator fit better the GATE calculations (within 10% out to depth of 0.6 cm) but still 
remain different by considering two-dimensional dose distributions. 
IV.2. DOSIMETRIC STUDY FOR ELECTRONS IN TISSUE 
IV.2.1. Correlation between CT numbers and tissue parameters needed for 
GATE simulations of clinical dose distributions 
IV.2.1.A. Introduction  
If we want to perform Monte Carlo studies in tissue inhomogeneities, we have to extract 
information concerning atomic composition and density from Hounsfield numbers part of the CT 
slices. Those quantitative information is needed in GATE Monte Carlo simulation to describe the 
phantom properties, e.g the human body. 
The imaging in a computed tomography (CT) scanner is done by measuring projected transmission 
profiles of x-rays penetrating a patient from different directions. By means of a reconstruction 
method, the projection values can be transformed into a series of cross-sectional images of the 
patient. Typical energies emitted during CT irradiation is between 50-100 keV, for these energies 
the three different physical processes occuring in the human body are: 
-The photoelectric absorption sph 
 -The coherent scattering (Rayleigh process scoh) 
 -The incoherent scattering (Compton process sicoh) 
 
In order to enable dosimetric calculations on human phantoms described by CT slices, we decided 
to reproduce the work of Schneider et al. [13 ], this work presents a method for a stoechiometric 
calibration of the CT number with the mass density and the elemental weights. In our case this 
method was applied to a CT scanner of the type General Electric LightSpeed 16 Pro used in the 
CHU of Clermont-Ferrand particularly for radiotherapy treatment planning. Measurements on the 
CT scanner part of the PET camera have also been performed. 
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IV.2.1.B. X-ray attenuation coefficient and CT numbers 
The linear attenuation coefficient m(E,t) of a tissue at position t along the projection line with length 
s is defined by the following equation: 
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with r (g.cm-3) the mass density, NA(mol-1) the Avogadro constant (6.022045 ´ 1023), I the element 
index, wi the elemental weight, si (barn/atom) the total cross section siph+sicoh+siicoh and Ai (g mol-
1) the atomic mass. 
In all this study, we will assume that the reconstructed attenuation values of the different tissues are 
completely independent of the location of the tissues. The mean attenuation can then be described in 
function of the polychromatic spectrum of x-rays defined by the independent spectral function 
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The values of 
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This CT number is defined in such way that water has always the value 0 and air the value –1000. 
As it is noticed by Schneider, the ratio (
__ __
2/ H Om m ) slightly depends on the spectral function f
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and therefore the CT number is scanner-dependent quantity with fixed values for water and air. 
We can then rely the tissue parameters (density and elemental weights) with the Hounsfield units, 
e.g the ratio (
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2/ H Om m ) with the equation: 
 
__
__
__
12
2
1 1
( )
n
i
iA
iH O i
H O
N E
A
wm
s
r mm =
æ ö
= ç ÷
è ø
å  
Equation IV-8 
 
 
IV.2.1.C. Calculation of the CT numbers of human tissues 
For the range of diagnostic x-ray energies and the elements contained in human tissues, the total 
cross section can be expressed by the following approximation shown by Rutherford et al. (1976) 
[14 ]: 
 
 2.86 4.62( ) ( ) ( ) ( )KN sca phi i i iE Z K E Z K E Z K Es = + +  Equation IV-9 
with KKN denoting the Klein-Nishina coefficient, Ksca defining the coherent scattering as well as the 
binding correction for the incoherent scattering and Kph the photoelectric absorption. 
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We can then add this expression in the Equation IV-10 to obtain the mean value of the attenuation 
coefficient: 
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The coefficients 
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Finally, the expression of the attenuation relative to water can be written as: 
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IV.2.1.C.1. Determination of the parameters k1 and k2 
Measurements of CT value for 10 different inserts have been performed using a CIRS phantom 
model 062 [15 ]. This phantom has the specificity to simulate head and/or abdomen, the inserts can 
be positionned at 17 different locations within the scan field. Figure IV- 25 shows the mass-density 
and chemical composition associated to each insert. 
 
Figure IV- 25: Phantom Model 062 from CIRS compagny. 
Phantom courtesy of J-B Guilhem part of the Association des Physiciens Médicaux of Orléans and regions. 
 
Table IV- 15: Mass-density and chemical composition of the 10 phantom materials used for the determination of 
k1 and k2 values (the titanium insert hasn’t been used for the measurements).
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The measurements have been performed with different tube voltage: 80 kV, 100 kV, 120 kV and 
140 kV.We decided to show the correlation between CT numbers and tissue parameters for the 120 
kV (typical voltage used for brain scanners), the same study has also been realized for 140 kV 
(voltage used to image thorax and pelvis). 
Inserts have been positionned in the “head part” of the phantom and in the “thorax part” of the 
phantom. Each measurement is given with an uncertainty, and the mean value of head and thorax 
measurement have been taken into account for each insert in the double position. 
 
Figure IV- 26:Schema of the phantom inserts with their composition and placement. 
 
 
Table IV- 16:CT numbers of the phantom inserts. The values H(meas.) are measured on a General Electric 
LightSpeed 16Pro CT scanner with a tube voltage of 120 kV. The values H (calc.) are calculated by means of 
Equation IV-11 with values k1=1.51 ´  10-4 and k2= 2.78 ´  10-5 
 
After having measured the CT numbers, we determine the values of (k1,k2) by carrying out a least 
square fit of the measured CT numbers to Equation IV-11, i.e., the expression 
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is minimized. For this calculation, we use the commercial software MATHEMATICA. 
The resulting values are k1=1.51 ´ 10-4 and k2= 2.78 ´ 10-5.  
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Figure IV- 27:Calculated versus measured Hounsfield units of the phantom inserts (values listed in Table IV- 
16). 
 
Then, by means of Equation IV-7 and Equation IV-11 together with the above values of k1 and k2 
we have calculated the CT numbers of 71 human tissues, whose mass densities and elemental 
weights are taken from the literature [16 ][17 ]. They are listed in Table IV- 17 and Table IV- 18  
respectively for soft and skeletal tissues. 
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Table IV- 17:Calculated CT numbers, mass-density and elemental weights of soft tissues. The tissue parameters 
are taken from Woodard and White (1986), the Hounsfield units are calculated using Equation V-7 and 
Equation V-11. In the column others are combined the elements Na, Mg, S, Cl, K and Fe. 
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Table IV- 18:Calculated CT numbers, mass-density and elemental weights of skeletal tissues. The tissue 
parameters are taken from White et al. (1987) and Woodward and White (1986), the Hounsfield units are 
calculated using Equation V-7 and Equation V-11. In the column others are combined the elements Na, Mg, S, 
Cl, K and Fe. 
 
From those Table IV-s we can see that the soft tissues are situated within the range between –86 and 
+105 Hounsfield units, whereas the CT numbers of the skeletal tissues take values from 71 up to 
1385. 
We could use the 71 human tissues to fit the data points (H,r) and (H, wi), but this method would 
take a long time, so we have followed the work of Schneider et al.[13 ]. 
IV.2.1.C.2. Usage of interpolation functions to fit Hounsfield units to tissue parameters 
The different skeletal tissues can be expressed by means of their proportions by weight of osseous 
tissue and bone marrow. 
If the skeletal tissue (r,wi,H) is composed of skeletal tissues (r1,w1, i,H1) and (r2,w2, i,H2), then we 
can expressed the elemental weight of the skeletal medium by: 
 1 1, 2 2, 1 1, 2, 2,( )i i i i i iW W Ww w w w w w= + = - +  Equation IV-13 
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 Equation IV-14 
After some substitutions with Equation IV-13 and Equation IV-14, we obtained the following 
relationship between the tissue parameters and the CT number for a composed medium: 
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-
 Equation IV-15 
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 Equation IV-16 
with H2 ³ H ³ H1 
Data fit in the range of skeletal tissues 
For skeletal tissues, the conversion of the CT number into the mass density and the elemental 
weights are expressed by the following functions: 
 3 3(1.011 0.656 10 ) .H g cmr - -= + ´  Equation IV-17 
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 Equation IV-18 
with   17 1385H- £ £  
wma,i and wcb,i denote the elemental weights of red/yellow marrow and skeleton cortical bone. 
 
 
Figure IV- 28:Mass density versus CT number in the range of skeletal tissues. The plot shows the data points of 
the skeletal tissues from Table IV- 18 together with the interpolation function. 
 
 
 
Chapter IV. 106Ru/106Rh ocular brachytherapy treatment planning using GATE. Preliminary studies using CT images. 
 154
 
 
 
 
Figure IV- 29:CT number versus elemental weights in the range of skeletal tissues. The plot shows the data 
points of the skeletal tissues together with the interpolation functions corresponding to Equation IV-18: (a) 
hydrogen (H) and nitrogen (N), (b) carbon (C) and oxygen (O), (c) phosphorus (P) and calcium (Ca). 
 
By means of the interpolation function, the densities of all skeletal tissues are fitted with an 
accuracy better than 0.01 g.cm-3. The weight of hydrogen is fitted with an accuracy of 0.2 pp( for 
cartilage, it is 0.6 pp) and the weight of nitrogen with 1.2 pp. The weights of carbon and oxygen are 
spread up to ± 10 pp around the interpolation functions, in the case of cartilage the deviation 
reaches ± 40 pp. However, the data sets of the sum of carbon and oxygen weights are well fitted 
with an accuracy of 1 pp. Those high differences between the carbon and oxygen data sets with the 
fits are due to the different proportion of red and yellow marrow in skeletal tissues. Concerning the 
weights of phosphorus and calcium the accuracy of the data is 0.4 and 0.9 respectively (cartilage: 
0.9pp). 
As it can be seen the fit model is not well adapted for cartilage tissue. 
Data fit in the range of soft tissues 
For soft tissues, those relationships between CT number and tissue parameters are much more 
complicated because as it was related by Schneider et al., those tissue are composed by three 
components (water, fat and protein) rather than of two. By plotting the proportion of fat and water 
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of the soft tissues between Adipose tissue3 and Connective tissue, we can remarked that those 
tissues are divided in two parts following their composition: adrenal tissue 3 to adrenal gland and 
Small intestine to connective tissue.  
The interpolation functions obtained for the fit of soft tissues are: 
For the tissues between adipose tissue 3 (at) and adrenal gland (ag): 
 3 3(1.012 0.952 10 ) .H g cmr - -= + ´  Equation IV-19 
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 Equation IV-20 
with 86 19H- £ £  
For the tissues between small intestine (si) and connective tissue (ct): 
 3 3(1.003 1.110 10 ) .H g cmr - -= + ´  Equation IV-21 
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 Equation IV-22 
with 24 105H£ £  
 
Plots of the functions together with the data points for soft tissues are shown in Figure IV- 30 and 
Figure IV- 31. 
The data points of the mass density are fitted with an accuracy better than 0.02 g.cm-3. 
The weights of hydrogen and nitrogen are respectively fitted with an accuracy better than 0.1 and 
2.5 respectively for the range of soft tissues between adipose tissue3 and adrenal gland, and are 
better than 0.4 and 2.4 in the range between small intestine and connective tissue. The weights of 
carbon and oxygen are respectively not well fitted (accuracy of 30.0 and 32.0 pp for at-ag, 11.2 and 
11.4 pp for si-ct). The sum of  carbon and oxygen weights are fitted with an accuracy of 2pp. 
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Figure IV- 30: CT number versus mass density in the range of soft tissues. The data points of the tissues from 
Table IV- 17 are plotted together with the interpolation functions according to Equation IV-19 and Equation 
IV-21. 
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Figure IV- 31: CT number versus elemental weights in the range of soft tissues. For each of the elements (a) 
hydrogen and nitrogen, (b) carbon and oxygen, the data points of the tissues from Table IV- 17 are plotted 
together with the interpolation Equation IV-20 and Equation IV-22. 
 
IV.2.1.D. Conversion of Hounsfield units into tissue parameters for GATE simulations 
In GATE simulations the file GateMaterials.db is read at the beginning of the execution of the 
simulation. In this file are described all the materials needed in the simulation (density, atomic 
weights) to generate the cross sectional data associated to each medium. 
As it has been shown previously, in the case of mass density, there’s a continuous correlation 
between CT number whereas for the elemental weights, a division of Hounsfield units into a 
number of bins can be performed. Figure IV- 32 shows a plot of the conversion of Hounsfield units 
into mass density. 
Concerning elemental weights, the step width have been selected by finding a compromise between 
the accuracy of the medium description and the production of cross sectional data files. 
In that way the step width have been considered has big as possible without loosing relevant 
information on elemental weights. 
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Figure IV- 32: Conversion of CT number to mass density. Equation IV-19 and Equation IV-21 are used for the 
range between –86 and 105 Hounsfield units. Above 105H, Equation IV-17 is applied. In the range between –
1000 and –86 H, the mass densities of air and adipose tissue 3 are interpolated by a straight line. 
 
 
Table IV- 19: Conversion of CT numbers to elemental weights. The scale of Hounsfield units is divided into 24 
bins. The first bin from –1000 to –950 H is assigned to the composition of air, the next bin up to –120 H with the 
composition of lung. The following five bins up to 18 H form a step function corresponding to Equation IV-20. 
Between 19 and 80 H the mean values of all tissues within this range are used. The composition of connective 
tissue (H=105) is assigned to the bin between 80 and 120 H. All bins above 120 Hounsfield units form a step 
function corresponding to Equation IV-18. 
  
In order to check the reliability of the density and elemental weights description, we develop a tool 
enabling the visualisation of CT images and the coloration of the voxels in function of their 
Hounsfield units value. This tool has been developped by Joel Bachelerie (engineer degree) in C++ 
(see Chapter IV).  
First, we image the CIRS phantom by highlighting in red some inserts to check the reliability of the 
transcription. Figure IV- 33 and Figure IV- 34 show the CIRS 062 phantom images by highlighting 
the bins –22-7 and 19-80 H. We can see that the inserts corresponding to the Hounsfield value are 
correctly identified by the C++ module and prove that the transcription realised is well adapted. 
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Figure IV- 33: CIRS phantom image. In red, has 
been highlighted the bins –22 to 7 H. 
 
Figure IV- 34: CIRS phantom image. In red, has 
been highlighted the bins 19 to 80 H. 
 
Secondly, we image a brain of a patient under 120 kV and enter it as input data in the module.  
Figure IV- 35 and Figure IV- 36 show the images of a brain slice by highlighting in red the bin 19-
80 and 80-120 H. We can remark that soft tissues are well identified in the brain. 
We repeated the same method of transcription for a tube voltage of 140 kV, the parameters k1 and 
k2 for this transcription have been found to be 6.12 ´ 10-5 and 2.24 ´ 10-5 respectively. 
We image a mediastin by highlighting in red the lung supposed to be transcript by the bin –950 to –
120 H. Figure IV- 37 shows that the lung is well identified in the image with our transcription. 
 
 
Figure IV- 35: Brain image. In red has been 
highlighted the bin 19 to 80 H. 
    
 
Figure IV- 36: Brain image. In red has been 
highlighted the bin 80 to 120 H.        
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Figure IV- 37: Mediastin image. In red has been highlighted the bin –950 to –120 H. 
IV.2.1.E. Influence of the media compositions on dosimetry 
In order to study the influence of different soft tissue compositions on GATE Monte Carlo dose 
calculations, we have performed simulations on three media: one of them is represented by the 
mean elemental weights of the 35 soft tissues and the two others are reprensented by elemental 
compositions of urine and skin1 for which the difference to the mean elemental weights are the 
greatest of all soft tissues. In the case of urine, the deviations are H= +0.7 pp, C= -13.1 pp, N= -1.9 
pp, O= +14 pp. The corresponding deviations for Skin1 are H= -0.3 pp, C= +11.4 pp, N= +1.7 pp, 
O= +12.8 pp. In Table IV- 20 are listed the mass-density and elemental weights assigned to those 3 
media. 
 
Table IV- 20: Mass-density and elemental weights of media used in GATE Monte Carlo simulations. 
A 2 ´ 2 cm2 electron beam of 6 and 21 MeV, perpendicularly impiging a homogeneous cubic 
phantom with 20 cm side length has been simulated with GATE. First, the density and atomic 
composition of the three media Urine, Skin1 and Mat-19-80 have been taken into account. We 
compared the absolute dose distributions on the central axis of the phantom obtained for the three 
media, see Figure IV- 38 and Figure IV- 39. For both energies, relative deviation between the dose 
distributions of Urine and Mat-19-80 and Skin1 and Mat-19-80 respectively has been calculated, 
results are shown in Figure IV- 41. For 6 MeV electron beam, the differences between the resulting 
dose distributions of the mean composition and urine are lower than 2.5% and the mean 
composition and skin1 are lower than 4%. For the 21 MeV the differences are respectively lower 
than 0.8% and 1.5%.  
 
Chapter IV. 106Ru/106Rh ocular brachytherapy treatment planning using GATE. Preliminary studies using CT images. 
 161
 
Figure IV- 38: Comparisons of dose distributions of a 6 MeV electron beam in Urine, Skin1 and Mat-19-80 
tissues. 
 
Figure IV- 39: Comparisons of dose distributions of a 21 MeV electron beam in Urine, Skin1 and Mat-19-80 
tissues. 
Concerning the 25 MeV photon beam (Figure IV- 40), the Compton scattering is the predominant 
process, the cross section per atom is approximatively equal to: 
 c
Z
A
s »  Equation IV-23 
If we look at the weighted sum of ratios of atomic number and mass for the three media, we can 
remark that the ratios remain quite the same (0.555 for urine, 0.550 for skin1 and 0.551 for Mat-19-
80). 
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Figure IV- 40: Comparisons of dose distributions of a 25 MeV photon beam in Urine, Skin1 and Mat-19-80 
tissues. 
 
 
(a) 
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(b) 
 
 
(c) 
Figure IV- 41: Relative deviations between dose distributions in the three media: (a) between Urine and Mat-19-
80 for 6 and 21 MeV electron beams, (b) between Skin1 and Mat-19-80 for 6 and 21 MeV electron beams, (c) 
presents deviations for 25 MeV photons beams. 
 
Concerning skeletal tissues the weights of high atomic number of the phosphorus and calcium 
elements justify a further subdivision in the range between 300 and 1600 HU. To show this 
specificity, we compared the dose distributions on the central axis of the phantom for three media: 
skeletal tissues between 300 and 400 HU, skeletal tissues between 1500 and 1600 HU and the 
composition of the Mean Bone (taken from Jones and Cunningham [18 ]).6 and 21 MeV electron 
beams and 25 MeV photon beam have been modeled. For the 6 MeV electron beam (Figure IV- 
42), the dose deviations between mean bone and mat-300-400 are lower than 11% of dose 
maximum, and between mean bone and mat-1500-1600 lower than 41% (difference observed at the 
entrance of the beam in the phantom). For the 21 MeV electron beam (Figure IV- 43) the 
Chapter IV. 106Ru/106Rh ocular brachytherapy treatment planning using GATE. Preliminary studies using CT images. 
 164
differences are respectively lower than 11 and 24%. Those big deviations are due to the different 
weights of calcium and phosphorus in skeletal tissues. 
 
Figure IV- 42: Comparisons of dose distributions of a 6 MeV electron beam in Mat-300-400, Mean Bone and 
Mat-1500-1600 tissues. 
 
 
Figure IV- 43: Comparisons of dose distributions of a 21 MeV electron beam in Mat-300-400, Mean Bone and 
Mat-1500-1600 tissues. 
 
The large deviations observed for the photon beam (Figure IV- 44) cannot be explained as the effect 
of calcium and phosphorus weights in the three media. Effectively, if we calculate the weighted 
sum of ratios of atomic number and mass for the three media, we can remark that the ratios remain 
different (0.539 for mat-300-400, 0.513 for mat-1500-1600 and 0.531 for mean bone). By removing 
the calcium and phosphorus related ratios of the weighted sum, we can see that the differences 
remain (0.497 for mat-300-400, 0.394 for mat-1500-1600 and 0.457 for mean bone). By removing 
the hydrogen related ratio of the weighted sum, the differences don’t appear anymore between the 
three media (0.458 for mat-300-400, 0.483 for mat-1500-1600 and 0.467 for mean bone). The 
weight of hydrogen is responsible of the large differences obtained in dose distributions for skeletal 
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tissues. Since the weight of hydrogen differs significantly between different skeletal tissues, the 
electron density can vary up to 3% depending of the hydrogen weight. 
 
Figure IV- 44: Comparisons of dose distributions of a 25 MeV photon beam in Mat-300-400, Mean Bone and 
Mat-1500-1600 tissues. 
 
IV.2.1.F. Conclusion 
Using interpolation functions instead of the method described by Schneider et al. (1996) [19 ] who 
had already established a stoechiometric calibration of CT numbers with electron densities and 
proton stopping powers, we gain in time without loosing in accuracy. In addition the non-affine 
relationship between CT numbers and elemental weights can be derived without having to perform 
non-affine fits. 
The results of GATE Monte Carlo simulations have shown that the weight of calcium and 
phosphorus for skeletal tissues have a big influence on the dose deposited by electron beams. The 
hydrogen weights play a high role in the differences obtained for photon beam in skeletal tissues. 
Considering soft tissues, the dose deposited is not influenced by elemental weights or densities. For 
both soft and skeletal tissues, the individual weights of carbon and oxygen are poorly described by 
means of CT numbers. 
CONCLUSION 
This chapter had for first goal to obtain with accuracy dose distributions of ocular brachytherapy 
treatments using 106Ru/106Rh ophthalmic applicators. Those treatments currently performed at 
Centre Jean Perrin of Clermont-Ferrand and planned thanks to Plaque Simulator software required 
comparisons and validations with Monte Carlo calculations. GATE using the physics of GEANT4 
version 6.2.p02 has been used to determine dose deposited on the central axis and isodoses for four 
ophthalmic applicators. The results have been compared with other Monte Carlo codes, Plaque 
Simulator and measurements. Despite the lack of reliability of the GEANT4 physics concerning the 
Multiple scattering implementation (our results have been affected by a relative error taking into 
account the disagreement in the results obtained for dose point kernel simulations in Chapter IV), 
results obtained are in good agreement with Plaque Simulator calculations, ACCEPT 3.0 and 
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measurements on the central axis of the plaques. The fast and easy method consisting into 
integrating dose point kernels to obtain isodoses don’t give reliable results near the ophthalmic 
applicator (distance lower than 1mm) and is in bad agreement with GATE concerning isodoses on 
the median plan. 
The second part of this chapter was dedicated to the determination of an accurate correlation 
between density and atomic composition of human tissues with CT numbers. Thanks to the CIRS 
phantom 062 we established a stoechiometric calibration of CT numbers with tissue parameters for 
the CT scan providing images for radiotherapy treatments. This method enabled a better 
determination of the calcium and phosphorus weights in the bone composition which are 
responsible for high differences in dose distributions of electron beams. 
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Chapter V.  
 
 
GATE Applications in a Grid Environment 
 
 
 
INTRODUCTION 
In radiotherapy-brachytherapy the goal is to evaluate accurately the absorbed dose in complex 
phantoms and at interfaces of tissue, where analytic calculations have shown some limits. The main 
drawback of Monte Carlo simulations is their high computing time. The aim of our research is to 
reduce the computing time by parallelizing a simulation on geographically distributed processors by 
benefiting of a grid architecture. The method is based on the parallelization of the Random Number 
Generator (RNG) used in Monte Carlo simulations. In order to let benefit the praticians and the 
physicists of the considerable gain in time that could be reached thanks to the distributed 
calculations, a web portal has been customized for GATE applications, asking the user for all the 
parameters necessary to launch the simulation and retrieve results. Different tests have been done in 
order to show first, the reliability of the physical results obtained by concatenation of parallelized 
output data and secondly the time gained for jobs execution using different modalities of 
submission and different infrastructure. Requirements and use cases caracterizing GATE 
applications in a grid environment have been detailed [1 ] in and largely mentioned in the EGEE 
NA4 deliverables [2 ] [3 ]and application migration report [4 ]. 
The first part will be dedicated to the method used to parallelize GATE simulations. Multiple 
computing time tests highlight the efficacy of such submission in a grid infrastructure. In a second 
part is described the transparent and secure access to the grid developed for GATE users and 
provided by the GENIUS web portal. Finally a synergy between the supercomputing grid DEISA 
and the EGEE infrastructure is discussed to run on the both infrastructures GATE simulations. 
V.1. PARALLELIZATION OF GATE SIMULATIONS WITHIN EGEE 
V.1.1. The installation 
The Experiment Software Manager (ESM) is the person from an experiment responsible for the 
installation of new software in the different sites. The ESM must have privileges to install software 
in a particular area of the CEs. There is dedicated space for each one of the supported VOs. An 
environmental variable holds the path to that space, for biomed applications, its format is the 
following: $VO_BIOMED_SW_DIR 
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If a site uses a shared file system for the WNs of its CEs, then the software is installed once in the 
filesystem, and the jobs that want to use it just need to use the $VO_BIOMED_SW_DIR variable to 
access the software. 
The GATE platform installation is not trivial as it depends of a large number of softwares to be 
executed. GATE is a C++ encoded platform and needs to be compiled with a defined environment 
before each installation. The installation of GATE platform depends on different requirements: 
§ The operating system: 
During the EDG project and at the beginning of the first year of the EGEE project, the 
operating system supporting the middleware and components of the grid was the Linux 
Redhat version 7.3 (RH7.3). Since April 2005, the operating system move to the Scientific 
Linux 3.0 (SL3). GATE installations have to adapt to the operating system changes and 
compiler versions (gcc 2.96 for RH7.3 and gcc 3.2.3 for SL3). 
§ The related softwares: 
ü The GEANT4 software with the data files for specific physics processes associated 
to: the three GATE versions that have been installed on the EDG first and then on 
the EGEE infrastructure are gate_v1.0.2 compatible with the GEANT4 software 
version 5.2.p02 on the EDG infrastructure and also on the LCG-2-EGEE-0 
infrastructure. The gate_v1.1.0 and gate_v1.2.0 respectively compatible with the 
6.2.p02 and 7.0.p01 GEANT4 versions have been installed during the first year of 
the EGEE project on the SL3 operating system. 
ü The CLHEP software, needed for the generation of pseudorandom numbers in the 
Monte Carlo simulations. (CLHEP-1.8.1.0 compatible with the 6.2.p02 and 7.0.p01 
GEANT4 versions) 
ü The data analysis softwares such as ROOT, AIDA, etc. The ROOT software [5 ] has 
been installed to enable the analysis of results (ROOT version 4.03.02 compatible 
with GEANT4 version 7.0.p01 and GATE version 1.2.0). 
ü  A visualization interface Mesa5.0.2 enabling the use of OpenGL to check geometry 
construction and particle’s trajectories during GATE simulations.  
§ The declaration of environment variables related to the previous software installations. 
  
As the installation of such softwares is not applicable to a grid environment using the usual 
procedure (generally the execution of a configuration script before a make or a gmake compilation), 
the choice has been done to create precompiled packages of those softwares using a packaging 
system available on Redhat distributions and named Redhat Package Manager (RPM). The 
packages must be created each time the operating system evolves and/or the compiler changes. For 
the SL3 operating system with the gcc 3.2.3 compiler version, the following packages have been 
created for the installation of the GATE platform (example is given for GATE-1.2.0 version 
compatible with the 4.7.0.p01 GEANT4 version): 
Package Description 
GATE-1.2.0-1.i386.rpm GATE version 1.2.0 platform 
GATE-geant4-7.0.p01-1.i386.rpm GEANT4 (version 7.0.p01) source 
code 
GATE-geant4-G4EMLOW-2.3-1.noarch.rpm, GEANT4 data files for description of 
the physic processes. 
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GATE-geant4-PhotonEvaporation-2.0-1.noarch.rpm, 
GATE-geant4-RadiativeDecay-3.0-1.noarch.rpm,  
GATE-geant4-G4NDL-3.7-1.noarch.rpm 
the physic processes. 
GATE-CLHEP-1.8.1.0-1.i386.rpm CLHEP version 1.8.1.0 . 
GATE-root-4.03.02-1.i386.rpm ROOT version 4.03.02 analysis 
software.  
GATE-Mesa-5.0.2-1.i386.rpm OpenGL visualization 
GATE-env-1.2.0-1.noarch.rpm Scripts describing the environment for 
installations.      
  
Those packages have been installed on each of the CEs hosting the biomed VO on the EGEE 
infrastructure. The packages have been installed by the software administrator by sending a job 
which create a  gate/ repository under the $VO_BIOMED_SW_DIR area and perform the RPMs 
installation. 
After each installation of GATE on a site, a test-job is sent on the site to check the well-running of 
the platform with the ROOT analysis. 
Finally, the software must be published in the Information System (IS), so that the jobs requesting 
for a particular piece of software can be directed to the appropriate CE. For that purpose, a tag is 
added to the GlueHostApplicationSoftwareRunTimeEnvironment attribute of the IS using 
the following perl command line in a job for the LCG-2 middleware: 
perl /opt/lcg/bin/lcg-ManageVOTag –host <CE_HOST> -vo biomed --add -tag 
VO-biomed-GATE-1.2.0-1 
 
At the date of the 2005, GATE version 1.1.0 compatible with the GEANT4 version 6.2.p02 have 
been installed on each site hosting the biomed VO (see Chapter II. for the biomed CEs resources). 
V.1.2. The parallelisation of GATE simulations and tests of submission to a grid 
environment 
V.1.2.A. Introduction 
Monte Carlo simulations use random numbers responsible for the name given to this technique 
which was introduced during the development of atomic energy in the post World War II era. 
Even though the cost of computing resources is continually decreasing thereby facilitating 
consequent calculations, Monte Carlo simulations can’t currently be used for clinical treatments 
planning for which the computing time remains too high on a single machine. So, there is a real 
interest for parallel and distributed Monte Carlo simulations in order to provide very accurate 
studies in medical physics. 
A Random Number Generator (RNG) used in Monte Carlo calculations generally involves a 
recursive deterministic algorithm to produce a sequence of pseudo random numbers. Because 
particles ranges in matter are independent of each other, parallel simulations are produced by 
partitioning the random sequence into independent streams. Then, we present a method to display 
the simulations on geographically distributed processors using a grid environment. The final 
outcome of the application is to provide a web portal to launch simulations in parallel.  
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V.1.2.B. The Random Number Generator (RNG) in Monte Carlo simulations 
The computing time of a Monte Carlo simulation depends on different parameters: the number of 
particles generated during a simulation, the medium where particles interactions occur. Depending 
on the type of material filling the medium and the type of particles generated, the number of 
physical interactions can vary. The number of calls to the RNG is consequently dependant on these 
parameters [6 ]. 
Even if the computing time of a simulation depends also on the construction of the geometry, 
physical processes used, etc.., the parallelization of such parameters appears to be tricky and won’t 
be tackled in this study.  
Each Monte Carlo simulation uses a sequence of random numbers to reproduce the probability of 
the physical interactions in matter. The more numerous the interactions in a medium are, the longer 
the sequence of random numbers generated for the simulation is. A simple way to reduce the 
execution time of a Monte Carlo simulation used in physical experiments, is to sub-divide a long or 
a very long simulation into little ones by indexing to each simulation a sub-sequence of random 
numbers obtained by partitioning a long sequence of random numbers. Sub-sequences have to be 
independent and as we explained before this method is valid only because the particles emitted in 
simulations are not dependant on each other. 
V.1.2.B.1. Principle 
Physicists need very good random number generators for Monte Carlo calculations. Random 
numbers generators can be classified according to the three types of random numbers [6 ][7 ]: 
 
§ Truly random numbers are unpredictable, they are not generated by a determinist process, 
and must be produced by a random physical process such as radioactive decay. 
§ Pseudorandom numbers are produced in the computer by a simple numerical algorithm, and 
are therefore not truly random.  
§ Quasirandom numbers are introduced to improve the accuracy of Monte Carlo integration; 
these numbers are not independent and thus cannot be used generally. 
 
Statistically sound random number sequences usually satisfy a set of requirements that can be 
divided into three main classes: randomness, practical qualities and performance [8 ]. In practice, all 
the requirements are not easily achieved concurrently since some of them are antagonistic. Monte 
Carlo simulations are very sensitive to the statistical soundness of pseudorandom number generators 
and scientists usually use high quality generators. In our study, we use a Very Long Period (VLP) 
shuffled pseudo random number generator; the general technique in order to run this type of 
generator is: 
§ The set up of an internal table, containing a large number of seeds (typically between 10 and 
a few hundreds), and the values of a few indices (typically two) pointing to seeds in the 
table, are also initialized. 
§ The generation of pseudorandom number by combining only those seeds corresponding to 
the current values of the indices. 
§ The update of the seeds just used and the pseudorandom generation of new indices to point 
to other seeds. 
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So, the sequences of random numbers generated are defined by a state (e.g seed and table) that 
contains all that is needed to initialize a recurrence formula which enables the generation of the 
random sequence.  
V.1.2.B.2. The parallelization of RNGs 
If sequential stochastic simulations always require a statistically sound RNG, in the case of parallel 
and distributed stochastic simulations, this requirement is crucial. Major scientists in this research 
field such as Paul Coddington state that: “Random number generators, particularly for parallel 
computers, should not be trusted. It is strongly recommended that all simulations be done with two 
or more different generators, and the results compared to check whether the random number 
generator is introducing a bias” [9 ]. Another well known paper in this domain warned scientists to 
be very careful with parallel Monte Carlo [10 ]. The main advice that specialists recommend is that 
random numbers should be generated in parallel, i.e. each Logical Processor (LP) should 
autonomously get its own sub-sequence of a global random sequence. Designers of parallel 
stochastic simulations always have to answer this fundamental question: how can we make a safe 
RNG repartition in order to keep, on the one hand, efficiency, and on the other hand a sound-
statistical quality of the simulation in order to obtain credible results ? Indeed the validation of such 
parallel simulations is a critical issue. Many research studies have been undertaken to design good 
sequential RNGs. Many others concern Parallel Random Number Generators (PRNGs). It appears 
that the key focus, which is how to assess the quality of random streams, remains a hard problem, 
and many widely-used techniques have been shown to be inadequate for some specific applications. 
 
An obvious way to get parallel random numbers streams is to partition a sequence of a given 
generator into suitable independent sub-sequences. This can be done in three major ways [7 ][8 ]:  
 The Leap Frog (LF) method (e.g., Figure V- 1) allocates in turn the random numbers of a sequence 
to a partition of streams like a deck of cards dealt to card players (as illustrated in figure 1). Thus, 
for a partitioning of a global sequence {xi, i = 0,1,2,…} into N parallel streams, the jth stream is 
{xkN+j-1, k = 0,1,2,…..}. Given the period p of the global sequence, the period of each stream can 
reach p/N. 
 
Figure V- 1: The Leap Frog method (with 4 parallel processes) 
 
The Sequence Splitting (SS) method (e.g., Figure V- 2) splits a sequence into non overlapping 
contiguous blocks, as shown in figure 2. Thus, for a partitioning of a sequence {xi, i= 0, 1, 2, …} 
into N streams, the jth stream is {xk+(j-1)m, k = 0, …, m-1}, where m is the length of each stream. One 
major difficulty is the determination of a good value for 'm', which must be chosen so that each 
stream is long enough to achieve the stochastic simulation performed by the corresponding 
processes. 
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Figure V- 2: The Sequence Splitting method (with 4 parallel processes) 
 
The Independent Sequences (IS) method (e.g., Figure V- 3) builds a partition of N streams by 
initializing the same generator with N different seeds. Figure 3 gives it an illustration. Such a 
technique can lead to overlapping streams, since a random number generated in one stream can 
match the seed used for another stream. Some generators exhibit several sub-cycles that can be 
encapsulated into other streams. Such generators seem to be well adapted to the IS method, since 
the seeds to use for parallel streams can be the first terms of the sub-cycles. 
 
Figure V- 3: The Independent Sequences method (with 4 parallel processes) 
 
Each way has its own specific flaw and whatever the solution retained, we have to check the 
correlations between subsequences. Indeed, the correlation phenomena observed in a sequential 
RNG are often induced in the parallel streams that are obtained from this generator. For instance, an 
initial correlation between distant numbers of a sequence can lead to auto-correlation inside parallel 
streams produced with the LF method, or cross-correlation between parallel streams produced with 
the SS method. Variants have been developed for three methods presented above such as the 
shuffling leap frog or the parameterization method which is a variant of the IS technique [11 ]. Its 
principle is to parameterize both the seed and recursive function. One of the main contributions of 
this variant is that it results in a scalable period, i.e. the number of different random numbers that 
can be used increases with the number of parallel streams. An interesting parameterization method 
is used in [12 ] to get parallel streams from a Linear Congruential Generator (LCG), by choosing for 
the jth  stream a multiplier a(j) and an additive constant c(j). It is shown in this case that good results 
can be obtained if c(j) is the jth prime number £ Ö(m/2) where m is the modulus. However testing 
pseudo-random numbers in their parallel context is essential. The usual approach in testing a PRNG 
is to apply standard tests which are available for sequential RNG to each random number parallel 
streams, and from all streams combined [13 ]. New techniques appear which are specific to PRNGs 
[14 ]. A parallel version of the well known spectral test has been developed in [12 ] for parallel 
LCG. So far, little work has been done in this area. Since not many rigorous results are known 
about the properties of PRNG, more stringent and varied tests are necessary. For our application we 
have chosen the Sequence Splitting parallelization method which is more convenient for our study. 
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Our simulation is based on the pseudorandom number generator developed following the algorithm 
of Fred James [15 ]. This algorithm implements the original universal random number generator as 
proposed by Marsaglia & Zaman in report FSU-SCRI-87-50 and coded in FORTRAN77 by Fred 
James. This generator is used in the CERN library routine and known as the RANMAR generator, 
which is also part of the MATHLIB HEP library [16 ]. The algorithm combines a Fibonacci 
sequence and an arithmetic sequence. This random number generator has been widely tested [17 ]; 
its period reaches 2144 and it allows the creation of 900 million different sub-sequences with each 
subsequence having a length of approximately 1030. 
V.1.2.C. Application of the parallel method  
The random number generator of F. James is implemented in the HEPJamesRandom module as part 
of the module HEPRandom of CLHEP (available in C++) [18 ] which is directly employed by our 
Monte Carlo simulation code. The HEPRandom module consists of C++ classes implementing 
different random “engines” and different random “distributions”. A distribution associated with an 
engine constitutes a random “generator”. The method consists in splitting a long simulation into a 
number of independent little ones that will use non-overlapping random number sequences 
generated with HEPJamesRandom.  
 
In order to do that, the method saveStatus( ) of the HEPRandom module is employed to save in a 
file the current status of a random engine. Then, another method is used to launch the simulation 
with the file containing the status saved before. This allows the user to avoid saving the totality of 
the random number sequences, which would generate too large files up to a hundred Tera-octets. 
On the contrary, the status of each sequence is very limited in size (around a few hundred octets). 
 
Consumption in pseudorandom numbers for different Monte Carlo simulations: 
 
In order to evaluate the size of the pseudorandom numbers sub-sequences that have to be generated 
by the RNG of F.James, the consumption of pseudorandom numbers has been studied for three 
representative medical Monte Carlo applications: ocular brachytherapy, nuclear medicine and 
radiotherapy simulations. Figure V- 4 shows an example of the consumption in pseudorandom 
numbers for a number of particles increasing. This consumption is linear as the number of particles 
emitted in the simulation increases and is entirely dependant of the type of simulation (e.g. the 
number of interactions occurring in the medium). To estimate the length of the sub-sequences, the 
brachytherapy simulation for which the consumption is the highest among the three studies has been 
taken into account. 
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Figure V- 4: Consumption in pseudorandom numbers for different Monte Carlo simulations 
 
Figure V- 5 shows the consumption in random numbers per particle for a number of particles 
generated increasing from hundred to twenty thousand particles. This figure highlights the 
fluctuations for low particles emission (100 to 1500 particles), the consumption is stabilised for 
twenty thousand particles emitted.  
 
 
Figure V- 5: Consumption in pseudorandom numbers per particle for different Monte Carlo simulations 
 
Therefore, the evaluation of the consumption is based on the generation of 20000 particles for the 
highest time consuming simulation (brachytherapy simulation) for which 2000 pseudorandom 
numbers are generated. The size of each subsequence has been calculated allowing a generation of 
10 million of particles overestimated by 10 % for each of them, we obtained a need of 3.1010 
random numbers. For instance, a list of two hundred files corresponding to different status of the 
random number generator is generated. This method is relatively long, it takes approximately 
twenty days on a PIV of 1,6 GHz to generate two hundred status of 3.1010 non-overlapping random 
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numbers, but the advantage is that it has to be done only once. Moreover, this time could be shorter 
with the latest generation of computers currently available. 
The file corresponding to all the status saved is loaded at the beginning of the run of each 
simulation.  
In 2003, during the EDG project, to facilitate the preparation of all the other files describing splitted 
simulations: the environment scripts, the macros describing the entire Monte Carlo simulation, the 
GATE material database (GateMaterials.db) file and the status files of the RNG; the software 
application JobConstructor, written in C++, was created. Relied to a job submitter tool (see part 
V.1.2.d), it was the first solution found for a convivial and easy parallel submission of GATE 
Monte Carlo simulations on the EDG testbed. 
V.1.2.D. Sending the simulations on a grid environment 
V.1.2.D.1. The Java Job Submission (JJS) tool 
Once the partitioning of the RNG is done, the jobs have been submitted on the EGD infrastructure 
using an Application Program Interface (API) written with the Java language (Java version 1.4) and 
based on a relational database: Java Job Submitter (JJS) [20 ]. 
Using EDG commands, the JJS API allows the launching of a list of jobs on any resources where 
the GATE simulation platform is installed without it is necessary for the user to be log on a UI 
machine to have access to the grid. The JJS tool bypasses also the Resource Broker machine by 
directly submit jobs on the computing resources of the grid. 
 illustrates the functionalities of the Java Jobs Submitter (JJS) API. 
 
Figure V- 6: Schema of the jobs management with JJS on a grid environment 
 
The first step consists into parsing the JDL file. Then (step2), each day, a local database on the 
client machine is updated by consulting the RGMA services [21 ] of the Grid to offset the non-
utilisation of the Resource Broker functionalities. The local database has been created using 
mySQL. Next, the Java Client consults the local database to update the list of the CEs enabling the 
computation of the jobs. In the third step, the list of the CEs matching the requirements are 
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downloaded on the Java Client. The JJS tool also allows the user to select the computing sites (CE 
and SE, belonging to the DataGrid computing environment) where he wants his jobs to be executed. 
In the fourth step, the Java Client uploads the files described in the InputSandbox of the JDL file to 
the SE. 
The fifth step consists in downloading all the JDL files on the CEs. The JJS command lines are 
identical to the EDG command lines but encoded in Java language (jjs-proxy-init, jjs-
submit, jjs-status, etc…). 
When each job is finished, the results are automatically uploaded on the SE (step6). To finish 
(step7), result files are downloaded on the Java Client.  
V.1.2.D.2. First approach for a web portal prototype to submit GATE simulations on the EDG 
testbed 
To produce a convivial tool for the submission of GATE simulations, the JobConstructor program 
and Java Job Submitter (JJS) functionalities have been combined under a prototype web portal (not 
accessible from a public web server). The user is asked his certificate password to access the EGD 
infrastructure. After having entered the macro file, the GateMaterials.db and the number of 
partitions fields, files are created, formatted following the JJS requirements and launched on the 
EDG sites where GATE is installed. The status of the jobs can be visualized on the portal and when 
the jobs are finished the user have the possibility to retrieve the results on his computer. 
All this functionalities have been generated using PHP language, buttons and instructions have been 
coded using respectively the HTML and C++ language. Figure V- 7describes the files created: the 
global.php file is in charge of configuring variables and repositories for the management of the 
files created, the parallelize.php file is in charge of splitting and submit GATE files on the 
EDG testbed using the jjs-submit command. A log index is created to view the status related to 
the job submission in the case of a usage of the portal by multiple users. The status of the jobs can 
be visualized on a table on the user’s computer screen (parsing of the jjs-status command 
output), when a job is finished the output is retrieved on the server (getResults.php file) and 
then on the user’s computer (downloadResults.php file) using http connexion. Figure V- 8 
shows a screenshot of the web portal prototype homepage. 
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Figure V- 7: Prototype web portal algorithmic schema. 
 
 
Figure V- 8: A web portal prototype for the parallelisation and submission of GATE simulations on the EDG 
testbed. 
V.1.2.E. Results 
All the calculations were distributed between the site of CC-IN2P3 worker nodes in Lyon and the 
site of Laboratoire de Physique Corpusculaire (LPC) in Clermont-Ferrand, on the EDG testbed. At 
this time (July 2003), CC-IN2P3 provided 200 dual-processors mixed in PIII 750 MHz, 1GHz and 
PIV at 1,4 GHz ; and the LPC provided 4 PIII mono-processors at 933 MHz. 
The distribution of jobs was managed by a batch manager developed at CC-IN2P3 named BQS 
(Batch Queuing System) and by PBS (Personal Batch System) at LPC. This management takes into 
account the CPU time specified by the user for his jobs.  
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V.1.2.F. Comparison of the physical results 
The first question to consider is whether local and parallel simulations give identical physical 
results. We have chosen to compare some physical data of interest for different medical physics 
problems. For all the problems, we have taken care to generate a sufficient number of particles in 
order to avoid statistical fluctuations in physical results. Two types of medical simulations were 
performed:  
 
§ In nuclear medicine (e.g., Figure V- 9): The simulation describes a gamma camera Philips 
Marconi. The two heads of the camera have been simulated, for each one a parallel 
collimator, a NaITl crystal, a photomultiplier and the leakage have been built. The 
radioactive source of 20 MBq in activity is contained in a capillary tube and emits 
monoenergetic photons of 140 keV (e.g 99mTc). The physical data output studied is the 
energy spectrum of the radioactive source of 99mTc.  
 
 
Figure V- 9: Energy spectrum of a capillary source of 20 MBq of 99mTc 
 
§ In brachytherapy (e.g., Figure V- 10): The simulation describes an ocular brachytherapy 
treatment with 106Ru/106Rh ophthalmic applicators. Particles emitted followed an electron 
emission spectrum of mean energy 1,5 MeV. The physical data output studied is the relative 
deposit dose along the central axis of the eye simulated by a water sphere of 24 mm in 
diameter. 
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Figure V- 10: Comparison of relative deposit doses along the central axis of the eye using a local and a parallel 
computation 
 
Results obtained for these medical physics simulations show the compatibility between local and 
parallel computation. The sequence splitting method seems to be very well adapted for parallelizing 
Monte Carlo simulations using the GATE platform. 
V.1.2.G. Tests of computing time using the JJS tool. 
With the enhanced Java API, the user is able to evaluate different computing times:  
§ The duration of jobs submission: the submission is realized using threads, the number of 
threads can be modified. 
§ The total computing time: launching, execution on Worker Nodes and retrieval of jobs on 
the user repository.  
When a job is finished, it is automatically downloaded in a repository specified by the user even if 
all the jobs are not finished. 
V.1.2.G.1. Influence of the number of threads on the computing time 
A thread is a thread of execution in a program. The Java API allows an application to have multiple 
threads of execution running with a pseudo-parallelism. The number of threads can be changed by 
the user. Figure V- 11 shows an example of the influence of 1, 2, 4 and 10 threads on the computing 
time of ten jobs launched in parallel. We can see that the more the threads are important, the lower 
the computing time is, but we have to note that the decrease in launching time is not proportional to 
the number of threads. 
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Figure V- 11: Influence of the number of threads in parallel launchings 
 
V.1.2.G.2. Influence of partitioning on computing time.  
The goal is to show the advantage for the Monte Carlo simulations to partition the calculation on 
multiple processors. The different jobs were launched using ten threads on CCIN2P3 in Lyon, the 
tests weren’t repeated in duration and are representative of the processors load at a given date.  
Figure V- 12 illustrates the computing time in minutes of a Monte Carlo simulation running on a 
single processor PIV of 1,5 GHz locally and the same simulation splitting in 10, 20, 50 and 100 jobs 
on multiple processors. In this specific case, the lowest computing time is obtained for 20 jobs 
running in parallel. Table V- 1 highlights also the speedups coefficients for these submissions. 
Such an example shows that the computing time is not proportional to the number of jobs running 
in parallel. This is in part due to three parameters: 
§ the launching time of the jobs, 
§ the building of the geometry at the beginning of each simulation which does not depend on 
the random generation of the particles,  
§ the LRMS managing of the jobs: even if the splitting of the simulation is very high the 
number of jobs waiting in the BQS depends on the CPU load of processors. 
 
Figure V- 12: Comparison of computing time between a local and a parallel submission 
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Table V- 1: Speedup for different jobs submission 
 
Figure V- 13 shows the influence of launching time compared to the total duration of the 
computation. Even if the launching time is longer for an increasing number of jobs, we can see that 
its responsibility in the computing time is not significant. 
In this study, we reach a factor 8 in the reduction of the computing time of the simulation between a 
computation on a processor PIV of 1,5GHz and a parallel launching by sending jobs at CCIN2P3.            
 
Figure V- 13: Influence of the launching time in parallel launching 
 
In order to test the reliability of such computing time tests, we repeated the submission of sets of 10, 
20, 50 and 100 jobs with 10 threads at CC-IN2P3 for a period of 22 days. Figure V- 14 shows the 
fluctuations concerning launching times, Figure V- 15 concerns the total computing times 
(launching time plus computing and retrieving time) of a set of 100 jobs. 
It can be seen that the jobs submission is well representative of the network performance between 
the local computer (Clermont-Ferrand) and the computing nodes (CC-IN2P3, Lyon); the relative 
deviation between two launching times can reach 46 % over 22 days of submission tests and 76 % 
concerning the total computing times.  
Table V- 2 illustrates in more details the computing time fluctuations with the characteristic 
speedups (minimum, maximum and mean) reached for the repetitive submission of a hundred jobs 
above 22 days. The high standard deviation revealed the difficulty to reproduce during the time a 
quasi-uniform computing time. 
Such results explain the difficulty to obtain a good repetitiveness and robustness for computing 
times on a single grid computing site. The next challenge becomes apparent, to reach lower 
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computing times and be able to provide daily for the user the best resources to compute his 
simulation on the grid. 
   
Figure V- 14: Launching times of a set of 100 jobs at CC-IN2P3 grid site over a period of 22 days. 
 
To enhance this quality of service some solutions have been studied: 
 
It’s obvious that, in addition with the number of CPU growing, a larger number of grid sites must 
be used for the calculations. The more the grid will be composed of many sites, the more the 
calculations will be scattered and won’t depend of a “non-working” site. 
                     
 
Figure V- 15: Total computing times of a set of 100 jobs at CC-IN2P3 grid site over a period of 22 days. 
 
 
Table V- 2: Speedup calculations for Total computing times of a set of 100 jobs at CC-IN2P3 grid site over a 
period of 22 days 
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The second point would be, for the user, to perform the evaluation of the CPU time required by the 
simulations before the submission on the grid. This attention could avoid the killing of the jobs by 
the batch queue system or the sending of the jobs to a batch queue not well adapted for the 
computation. The MaxCpuTime variable accepted in the requirements of the JDL is the best way to 
describe the CPU time consuming of a job. 
 
To speed up the calculations, we can think about enabling a new submission for the jobs that are 
waiting for a too long time in the batch queue in order to be computed. In the future, it is envisaged 
to fix, with the JJS tool, a waiting time in the batch queue equivalent to 10 % of the total estimated 
computing time of the jobs, after this delay the jobs still in the waiting status will be stopped and 
submitted again. The new submission will be realized on another grid site where either the number 
of free CPU is consequent or the running status is reached quickly for the jobs. 
 
It’s also important to daily update information concerning the status of each grid site to avoid the 
launching of jobs on “non-working” sites. This point is already enabled with the new JJS tool, as 
discussed in paragraph V.1.2.d.1. 
V.1.2.H. Tests of computing time on the EGEE testbed using the usual LCG-2 jobs 
submission [22 ] 
We repeated the same tests of computing time by splitting a radiotherapy simulation in 10, 20, 50 
and 100 parts. We launched the jobs on the CCIN2P3 (cclcgceli01.in2p3.fr:2119/ 
jobmanager-bqs-A) and LPC (clrce01.in2p3.fr:2119/jobmanager-lcgpbs-long and 
clrce02.in2p3.fr:2119/jobmanager-lcgpbs-long)  EGEE sites. The CCIN2P3 provided 
50 dual-processors  Pentium ¾ and the LPC, 64 dual-processors Pentium 4. 
V.1.2.H.1. Influence of the jobs various status times  
In order to understand the contribution in the computing time for the various jobs’ status, we 
compared the time duration of each status for different splitting of the GATE simulation. 
We can remark that for the both sites, CCIN2P3 and LPC, the computing time for the submitted, 
waiting and ready status are negligible comparing to the other one.  
Concerning the CCIN2P3 site (see Figure V- 16), the submitted status doesn’t overlapp 15% 
maximum of the total computing time for all the partitions. The ready and waiting status count for 
1.5 % and 0.5% maximum respectively of the total computing time for all the submissions. 
However, we can remark that the scheduled status is the limiting time for the submission, until 80% 
of the total computing time can be spent in the batch queue of the node.  
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Figure V- 16: Time per status for different simulation parts on the CCIN2P3 site. 
 
Concerning the LPC site (see Figure V- 17), the total computing time are globally shorter than for 
the CCIN2P3 site. The scheduled time can reach 33 % of the total computing time for 100 
partitions. 
  
 
Figure V- 17: Time per status for different simulation parts on the LPC site. 
 
We have shown that the time spent in the Workload Management System (WMS) operations is 
negligible comparing to the time spent to wait in the batch queue system (Scheduled status) for the 
computation. The number of Free CPUs is the limiting factor for the scheduling time and therefore 
for the computing time.  
V.1.2.H.2. Influence of the jobs global computing times  
Figure V- 18 and Table V-3 illustrates the computing time in minutes of a GATE simulation 
running on a single processor Intel Xeon 3.06 GHz locally and the same simulation splitted in 
10,20, 50 and 100 jobs on the CCIN2P3 site. In this case the lowest computing time is obtained for 
20 jobs running in parallel. Concerning the same type of submission on the LPC site (Figure V- 19 
and Table V-4), the lowest computing time is obtained for the maximum splitting (100 partitions). 
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A gain factor of 28.2 is reached for this last submission that enables the user to run his simulation in 
10 minutes instead of more than 4 hours on a single processor.  
 
Figure V- 18: Comparison of computing time between a local and a parallel submission on the CCIN2P3 site. 
 
 
Figure V- 19: Comparison of computing time between a local and a parallel submission on the LPC site 
 
 
Table V- 3: Sequential versus grid computation time on CCIN2P3 site. 
 
 
Table V- 4: Sequential versus grid computation time on LPC site. 
V.1.2.I. Conclusion and future prospects 
There have been some remarkable developments in the last few years which have taken the concept 
of using Monte Carlo for clinical treatment planning out of the research lab and into commercial 
implementations. This will become an imperative issue in order to have sufficient precision in 
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cancer treatments. However, the computing time using Monte Carlo calculations must stay 
comparable to what it is currently with analytical calculations. 
It can be seen that the parallelization of Monte Carlo simulations by splitting pseudorandom 
numbers generator sequences into a multitude of streams is a simple, rigorous and generic method 
(e.g it can be applied for each Monte Carlo codes used in physics with a pseudorandom number 
generator). 
The comparison between a local and a parallel computation of some physical results of interest 
shows that the output data stay unchanged and therefore validate the parallelization method used. 
The gain in computing time obtained by splitting the simulations is encouraging. Even if a parallel 
launching using a consequent number of threads speeds up the computing time, it is not responsible 
for the time consumption. The construction of the geometry in a Monte Carlo simulation and 
especially the CPU load of processors are the limiting factors in reducing time consumption. 
Up to now, 1000 status of the pseudorandom numbers generator have been generated and allow the 
user to parallelize a simulation in 1000 jobs. With the CPU resources increasing in future grid 
projects, we can expect to reach up to a factor 1000 in order to reduce time consumption. 
Thereafter, the development of a convivial tool to split, launch and retrieve Monte Carlo 
simulations on a grid environment using a web portal is the answer to the parallelization of Monte 
Carlo simulations in physics. 
V.2. GATE APPLICATIONS ON THE GENIUS WEB PORTAL 
At the beginning of 2002, the Italian INFN Grid Project [23 ] started the GENIUS Portal Project in 
conjunction with the Italian web company NICE srl [24 ]. The goal of this collaboration was to 
create a web portal that would overcome all the difficulties related to the complex command lines 
interfaces (CLI) and the job description language (JDL) that a user encounters when he has to 
submit his application in a grid environment. We will describe first the architecture and 
implementation of the portal, the services offered and to finish the work realized (since April 2004) 
to customize the portal in order to allow transparent GATE jobs submission and management on the 
EGEE-LCG2 infrastructure.  
V.2.1. Architecture and implementation of the portal 
The GENIUS [25 ] [26 ] web portal is carried out on the top of the middleware services of the 
EGEE infrastructure (and before the EU DataGrid Project). The layout of the portal can be 
described by a three-tier architecture model, see Figure V- 20. 
From the user’s workstation (the client, on the right top on the figure), a web browser is running 
(Internet Explorer and Mozilla are the two web browsers compatible with GENIUS) and enable the 
access to the EGEE grid infrastructure by having access to the User Interface.  
The EGEE User interface (UI) machine (the server, on the left side of the figure) runs the Apache 
web server, the Java/XML framework EngineFrame developed by NICE and GENIUS itself. From 
the User interface via the portal the user has access to the remote resources: the Grid. 
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Figure V- 20: Three-tier architecture of the GENIUS portal 
Using those services, the user can interact with files on the UI and from there the user can launch 
jobs to the grid and manage the data belonging to his VO membership. 
In order to guarantee a secured access to the grid, GENIUS has been implemented with a multi-
layered security infrastructure: 
§ All web transactions are executed under the Secure Socket Layer (SSL) via HTTPS 
§ The user has to obtain an account on a UI machine of the grid and be part of a VO. 
§ At each time a user wants to interact with files on the UI machine, he is prompted for the 
username and password he obtained on that machine. 
§ When the user wants to interact with the grid (submission, monitoring, data management, 
etc), he has to create the credentials from a MyProxy server using the command line: 
 
[maigne@grid019:~]$ myproxy-init -s grid001.ct.infn.it 
Your identity: /C=IT/O=GILDA/OU=Personal Certificate/L=Laboratoire de 
Physique Corpusculaire/CN=Lydia MAIGNE/Email=maigne@clermont.in2p3.fr 
Enter GRID pass phrase for this identity: 
Creating proxy ............................... Done 
Proxy Verify OK 
Your proxy is valid until: Thu Apr 21 09:51:11 2005 
Enter MyProxy pass phrase: 
Verifying password - Enter MyProxy pass phrase: 
A proxy valid for 168 hours (7.0 days) for user maigne now exists on 
grid001.ct.infn.it.  
 
To increase the security, usernames and passwords typed on the browser are not saved anywhere, 
they are streamed under the https protocol and then destroyed. The GENIUS portal logs out 
automatically if no actions have been done on the web browser for more than 30 minutes to avoid 
unwanted accesses, see Figure V- 21. 
As the user is authenticated and authorized to use the portal, he can have access to more than 100 
functionalities on it, all the GENIUS services are described in the User’s manual that can be 
browsed from the official site [27 ]. 
In the following, we will concentrate on all the developments performed for GATE applications. 
V.2.2. Encoded functionalites for GATE applications on the Genius web portal 
In order to enable a transparent and interactive use of GATE applications on the grid, we have 
developed, in joint collboration with the department of Physics and Astronomy of the Catania 
university, all the functionalities to run GATE simulations on distributed resources, see Figure V- 
22. 
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Those developments are intended to researchers part of the GATE collaboration willing to have 
access to large computing resources to run long simulations but has been designed also to answer 
the needs of physician and medical physicist in a clinical structure (typically the Centre Jean Perrin) 
to compute dosimetric studies using Monte Carlo high precision for specific applications; ocular 
brachytherapy treatments using ophthalmic applicators of 106Ru/106Rh are one of them. 
We will explain in the following the current and future developments done on the GENIUS portal to 
enable a transparent and convenient access to the grid for GATE applications. 
 
Two informatic languages are used to implement functionalities on the portal: 
§ Bash coded files enable to define and call all the command lines interface needed for the 
application, the creation of files such like scripts, jdls and the interactions with the grid 
(submission, monitoring, etc).  
§ XML coded files enable the creation of the buttons and functionalities appearing on the web 
portal screen.  
V.2.2.A. Test phase on the GILDA infrastructure 
The functionalities dedicated to GATE applications have first been encoded for the GILDA VO and 
infrastructure intended to tutorials and demonstrations [28 ]. The UI hosting the GENIUS portal 
was located in Catania (recheable to https://grid-tutor.ct.infn.it) to have access to the GILDA grid.  
GATE has been installed in a first time on each site of the GILDA infrastructure. 
After some improvements and testing, the GENIUS portal customized for GATE applications has 
been installed on the EGEE UI of Clermont-Ferrand (recheable to https://clrglop208.in2p3.fr) to 
enable launching and monitoring on the EGEE-LCG2 infrastructure.  
In the following we will explain the organisation of the files and the portal functionalities as part of 
the BIOMED VO services. 
V.2.2.B. Implementation of GATE functionalities 
V.2.2.B.1. The files configuration 
On the UI, two files locations are used: 
The XML file is located in  
/opt/genius/apache/htdocs/biomed/ under the name biomed.grid.xml 
The bash files are located in  
/opt/genius/ef/plugins/infngrid/bin/biomed/ under the names: 
biomed.grid.sh
/gate/gate.grid.sh 
/gate/start_gate_jobs.sh 
/gate/templates/script.sh 
/gate/templates/script.sh.lfn 
/gate/templates/gate_job.jdl.template 
/gate/templates/gate.job.jdl.template.last 
/gate/Root_macros/merge.C 
/gate/Root_macros/Viewer.C 
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Figure V- 21: Screenshot of the web portal Genius. The connexion to the Grid using the user’s MyProxy 
Passphrase. 
 
 
 
Figure V- 22: Screenshot of the web portal Genius. GATE applications for biomed VO services. 
 
The gate.grid.sh file is in charge to create all the files needed to submit and compute GATE 
simulations on the grid, Figure V- 23 represents the algorithmic schema of the gate.grid.sh 
file.  
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Figure V- 23: Algorithmic schema of the gategrid.sh file. 
V.2.2.B.2. Creation of the GATE files 
The Job Settings folder makes appear to the user a web page enabling the creation of the GATE 
files (gate_job_settings_create() function), their removing from the UI and the jdl files 
creation to launch them on the grid for the computation. 
Figure V- 24 shows a screenshot of the web page allowing the creation of the GATE files. 
§ First, the user is asked a name of repository where all the files will be created in, this 
repository is located in the GATE repository in the user $HOME repository on the UI 
machine. In the case of the user re-uses the same name for a repository, the gate.grid.sh 
file allocate automatically a number following the name to prioritize the files having the 
same name. 
§ Then, the user is asked if a ROOT analysis has to be performed at the end of the simulation. 
Effectively, the user has the possiblity to run ROOT analysis classes after having recovered 
simulations on the UI to obtain directly on the screen the results on histograms or graphs. 
This specific usage has been implemented especially for ocular brachytherapy treatments, 
the output files are merged (merge.C file) on the UI and an analysis file (Viewer.C) 
enables the production of a histogram as a GIF file that is visualized on the web page.  
§ The files needed to run the GATE simulations are then required: the material database file 
GateMaterials.db, the prerunGate.mac file, the Root files to analyse results, such as 
MakeClass.C and .h and other macro files called at the execution. Those files have to be put 
in the Input Sandbox in the jdl files. A condition test is implemented to check if the input 
sandbox is empty. 
§ The lfn of the medical image (binary file) if the simulation use CT data. Beforehand, the 
user  will have registered the binary file on a SE of the grid and replicated it on multiple 
sites. 
§ The macro file of the user where all the characteristics of his simulated experiment are 
described by command lines. Condition tests are implemented to check if the field is empty 
or if the macro file has the good extension (.mac).  
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§ The number of partitions that corresponds to the splitting number of the simulation. For this 
splitting especially, the gategrid.sh file is in charge of finding the number of particles 
emitted in the simulation, the time of emission of those particles and the output file names 
created in the macro file (for the moment the portal manages ascii and root output formats. 
In function of the number of partitions, files will be duplicated and the number of particles 
emitted in each file is divided. A condition test is implemented to check if the number of 
partitions is between the values 1 and 200. 
§ The status files necessary to run simulations by using non overlapping random numbers. A 
thousand of random status files have been created to launch multiple GATE simulations. 
Figure V- 25 shows a direct access to the repository STATUS/ in the $HOME/GATE/ 
repository offered to the user. A condition test is implemented to check if the number of 
files given by the user is equal to the number of partitions. 
§ Finally on the UI, are created the splitted files: the macro files macro###.mac, the script files 
script###.sh that will be executed on each node, the required files and the status files 
status###.rndm.  
 
Prepared template files just need to be completed with the requirements of the user automatically by 
the portal. Figure V- 26 represents the script template that is modified by the GENIUS portal by 
taking into account the parameters of the user to obtain the final script to be submitted on the grid, 
see Figure V- 27. The lfn name or Root analysis are taken into account in the script creation if the 
user selects those fields. 
 
For a number of partitions equal to four, in the GATE repository located in the $HOME, we can see 
appear the following sub-directories with a Root analysis required: 
$HOME/GATE/Example_1/macro/ 
macro000.mac 
macro001.mac 
macro002.mac 
macro003.mac 
$HOME/GATE/Example_1/script/ 
script000.sh 
script001.sh 
script002.sh 
script003.sh 
$HOME/GATE/Example_1/required/ 
GateMaterials.db 
prerunGate.mac 
Batch000.C 
Batch001.C 
Batch002.C 
Batch003.C 
AnalyseClass000.C 
AnalyseClass001.C 
AnalyseClass002.C 
AnalyseClass003.C 
AnalyseClass000.h 
AnalyseClass001.h 
AnalyseClass002.h 
AnalyseClass003.h 
$HOME/GATE/Example_1/status/ 
status0000.rndm 
status0001.rndm 
status0002.rndm 
       status0003.rndm 
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Figure V- 24: Screenshot of the web portal Genius.The creation of the GATE files. 
 
Figure V- 25: Screenshot of the web portal Genius. The selection of the status files. 
V.2.2.B.3. Creation of the JDL files 
The second step is the elaboration of the JDL files, see Figure V- 28, the functions 
gate_make_jdl_next() and gate_make_jdl() are used. The user is asked a repository name 
and the CPU time estimated for each splitted macro. This parameter appears in the requirements 
line of the jdl file under the name other.GlueCEPolicyMaxCPUTime. The expression given for 
the Requirements specifies the constraints necessary for a job to run. In our case, a site hosting the 
GATE platform (VO-biomed-GATE-1.0.0-3) and other.GlueCEPolicyMaxCPUTime>Number, 
to express that a job requires at least 100 minutes of CPU time to run. If more that one resource 
matches, then the rank is used to determine which is the most desirable resource. To optimize the 
submission, we choose the site with none waiting jobs, if it’s not the case, the sites with the largest 
number of free CPUs. The jobs will only be submitted to the resources which satisfy these 
conditions.  
In the jdlfiles repository are created the JDL files where all the informations concerning the jobs are 
described. The executable, arguments, standard outputs and error, the OutputSandbox, the number 
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of retry count, the JobType, the Type, the InputSandbox, the requirements and the rank are 
mandatory fields to launch GATE simulations. Figure V- 29, Figure V- 30, Figure V- 31 show the 
template JDL files and the final JDL file created by the portal. 
 
 
Figure V- 26: Script template (script.sh) to launch GATE simulations 
 
 
Figure V- 27: Script file created automatically by the GENIUS portal from the script template 
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Figure V- 28: Screenshot of the web portal Genius. The creation of the jdl files. 
 
 
Figure V- 29: JDL template part1 (gate_job.jdl.template) 
 
 
Figure V- 30: JDL template part 2 (gate_job.jdl.template.last) 
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Figure V- 31: Example of a JDL file created by the GENIUS web portal 
 
V.2.2.B.4. Launching of the simulations on the EGEE infrastructure 
The user is now able to launch his jobs created, this functionality is accessible in the Jobs 
Submissions folder. The functions gate_job_submit_next() and 
gate_job_submit_match() and gate_job_submit() are called with a special use of 
start_gate_jobs.sh file for the submission.  
The gate_job_submit_next() function enables the choice of the repository to launch. The 
gate_job_submit_match() function allows the user to select the resources or let the Resource 
Broker chooses. This function calls the edg-job-list-match command with the current 
Resource Broker config file and the current VO config file as arguments. 
edg-job-list-match --config ${RB_CONFIG_FILE} --config-vo 
${RB_VO_CONFIG_FILE} file.jdl  
 
Figure V- 32 and Figure V- 33 represent respectively the Resource Broker configuration file and the 
VO configuration file, the Resource Broker of the IFAE site in Spain has been taken as example
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Figure V- 32: Resource Broker configuration file. 
 
 
Figure V- 33: Resource Broker and VO 
configuration file.
 
Figure V- 34 shows the sites matching the jobs requirements (CE with batch queues). The user has 
the choice to select specific sites or let the Resource Broker chooses.  
 
Figure V- 34: Screenshot of the web portal Genius. The choice of the CE resources. 
 
                                                                                                        Chapter V.GATE Applications on a Grid Environment 
 197
V.2.2.B.5. Job Monitoring and retrieving 
To monitor the current status of the group of jobs launched, the Jobs Queue folder offers to 
visualize the ID of the jobs with their location, the time when they have been submitted and their 
status (Submitted, waiting, scheduled, running and Done), see Figure V- 35. 
In the gate_grid.sh file, in the gate_jobs_status() function the jobs IDs are in fact copied 
in a file in $HOME/GATE/Example_1/.genius/gate_job_list_$RUNDATE_$RUNTIME, the date 
and time of submission are specified in case of multiple submission of the same repository (in this 
case Example_1).  
Preceded of the https:// letters, the edg-job-status command line is applied on a 
job_id_list_input file grouping together the current job IDs. The outputs of each job status are 
then placed in a job_id_list_output file and listed in the XML table. This table is directly 
visualised by the user on the web page. 
The web page containing the status table is automatically refreshed each minute to advise the user 
about the status of his jobs. 
When a status of a job is Done with an Exit code equal to 0 (to warn the user that the job has 
finished without any error outputs), the job is retrieved on the UI in the directory 
$HOME/GATE/outputs/gate_job_list_$RUNDATE_$RUNTIME. The user is informed about each 
job retrieval by a warning on the web page, like it is indicated on Figure V- 36. 
In the case of the user choose to analyse his files at the end of each simulation on a node, then he 
will have the possibility to visualize directly on the screen histograms or graphics produced. Figure 
V- 37 and Figure V- 38 illustrate the outputs visualization of an ocular brachytherapy treatment. 
 
Figure V- 35: Screenshot of the web portal Genius. Visualisation of the status of the jobs. 
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Figure V- 36: Screenshot of the web portal Genius. Retrieval of jobs outputs when each job has the status Done 
with an Exit code 0. 
 
 
Figure V- 37: Screenshot of the web portal Genius. Visualization of the output directories. 
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Figure V- 38: Screenshot of the web portal Genius. Visualization of the ocular brachytherapy isodoses. 
V.2.2.B.6. Some remarks 
More functionalities will be integrated on the portal in a near future.  
In a first time, for the users who don’t want to perform any analysis on their output files produced at 
the end of the simulations, we have to implement a function that enable to register the output files 
on a SE by giving to the user a logical file name (lfn) to have access to for post-analysis on the grid 
or not. 
The data management hasn’t been encoded yet on the portal. But, at term, this functionality should 
allow the management of anonym medical data by physicists and/or physicians by linking the 
anonym information concerning the patient and the disease in a database to the medical data 
registerd on the grid (see Chapter II. For more details). 
The VNC tool [28 ] has been integrated to GENIUS so that, using its Remote Frame Buffer 
protocol, users can open their graphic desktops on the UI machine and do interactive analysis. This 
tool could be practical to use to run a medical data viewer to manipulate images before their storage 
on the grid, or analysis data tools. 
V.3. DEISA AND EGEE: GATE PILOT APPLICATION ON A JOINT 
INFRASTRUCTURE 
The collaboration between EGEE and DEISA aims at defining a joint strategy to address the needs 
of medical physicists and physicians in clinical routine [29 ]. At a first step, the way to submit 
GATE simulations is under study. The parallelization technique has to be modified to take 
advantage of the supercomputing infrastructure in order to obtain consequent gain in terms of 
computing time and quick access to medical data. In a second step, the GENIUS grid portal is going 
to be customized to allow job submissions to both infrastructures. The portal functionalities will be 
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enhanced in order to allow submission to either DEISA or EGEE depending on the jobs parameters 
(CPU time consumption, medical data computations…) and the grid sites’ availability. 
The use of a common application is an example of a pilot project where two infrastructure projects 
can combine their forces and provide better and more cost-effective service for a user community. 
This way a relatively large user community can gain an access to a unique, exceptionally efficient 
set of resources for their time-critical jobs. At the same time, the less urgent tasks can be handled by 
more affordable resources that are more readily available in a large-scale Data Grid infrastructure. 
One of the main challenges related to the usage of grids in clinical routine is the guaranteed 
response time: submission on supercomputers should be the best alternative to meet such 
requirements.   
The IDRIS-CNRS supercomputing centre is the pilot DEISA grid site on which GATE platform has 
been installed. DEISA infrastructure fully exploits the network bandwidth and offers the possibility 
to redistribute the computational workload by migrating jobs across different supercomputers.  
The submission modalities are different for pc farms and supercomputers. As there is no massively 
parallel implementation of GATE, the performances on DEISA infrastructure have to be studied in 
the near future. As well, the strategy for optimal deployment has to be defined. 
GATE has been installed on the different computers which composed the DEISA infrastructure. 
The phase 1 of the AIX super-cluster involves four IBM Power4 platforms (IDRIS, CINECA, 
JULICH, RZG Garching) 
In a first time, GATE-1.0.2 and geant4.5.2.p02 have been installed on the IBM SP4 platform and on 
CRAY XD1 which will be integrated in the second phase of the project, we also installed GATE on 
SGI Altix and Origin (installation at CINES Montpellier). At each time modifications has been 
performed on the Geant4 and GATE codes to compile them on those platforms. 
Computing time tests have been performed on single processor on the different platforms. Figure V- 
39 shows the computing times obtained for a GATE simulation between PC AMD athlon (known as 
one of the fastest platform to run Geant4 code). 
 
Figure V- 39: Test of computing time obtained on different computer: PC AMD, IBM SP4 (32 bits), IBM SP4 (64 
bits), SGI ALTIX 3700 (64 bits), SGI ORIGIN 3800 and CRAY XD1. 
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The gain in computing time on IBM SP4 64 bits is inexistent. The CRAY XD1 platform is the more 
suitable for Geant4-GATE execution (72 biprocessors nodes available) but will only be integered 
on the CINECA site in the second phase of the DEISA project. 
It appears after some tests that Geant4 was the responsible for the very low execution on IBM SP4. 
Very long time is spent in dynamic allocations in the code, the memory management on IBM SP4 
seems to be in cause. 
The Geant4 collaboration has been contacted on this subject, but as the IBM/xlC is not support for 
the installation of GEANT4 software, the execution time will be hardly reduced. 
 
CONCLUSION 
The parallelization of GATE simulations on the grid has shown its efficacy. The results obtained are 
very encouraging and let suppose that with the CPU resources increasing in future grid projects, we 
can expect to reach up to an increased factor in order to reduce time consumption. Despite the 
number of resources, we have to find an optimal use of the grid to benefit of the maximum available 
computing resources for the calculation. A well updated Information System (IS) is one of the key 
for an optimal submission. The migration of the jobs to an other site if the previous one has failed is 
essential to optimize the reliability of the grid. In the same way, a migration of the jobs from an 
overloaded site to a less overloaded one  is to envisage if we want to keep a high gain in computing 
time. The convivial, transparent and secure job submissions enabled by the GENIUS web portal has 
been tested to be a practical tool for a “clinical routine” usage.  
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General Conclusion 
 
 
 
This thesis aimed at the creation of a convivial usage of Monte Carlo simulations in clinical practice 
for dosimetry applications. The study of these features implied the validation of the GATE platform 
using the GEANT physics libraries for absorbed dose calculations concerning electrons, particularly 
in ocular brachytherapy. It has been decided to exploit a grid architecture functionalities to 
distribute our accurate Monte Carlo simulations in order to obtain a significant gain in computation 
time to compete with analytic softwares currently used in hospitals for radiotherapy treatment 
plannings.  
Since 2002, the GATE platform has been used for dosimetry applications in PCSV team. This work 
has been encouraged by the creation of two working groups among the OpenGATE collaboration 
after the release of the open source GATE package in May 2004: one concerning dosimetry and an 
other for cluster/grid processing. 
In addition, the involvement of our team and the Laboratoire de Physique Corpusculaire in the 
DataGrid and next in the EGEE projects enabled us to propose innovative solutions to reduce the 
computation time of our Monte Carlo platform in order to use it in a clinical practice or help 
researchers in their work.   
GATE and a grid infrastructure were the two primary tools to enable the approach of fast and 
accurate dosimetry calculations for a clinical practice. 
GATE has been first designed to answer the needs in SPECT and PET applications, the idea was to 
deal with this platform for dosimetric studies in brachytherapy and radiotherapy applications. As it 
has been demonstrated, the primary functionalities of the platform are not yet sufficient for a 
convivial and dedicated usage of Monte Carlo code for dosimetric studies but are encouraging.  
The first aspect is that geometry encoding is still restricted to simple predefined volumes that can’t 
be associated or can’t be overlaped between each other which limits the creation of complex 
geometries. Then, there’s no dedicated system for linear accelerators or radioactive sources 
features. Output data of the simulations concern for the moment basic information concerning each 
interaction of particles in media such like energy deposited and the position of interactions in space. 
A necessary implementation is required to evaluate the dose deposited in volumes of interest 
directly from the simulation without a post-analysis of data.   
Despite those negative points, the GATE platform with its ease of use, proposes or will propose in a 
near future attractive and convenient tools for dosimetry. The major asset of the platform is the 
possibility to import CT images in the simulations to describe patient’s body. The encoding of 
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parameterised volumes in the platform will improve the tracking of particles in voxelized matrices 
representing tissue heterogeneities. The visualization of such matrices will also benefit of this 
feature. 
Validation of physic processes encoded in GEANT4 implying electrons is also a necessary step to 
compete with other Monte Carlo codes such as EGSnrc for which electron transport has been better 
developed with improved energy loss evaluation techniques and correct fictitious discret 
interactions. 
The simulation of monoenergetic and polyenergetic electron dose point kernels using GEANT4 
standard and lowenergy physics packages and the comparison with other Monte Carlo codes of 
interest in the field of dosimetric applications has shown discrepancies. Differences between 
GEANT4 versions (5.2.p02, 6.2.p02 and 7.0.p01) in the simulation of the kernels highlighted the 
fact that the multiple scattering implementation was in cause with an inadequate angular 
distribution definition. A new implementation of the process is due in the release 8.0 of the 
GEANT4 software.  
In a second step, GATE using the standard package of GEANT4 version 6.2.p02 was tested for 
ocular brachytherapy treatment simulations using 106Ru/106Rh beta emitter sources. Comparisons of 
GATE results with other Monte Carlo, measurements and analytic calculations provided by the 
treatment planning software used in clinical practice showed a good behaviour of the platform for 
such dosimetry. 
In order to use CT data in GATE simulations, a procedure enabling the correlation between CT 
numbers and tissue parameters (density and atomic weights) has been developed and tested. This 
study has shown a well determination of the calcium, phosphorus and hydrogen weights in skeletal 
tissues. Carbon and oxygen weights in tissues (in particularly soft tissues) are poorly resolved by 
means of the CT numbers which imply to find an other alternative to describe soft tissues, for 
example using MRI images. Results of GATE calculations show the impact of atomic weights 
definition on dose distributions from electron and photon beams. 
 
As the computation time is one the major limiting factor for the utilization of  Monte Carlo in a 
clinical practice, we engaged into splitting the simulations in a grid environment by taking into 
account the non reproducibility of the calculations. To achieve this goal, a detailed analysis of the 
Random Number Generator used by the GATE platform was done with an evaluation of the 
consumption in random numbers for different simulations in medical physic fields. As a 
consequence, a thousand of independent random number sequences were produced with a suitable 
size in order to fit the duration of simulations. 
We tested how the functionalities offered by a grid infrastructure could answer the needs in 
reducing the computation time and also could fit the requirements imposed by a deployment of 
tools for the medical staff. The DataGrid project was the first grid infrastructure on which we tested 
the parallelization of GATE simulations using the independent sequence splitting of the random 
number generator. Results concerning computation challenges obtained during the second year of 
the project was very encouraging. We reached up to a speed-up factor of 7.78 by splitting in 20 
simulations, a simulation running in more than 2 hours and 30 minutes on a single 1.5 GHz 
processor. The deployment of GATE simulations on the EGEE production grid infrastructure 
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improved again the gain in computation time thanks to the federation of more computing resources. 
An important speed-up factor of 28.2 was reached during our tests. 
 
An other major development integrated in this thesis was the creation of web services allowing the 
transparent submission of GATE simulations in a grid environment. The GATE platform was first 
packaged and installed on the 20 nodes of the grid hosting the biomed organisation at this date. An 
efficient and fast procedure of installation on the grid using grid middleware functionalities has 
been set up. Because of its multi-layered security infrastructure, the web portal GENIUS was 
chosen to host the encoding modalities to launch in a transparent way GATE simulations on the 
EGEE infrastructure. The functionalities encoded allow the end user to enter its GATE simulation 
and files associated to in order that it is divided into smaller simulations by associating independent 
random number sequences. The preparation of the necessary files to launch jobs on the grid are 
automatically created in background. The functionalities enable also the allocation of medical 
images to the simulations in the case of calculations on CT patient data for which GATE is able to 
plan a dosimetry. 
A first prototype of the GENIUS web portal (https://clrglop208.in2p3.fr) hosting GATE 
functionalities is now available using a secure internet connection and grid certificates. The web 
portal is accessible from the Centre Jean Perrin where medical physicists are able to launch GATE 
simulations on ocular brachytherapy using 106Ru/106Rh applicators.   
 
We can’t conclude at this date that GATE simulations distributed on a grid environment are used 
for clinical routine treatment planning. To enable such usage in a near future the work performed in 
this PhD thesis has to be followed by additional studies.  
 
Concerning the usage and testing of grid added value in the reduction of the calculation time for 
GATE simulations, some points have to be detailed following this priority order: 
 
§ Large scale grid computing time tests need to be performed to evaluate failures and the gain 
in time occuring in a daily usage of the grid. 
§ Alternatives have to be proposed against grid bottlenecks that prevent a usage of the GATE 
simulations in clinical practice, for example: the Resource Broker failures and the 
computing resources load balancing. 
§ Encoding of the management of medical images in the next releases of the GENIUS web 
portal should be studied. Associated to a relational database located at hospital, it would 
enable the correlation between metadata related to patient such as the name, the pratician, 
the characteristics of the disease, etc, and anonym medical images registered on the grid.   
§ A simplified utilization of the GENIUS web portal should be developed to allow its use by 
novice users. No time should be spent by the medical physicist or pratician to assimilate the 
functionalities proposed by the web portal, its utilization should be as intuitive as required. 
For the moment the prototype version has required training course to use it.  
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Concerning the validation of the GATE platform for dosimetry applications: 
 
§ dedicated developments for dosimetric applications in GATE, with the creation of new 
systems to define linear accelerators and radioactive sources. Output data concerning dose 
deposited should also be implemented to facilitate the usage of the platform. 
§ A validation of the GEANT4 accuracy for dosimetric calculations implying electrons. The 
criteria of comparison of the GATE platform with other Monte Carlo codes for dosimetry 
should take into account the availability, convenience of use, flexibility for simulating 
complex detector geometries and experimental arrangements and support and maintenance. 
In that way, GATE should be compared with the GEANT release 8.0 in a near future 
especially with EGSnrc and MCNP.  
§ a validation of the incorporation of CT data in GATE simulations by benefiting of the 
transcription of CT numbers into tissue parameters developed in this thesis. This work 
would deserve a validation and a comparison with results obtained in homogeneous medium 
to estimate better the influence of density and atomic composition of tissue on dose 
distributions. Ocular brachytherapy treatments would benefit of an accurate location of the 
tumour with an allocation of correct density and tissue parameters to uveal melanoma and 
some eye structures. 
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Conclusion générale 
 
 
 
Cette thèse a abouti à la création d’une utilisation conviviale des simulations Monte Carlo en 
routine clinique pour les applications en dosimétrie. Cette étude a impliqué la validation de la plate-
forme GATE utilisant les librairies physiques de GEANT4 pour le calcul de la dose absorbée par 
des électrons, notamment pour la curiethérapie oculaire. Il a été décidé d’exploiter les 
fonctionnalités d’une architecture de grille pour distribuer nos simulations Monte Carlo afin 
d’obtenir un gain significatif en temps de calcul de manière à rivaliser avec les logiciel analytiques 
actuellement utilisés en centres hospitaliers pour les planifications de traitement en radiothérapie. 
Depuis 2002, la plate-forme de simulation GATE a été utilisée pour des applications en dosimétrie 
dans l’équipe PCSV. Ce travail a été encouragé par la création de deux groupes de travail au sein de 
la collaboration OpenGATE après la parution du premier package dont les fichiers sources ont été 
rendus disponibles en mai 2004 : un concernant les calculs en dosimétrie et le second concernant le 
calcul sur ferme ou grille. 
De plus, la participation de notre équipe et du Laboratoire de Physique Corpusculaire dans les 
projets DataGrid et par la suite EGEE nous ont permis de proposer des solutions innovantes pour 
réduire le temps de calcul de notre plate-forme Monte Carlo dans le but de l’utiliser en routine 
clinique ou d’aider des chercheurs dans leur travail. 
GATE et l’infrastructure de grille ont été les deux outils premiers permettant une approche rapide et 
précise des calculs de dosimétrie pour la routine clinique. 
GATE a été dans un premier temps élaboré pour répondre aux besoins en imagerie SPECT et TEP, 
mais l’idée était d’utiliser cette plate-forme également pour des études dosimétriques en 
curiethérapie et radiothérapie. Comme il a été démontré, les premières fonctionnalités de la plate-
forme ne sont pas encore suffisantes pour une utilisation conviviale et dédiée aux études 
dosimétriques mais sont néanmoins encourageantes. 
L’encodage des géométries dans GATE est restreint à l’utilisation de volumes géométriques simples 
prédéfinis qui ne peuvent ni être associées ni se recoupés pour créer des volumes complexes. De 
plus, aucun système n’est dédié pour la modélisation d’accélérateurs linéaires ou de sources 
radioactives. Enfin, les sorties de données des simulations traitent des informations standard 
relatives aux interactions des particules dans un milieu comme l’énergie déposée ou les positions 
d’interactions dans l’espace. Une implémentation est nécessaire pour permettre le calcul de dose 
déposée dans des volumes d’intérêt directement à l’issue d’une simulation et non plus grâce à une 
post-analyse des données. 
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En dépit de ces points négatifs, la plate-forme GATE avec sa facilité d’utilisation propose ou 
proposera dans un futur proche des outils pratiques et interactifs pour la dosimétrie. L’atout majeur 
de la plate-forme est la possibilité d’importer des images scanner dans les simulations pour décrire 
le corps du patient. L’encodage des volumes paramétrés dans GATE permettra le suivi des 
particules dans des matrices de voxels représentant les hétérogénéités des tissus. La visualisation 
aisée de ces matrices bénéficiera aussi de cette caractéristique. 
La validation des processus physiques encodés dans GEANT4 et impliquant les électrons est une 
étape nécessaire pour rivaliser avec d’autres codes Monte Carlo, en particulier EGSnrc pour lequel 
le transport des électrons a été développé avec une meilleure évaluation des techniques de perte 
d’énergie et des interactions discrètes corrigées.  
La simulation de point kernel d’électrons mono-énergétiques et poly-énergétiques utilisant les 
packages standard et basse énergie de GEANT4 ainsi que la comparaison avec d’autres codes 
Monte Carlo d’intérêt dans le domaine des applications dosimétriques ont montré des différences. 
Les différences entre les versions de GEANT4 (5.2.p02, 6.2.p02 et 7.0.p01) dans la simulation des 
points kernels a mis en évidence le fait que l’implémentation de la diffusion multiple était en cause 
avec une définition inappropriée de la distribution angulaire. Une nouvelle implémentation de ce 
processus est prévue pour la version 8.0 du logiciel GEANT4. 
Dans un deuxième temps, GATE utilisant le package standard de la version 6.2.p02 de GEANT4 a 
été testé pour des simulations de traitement de curiethérapie oculaire utilisant des sources de 
106Ru/106Rh émettrices béta. Les comparaisons des résultats obtenus avec GATE et d’autres 
calculs Monte Carlo ainsi que des mesures et des calculs analytiques fournis par le logiciel de 
planification de traitement utilisé en routine clinique, ont montré un bon comportement de la plate-
forme pour ce type de dosimétrie. 
Dans le but d’utiliser des données scanner dans les simulations GATE, une procédure a été 
développée et testée pour permettre une corrélation entre les nombres Hounsfield et les paramètres 
tissulaires (densité et poids atomiques). Cette étude a montré une bonne détermination des 
composés calcium, phosphore et hydrogène dans les tissus osseux. Les composés carbone et 
oxygène dans les tissus (en particulier les tissus mous) sont mal quantifiés au moyen des nombres 
Hounsfield ce qui implique de trouver une autre alternative pour décrire les tissus mous, par 
exemple en s’aidant des données de l’IRM. Les simulations GATE réalisées montrent l’impact de la 
définition des composés atomiques sur les distributions de dose causées par des faisceaux de 
photons et d’électrons.  
 
Comme le temps de calcul est un des facteurs majeurs limitant l’utilisation du Monte Carlo en 
pratique clinique, nous nous sommes engagés à diviser les simulations dans un environnement de 
grille en prenant en compte la non reproductibilité des calculs. Pour atteindre ce but, une analyse 
détaillée du générateur de nombres aléatoires utilisé par la plate-forme GATE a été effectuée avec 
une évaluation de la consommation de nombres aléatoires pour différentes simulations dans les 
domaines de la physique médicale. En conséquence, mille séquences de nombres pseudo-aléatoires 
de taille suffisante pour correspondre avec la durée des simulations réalisées, ont été produites. 
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Nous avons testé comment les fonctionnalités offertes par la grille pouvaient répondre aux besoins 
de réduction du temps de calcul et aussi au déploiement d’outils pour une équipe de soin médicale. 
Le projet DataGrid a mis en place la première infrastructure de grille sur laquelle nous avons testé 
la parallélisation des simulations GATE en utilisant des séquences indépendantes du générateur de 
nombres aléatoires. Les résultats concernant les challenges impliqués par de tels calculs ont été 
encourageants durant la deuxième année du projet. Un gain de 7.78 a été atteint en divisant une 
simulation se déroulant en plus de 2h30 sur un simple processeur de 1.5GHz en 20 simulations. Le 
déploiement des simulations GATE sur l’infrastructure de grille de production EGEE a amélioré 
encore ce gain grâce à la fédération de plus importantes ressources de calcul. Un gain maximum de 
28.2 a été atteint durant nos tests. 
 
Un autre développement majeur intégré dans ce travail de thèse a été la création de services web 
permettant la soumission transparente de simulations GATE sur un environnement de grille. La 
plate-forme GATE a été tout d’abord packagée et installée sur 20 nœuds de la grille accueillant 
l’organisation biomed à ce jour. Une procédure d’installation rapide et efficace utilisant les 
fonctionnalités de l’intergiciel de grille a été mis en place. Grâce à son infrastructure de sécurité 
« multi-couches », le portail web GENIUS a été choisi pour accueillir les modalités pour soumettre 
de manière transparente, les simulations GATE sur l’infrastructure EGEE. 
Les fonctionnalités encodées permettent à l’utilisateur final de diviser sa simulation ainsi que ses 
fichiers associés en de plus petites simulations en associant à chacune d’elle une séquence de 
nombres aléatoires indépendante. La préparation des fichiers nécessaires pour le lancement des jobs 
sur la grille sont automatiquement crées en arrière plan. Les fonctionnalités permettant une 
allocation d’images médicales aux simulations dans le cas d’une planification de traitement utilisant 
des images scanner avec GATE sont disponibles. 
Un premier prototype du portail GENIUS accueillant les fonctionnalités pour GATE 
(https://clrglop208.in2p3.fr) est à présent disponible en utilisant une connexion internet sécurisée et 
des certificats d’authentification pour  l’accès à l’infrastructure de grille. Le portail web est 
accessible depuis le Centre Jean Perrin où des physiciens médicaux sont capables de lancer des 
simulations GATE pour des traitements de curiethérapie oculaire utilisant des applicateurs de 
106Ru/106Rh. 
Nous ne pouvons pas conclure à ce jour que les simulations GATE sont utilisées pour la 
planification des traitement en routine clinique grâce à l’environnement de grille de calcul. De 
manière à permettre une telle issue, le travail commencé au cours de cette thèse doit être poursuivi 
par des études additionnelles. 
 
Concernant l’étude des performances de la valeur ajoutée de la grille sur la réduction des temps de 
calcul des simulations, d’autres points sont à étudiés suivant cet ordre de priorité : 
 
§ Des tests de temps de calcul à plus grande échelle sont nécessaires pour évaluer les limites 
ainsi que le gain pouvant être obtenus par une utilisation journalière de la grille. 
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§ Des alternatives doivent être trouvées contre les goulots d’étranglements inhérent à la grille 
pour une utilisation de GATE en routine clinique, nous pouvons citer à titre d’exemple les 
inconvénients du Resource Broker et la distribution de la charge sur les ressources de calcul. 
§ Les fonctionnalités concernant la gestion des images médicales sur grille devraient être 
encodées au niveau du portail web GENIUS. Associées à une base de données relationnelles 
localisée en centre hospitalier, la corrélation entre les méta-données relatives au patient, 
comme le nom du patient, du praticien, les caractéristiques de la maladie, etc, et les images 
médicales anonymes enregistrées sur la grille.  
§ Une utilisation plus simplifiée du portail GENIUS devrait être mise en place pour les 
utilisateurs novices. Il est à prohiber une utilisation du portail qui ne serait pas la plus 
intuitive possible. Jusqu’à présent, l’utilisation du portail web a nécessité de cours pour 
apprendre son fonctionnement. 
 
Concernant la validation de la plate-forme GATE pour les applications en dosimétrie : 
 
§ Des développements dédiés pour effectuer des études dosimétriques avec GATE sont 
nécessaires, de nouveaux systèmes aidant à la modélisation d’accélérateurs linéaires et de 
sources radioactives scellées sont à pourvoir. Les sorties de données relatives aux dose 
déposées devraient être implémentées. 
§ Une validation du logiciel GEANT4 pour les applications en dosimétrie utilisant les 
électrons doit être poursuivie. De plus, les critères de choix de la plate-forme GATE en 
comparaison d’autres Monte Carlo devront se baser sur son accessibilité, sa facilité 
d’utilisation, sa flexibilité à simuler des géométries de détecteur complexes, des procédés de 
mesures expérimentales ainsi qu’un support et une maintenance du code. Dans cette 
perspective, GATE associé à la version 8.0 de GEANT4 devrait être comparé avec EGSnrc 
et MCNP. 
§ Une validation concernant l’incorporation d’images scanner dans les simulations GATE doit 
être faite en bénéficiant de la transcription des nombres Hounsfield en paramètres tissulaires 
effectuée au cours de cette thèse. Ce travail servirait de validation et de comparaison avec 
des résultats obtenus en milieu homogène pour mieux estimer l’influence de la densité et de 
la composition atomique des tissus sur les distributions de dose. Les traitements de 
curiethérapie oculaire bénéficieraient en outre d’une meilleur localisation de la tumeur avec 
une allocation correcte de la densité et des paramètres tissulaires des mélanomes de l’uvée et 
des structures oculaires. 
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Abstract 
Although often quite time consuming, Monte Carlo method is the calculation algorithm that most 
closely models the actual physics of the energy deposition process. The idea is to use Monte Carlo 
calculations in daily cancer treatment using radiation to compete with treatment planning systems 
(TPS) in the delivering of absorbed dose to tumour for specific treatments. To achieve this goal, two 
points have been particularly studied in this thesis:  the validation of the GATE platform for 
dosimetry applications using electrons, with a specific study concerning ocular brachytherapy 
treatments using 106Ru/106Rh ophthalmic applicators and the deployment of GATE simulations in a 
grid environment to reduce the very high computation time of those simulations. 
Monoenergetic and polyenergetic electron dose point kernels have been simulated using the GATE 
platform and compared with other Monte Carlo codes. Three versions of the GEANT4 physics 
package have been used for the comparisons (5.2, 6.2 and 7.0). Results show that the Multiple 
Scattering implementation is responsible for the discrepancies observed between the codes. 
Simulations of ocular brachytherapy treatments compared with Monte Carlo and measurements show 
a good agreement. The transcription of Hounsfie ld units from CT images of patient’s anatomy to 
tissue parameters is the other work presented for a next usage of GATE on voxelized images for 
personnalized dosimetry. The DataGrid and then the EGEE infrastructures were used to deploy 
GATE simulations to reduce their computation time in order to use them in clinical practice. 
The method used to parallelize the GATE simulations is the splitting of the random number generator 
(RNG) into independent sequences. Computing time tests performed on the grid testbeds show that a 
significant speed-up is obtained. Functionalities to split, launch and monitor GATE simulations on a 
grid infrastructure have been implemented on the GENIUS web portal. A first prototype of this portal 
is accessible from hospital to use the accurate Monte Carlo algorithms in a transparent and secure 
way for ocular cancer treatments.  
Keywords: GATE, GEANT4, EGEE, grid, Monte Carlo simulations, dosimetry, ocular brachytherapy, 
CT numbers.  
Résumé 
Bien que souvent assez consommatrice en temps de  calcul, la méthode Monte Carlo est l’algorithme de 
calcul qui modélise au plus près la physique liée aux processus de dépôts d’énergie. L’idée est d’utiliser 
les calculs Monte Carlo dans le traitement quotidien du cancer par rayonnement pour rivaliser avec 
les systèmes de planification de traitement (TPS) existants dans  le but de délivrer une dose absorbée à 
la tumeur pour des traitements spécifiques. Pour atteindre cet objectif, deux points ont été 
particulièrement étudiés au cours de cette thèse : la validation de la plate-forme de simulation GATE 
pour des applications en dosimétrie utilisant des électrons, une étude particulière est faite concernant 
les traitements de curiethérapie oculaire utilisant des applicateurs ophtalmiques de 106Ru/106Rh, et le 
déploiement des simulations GATE dans un environnement de grille pour réduire les temps de calcul 
très élevés de ces simulations. 
Des points kernels de dose d’électrons mono-énergétiques et poly-énergétiques ont été simulés en 
utilisant la plate-forme GATE et comparés à d’autres codes Monte Carlo.  Trois versions des packages 
de librairies ont été utilisées pour les comparaisons (5.2, 6.2 et 7.0). Les résultats montrent que 
l’implémentation de la diffusion multiple est responsable des différences observées e ntre les codes. Les 
simulations de traitements de curiethérapie oculaire comparées avec d’autres Monte Carlo et des 
mesures montrent un bon accord. La transcription des unités Hounsfield, à partir des données scanner 
sur l’anatomie du patient, en paramètre s tissulaires est l’autre étude présentée pour une utilisation 
prochaine de GATE sur des images voxélisées pour la dosimétrie personnalisée. Les infrastructures 
des projets DataGrid puis d’EGEE ont été utilisées pour déployer les simulations GATE afin de 
réduire leur temps de calcul dans le but de les utiliser en routine clinique. 
La méthode utilisée pour paralléliser les simulations GATE est la division du générateur de nombres 
aléatoires (RNG) en séquences indépendantes. Des tests de temps de calcul réalisés sur des bancs tests 
de grille montrent qu’un gain significatif est obtenu. Les fonctionnalités pour diviser, lancer et 
contrôler les simulations GATE sur une infrastructure de grille ont été implémentées sur le portail 
web GENIUS. Un premier prototype de ce portail est accessible à partir d’un centre hospitalier pour 
l’utilisation de la précision des algorithmes Monte Carlo de manière transparente et sécurisée pour des 
traitements de cancer de l’œil. 
Mots clés : GATE, GEANT4, EGEE, grille de calcul, simulations Monte Carlo, dosimétrie, 
curiethérapie oculaire, nombres Hounsfield. 
